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ABSTRACT 
 Alzheimer’s disease (AD) is a heterogeneous brain disease with multiple interacting risk 
factors, suggesting equifinality. Research indicates that the pathophysiological processes 
involved in AD are evident years prior to disease onset with significant variability in 
neurocognitive functioning being apparent during preclinical stages. Identification of individuals 
in preclinical stages is vital, as earlier interventions may prove more effective at ameliorating 
AD’s devastating effects. In this respect, clarifying relationships between risk factors and 
neurocognitive functioning in cognitively intact older adults can improve our understanding of 
mechanisms involved in preclinical AD, which may allow for earlier detection and intervention.  
 The present study employed Latent Growth Curve modeling to longitudinally examine 
relevant risk factors relationship with neurocognitive functioning via neuropsychological 
assessment of executive attention, processing speed, episodic memory, language and working 
memory in 576 relatively healthy older adults over a three-year period. Results indicated on 
average Executive Attention/Processing Speed declined over time, while Memory and Language 
performance benefitted from practice effects over the three-year period. Substantial 
heterogeneity in initial levels of neurocognitive functioning and in linear changes in these 
processes were explained by individual differences in patterns of risk and resiliency variables. 
Specifically, differences in age, sex (men), and race (African Americans) respectively predicted 
worse neurocognitive functioning and Neurocardiovascular risk, while higher education and 
estimated intelligence predicted better neurocognitive functioning. Women were significantly 
higher in Depression/Endocrine risk. Neurocardiovascular and Depression/Endocrine risk factors 
emerged as unique predictors of worse neurocognitive functioning. Genetic risk for AD 
  viii
(apolipoprotein E genotype: APOE-e4) specifically associated with worse baseline Memory 
functioning, supporting episodic memory’s role as a neurocognitive endophenotype for AD. 
APOE-e4 also associated with lower estimated intelligence and Depression but not 
Neurocardiovascular history. In sum, the present study found distinct yet identifiable cognitive 
profiles of risk for neurocognitive decline. These results support conceptual models that suggest 
individual differences in sex, genetic risk, cognitive reserve, medical and mental health 
comorbidities in combination influence cognitive decline with age. These data have important 
treatment implications as they strongly indicate that there are modifiable risk factors that 
influence neurocognitive decline that can be targeted early on through behavioral and/or medical 
interventions.  
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CHAPTER 1: INTRODUCTION  
Alzheimer’s disease (AD) is a complex progressive brain disease that is the most 
common cause of dementia among older adults (National Institute on Aging, 2013). From a 
public health standpoint, the societal, individual, and financial costs of AD in the United States 
are enormous. According to the Center for Disease Control (CDC; 2014), AD is one of the top 
ten leading causes of death in the United States and it is believed that five million individuals in 
the United States aged 65 years or older have AD as of 2013. This number is expected to 
increase to nearly 14 million individuals by 2050 (CDC, 2014). Projected costs of AD from 2010 
were estimated to fall between 159 and 215 billion dollars; this number is expected to be as high 
as 500 billion dollars by 2040 (CDC, 2014). Relevantly, to date, interventions for AD have not 
proven to be very effective at ameliorating its devastating effects. In this regard, early 
identification of individuals at risk for AD remains the holy grail within AD research, in that it is 
possible that interventions (both pharmacological and behavioral) that target systems involved in 
these earlier changes may slow or ideally impede propagation to other neural systems, prior to 
the development of likely psychological and neural compensatory changes as a result of these 
earlier liabilities.  
 A continuum model of AD pathology and neurocognitive decline that has been proposed 
by the National Institute on Aging (NIA) in conjunction with the Alzheimer’s Association is that 
there is a “preclinical” stage of AD (and other dementia disorders) that precedes the diagnosis of 
mild cognitive impairment (MCI, which comes before transition to dementia along this 
continuum; Sperling et al., 2011). MCI is posited to be an earlier stage of dementia in which 
deficits in memory and/or thinking skills is evident yet the individual does not meet criteria for 
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dementia (see Petersen, 1999, 2004; Morris et al., 2001). MCI has gained acceptance among the 
medical field as a diagnosis, and the International Classification of Diseases, Revision 9 now has 
a billing code for MCI; consistent with NIA’s continuum model many health professionals view 
MCI as early AD given the observed high rate of clinical conversion to AD in MCI individuals 
(see Roberts et al., 2010). According to the NIA-Alzheimer’s Association (NIA-AA) guidelines, 
clinical diagnosis of MCI requires that there is a noticeable reported change in cognitive 
functioning beyond that of normal-advancing age decline (Sperling et al., 2011). There should 
also be evidence of worse neurocognitive performance in one or more processes as measured by 
tests beyond what would be expected based on the individual’s age and years of education; and, 
if repeated measures are available than there should be a noticeable decline in their performance. 
When memory is the function primarily affected this is considered to be amnestic MCI (aMCI) 
and non-amnestic MCI refers to when cognitive abilities other than memory are affected (e.g., 
the ability to plan and sequence events and/or visual perception deficits). While individuals with 
MCI may be less efficient at instrumental activities of daily living (iADLs) these functions 
remain relatively well preserved. This definition of MCI and its research has informed the 
Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition (DSM-5) diagnosis of 
mild neurocognitive disorder (mNCD), which is also defined as a noticeable change in cognitive 
functioning in one or more cognitive domains in the absence of decline in ADLs (American 
Psychiatric Association, 2013).  
Although clinical research has begun to intervene at the MCI stage, the NIA-AA’s task 
force suggests that this may even be too late for optimal treatment effects (Sperling et al., 2011). 
For research settings, the NIA-AA has defined a preclinical phase in which brain changes may 
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already be in process; however, significant clinical symptoms are not yet evident (Sperling et al., 
2011) Preclinical individuals display subtle signs of neurocognitive decline but do not yet meet 
criteria for MCI. Importantly, this preclinical period (prior to substantial beta-amyloid 
accumulation and clinical symptoms of AD) can last for over a decade, and may represent an 
opportunity for preventive measures and/or potentially more successful pharmacological and 
behavioral interventions within individuals who are defined as high-risk for MCI/AD (Sperling 
et al., 2011). Thus, a critical research direction proposed by the NIA-AA is the need to better 
define biomarkers and/or neurocognitive profiles that can best predict progression from the 
preclinical to the clinical stages of MCI and AD (Sperling et al., 2011). This continuum model of 
preclinical levels of neurocognitive decline provides a conceptual framework that inspired this 
study’s design.  
There is increasing evidence that many factors appear to contribute to the pathogenesis of 
AD and other dementia disorders. Notably, while there is a high conversion rate of individuals 
from MCI to AD, many individuals with MCI remain clinically stable and a subset of individuals 
diagnosed with MCI have been found to revert back to normal cognitive functioning 
(Alzheimer’s Association, 2014). Thus, it is possible that certain MCI cases have been 
misclassified due to lack of sensitivity and/or specificity of the clinical assessment measures 
used (see Bondi & Smith, 2014), and it also possible that there are specific factors involved in 
maintaining clinical stability (or even providing resiliency) in those with MCI. Of further 
relevance, while research has identified several important risk factors for neurocognitive decline 
and subsequent development of MCI /AD, these findings have been largely mixed and there still 
remains a substantial amount of uncertainty regarding the causal relationships between these 
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predictors. Furthermore, it has become increasingly evident that none of the known risk factors 
to date are alone sufficient to accurately predict neurocognitive decline within older adults. Thus, 
the present study aimed to help to disentangle the relationships between age-related declines in 
specific neurocognitive processes (using objective sensitive neuropsychological test measures) 
and theoretically important predictors of risk over time in order to better define “normal” as 
compared to potentially preclinical neurocognitive variability in older adults. 
Etiological model of risk for MCI/AD. A current challenge within cognitive aging 
research is distinguishing normal age-related changes in neurocognitive functioning from 
potential preclinical disease stages of MCI/AD. While memory impairments are a hallmark of 
AD, a growing body of research has implicated subtle deficits in executive functioning, attention, 
processing speed, and language processing in the earlier clinical manifestations of MCI/AD (see 
Bondi et al., 2008; Elias et al., 2000; Sperling et al., 2011; Weintraub et al., 2009). There is also 
evidence that individual differences in neural and “cognitive reserves” with age, as well as 
certain demographic and health related risk factors differentially influence the trajectory of 
neurocognitive decline within older adults with suspected AD pathology (e.g., Okonkwo et al., 
2010; Sperling et al., 2011; Wilkosz et al., 2010). And, as will be discussed, there is a growing 
body of evidence that suggests age-related shifts in neural recruitment (e.g., increased bilateral 
activity in frontal and posterior parietal brain regions) might serve to help older adults 
compensate for declines in other neural resources with advanced age (e.g., Cabeza et al., 2004; 
Davis et al., 2008; Grady, 2012). Notably, these same regions posited to compensate for age-
related shifts that are associated with preserved neurocognitive functioning have been implicated 
in early stages of neuronal degeneration in MCI/AD. Other relevant factors that have been 
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associated with an increased risk of developing MCI/AD and its course (i.e., the degree of 
impairment and rate of deterioration) include individual differences in demographic (age, race 
and sex), genetic (presence of APOE-e4) and health-related risk factors (e.g., depression, 
cardiovascular issues, diabetes, hypertension), which as will be later discussed have been shown 
to have additive and interactive effects with one another. 
Lastly, while structural and functional changes in neurocognitive capacity can occur with 
normal aging, overall evidence across a broad age range of older adults (including the “oldest-
old”) suggests that well-educated healthy aging adults do not experience measurable declines in 
neuropsychological test performance over a four-year period (Hickman et al., 2000). This notion 
corresponds well with cognitive reserve theory, which suggests that individual differences in 
education, intelligence, and other psychosocial factors increase resiliency to cognitive decline 
through their beneficial effects on brain structure and function (Stern, 2006). According to 
cognitive reserve theory, underlying neurocognitive processes and/or differences in preexisting 
brain networks appear to allow certain individuals to more effectively cope with brain damage 
through these greater cognitive reserves (See Stern 2002, 2006, 2009). Indeed, higher levels of 
education and intelligence, as well as measures of quality of life have been shown to have a 
protective effect on neurocognitive functioning in the face of neural insult and are also associated 
with reduced dementia incidence rates (Kukull, et al., 2002; Stern, 2009).  
In summary, it has become increasingly evident that there is substantial variance in the 
earlier clinical manifestations of AD as well as within “normal” aging. Importantly, despite 
increased recognition of heterogeneity within neurocognitive functioning with age, to date there 
has been little longitudinal research that has concurrently investigated for well-known risk 
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factors for MCI/AD (demographic, genetic, and health-related risk factors) in relation to specific 
changes in neurocognitive functioning within cognitively intact older adults. To address 
important gaps within the literature, the present study systematically investigated the interplay 
between memory, executive function, attention/processing speed, language, and working 
memory at baseline and over time; and, the degree to which genetic risk for AD (APOE-e4 
allele), demographic factors (age, race, and sex), factors associated with cognitive reserves 
(levels of education and estimated intelligence), and health related risk factors explained 
heterogeneity in interindividual differences in neurocognitive functioning in older non-demented 
adults over a three-year period.  
Given the complexity of the variables involved within this study and the vast literature 
for each respective component, it was beyond the scope of this study to provide a comprehensive 
literature review of each factor. Instead, some key findings and reviews were selected to provide 
a summary that should enable the reader to fully conceptualize this study’s rationale, aims, and 
reasons for selected methodology. To begin, a brief description of AD pathophysiology in 
relation to genetic risk for AD is provided. Next, context for Aim 1’s hypotheses is provided 
through an overview of developmental theories on the relationship between aging and cognition, 
and a discussion on age-related changes in brain functioning. Subsequently, anatomical findings 
that are relevant to the present study are presented, and are followed by a summary discussion. In 
the following section, relevant theories and/or research in relation to Aim 2’s posited risk factors 
are presented. This is followed by a brief discussion on practice effects and validity concerns. 
Study variables are then integrated and presented within the study’s aims and specific 
hypotheses. This is followed by a description of the study’s design and method(s). To conclude, 
  7
the results and their theoretical importance for future research on studying neurocognitive change 
in older adults are discussed. 
Prevalent theory on AD pathophysiology. This section provides a brief description of 
molecular events that are crucial to understanding AD pathology. While it is outside the scope of 
this study to address the underlying hypothesized biochemistry that occurs in the preclinical and 
clinical stages of AD pathology (as well as other certain neurodegenerative disorders) – for the 
purpose of this study and its conceptualization it is important to note that beta-amyloids (Aβ, a 
biomarker of AD) are believed to disrupt the architecture of neural tissue and that the 
apolipoprotein E (APOE) gene is posited to exert its effects through modulation of the amount of 
Aβ deposits during what is considered the initiation stage (Johnson, McCleary, Oshita, & 
Cotman, 1998). The initiation stage of AD disease processes is conceptualized as Aβs triggering 
a cascade of biological events at the molecular level, and there is a growing consensus that once 
the Aβs initiation of pathophysiological events occurs, these activated processes may come to act 
independently of the initiating amyloid. The end result being the structural and functional 
changes observed within the brain in relation to AD pathology (i.e., the propagation stage; 
Hyman, 2011; Johnson et al., 1998; Sperling et al., 2011).  
In relation to genetic risk and AD pathophysiology, the APOE-e4 genotype is the 
strongest known genetic risk factor for late-onset AD (NIA, 2013; Sperling et al., 2011). The 
APOE gene provides instructions for making its namesake protein, apolipoprotein E. 
Apolipoprotein E is one of the proteins that combines with lipids to form lipoproteins that are 
responsible for packaging and transporting cholesterol through the blood stream (Uranga & 
Keller, 2010). There are several gene variations of the APOE in humans that significantly differ 
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both in their structure and function. The three major APOE allelic variations are ε2, ε3, and ε4 
with the ε3 allele being the most common (alleles respective frequency: 8%, 77%, 14%; see 
Corder et al., 1994). The ε4 allele (APOE-e4) remains the most robust predictor of genetic risk 
for late-onset AD, whereas the ε2 allele (APOE-e2) is associated with decreased risk for late-
onset AD (see National Institute on Aging, 2013). Furthermore, the presence of one or two 
APOE-e4 alleles has been specifically linked to poor performance on neuropsychological tests of 
learning, memory, and psychomotor speed across a wide range of ages in non-demented 
individuals (see Waldstein, 2000).  
Although the exact role of the APOE gene in AD pathology remains uncertain, different 
polymorphisms in the gene appear to play a role in the efficiency in which plaques are removed 
from the brain as they have been differentially implicated in levels of Aβ accumulation (Sperling 
et al., 2011; Uranga & Keller, 2010). In studying autopsied brains, Johnson et al.’s (1998) 
seminal work found that: (1) the APOE-e4 allele was related to the initiation of Aβ and earlier 
AD onset, while (2) the APOE-e2 allele and sex were the best predictors of Aβ accumulation. 
These findings indicated that once initiated, the degree of Aβ accumulation was less pronounced 
in APOE-e2 allele carriers and that its protective effect was greater in males as compared to 
females. This study provided the first neuroanatomical evidence of different factors being 
involved in the initiation and propagation of amyloid plaques.  
Of relevance, research currently is uncertain as to whether Aβ accumulation is itself a 
risk factor or whether Aβ accumulation is an early biomarker/detectable stage of AD (see 
Sperling et al., 2011). Knopman et al.’s (2013) novel cross-sectional findings suggest that brain 
injury biomarkers may precede or be independent of β-amyloidosis within preclinical stages of 
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AD. In this study, cognitively intact individuals with and without presumed preclinical AD 
pathology did not differ in their brain injury biomarkers (e.g., lower hippocampal volume or 
reduced glucose metabolism as measured by positron emission tomography), cardiovascular, or 
cerebrovascular characteristics. Rather, AD suspected as compared to non-Alzheimer pathway 
(characterized as individuals with brain injury but normal brain β-amyloidosis) groups only 
differed in their ratio of APOE-e4 carriers and the presence of β-amyloidosis. Results from this 
study suggest that brain injury might occur independent of β-amyloidosis within AD suspected 
pathology, and also potentially indicates that these factors interact in such a way that might 
accelerate pathological processes. Similarly, Jack et al.’s work (2015) strongly indicates that 
pathological processes other than β-amyloidosis cause declines in brain structure and memory 
function in middle age. Such findings are extremely relevant to the field as they suggest that 
preclinical stages of MCI/AD presumed pathology might have multiple etiologies that occur 
independent of β-amyloidosis. In this respect, linking relevant genetic, behavioral health and 
mental risk factors to specific neurocognitive profiles can inform research that might lead to 
earlier intervention entry points, which in turn may prove to have more success than current 
interventions in slowing and/or altering the progression of MCI/AD pathology and its 
debilitating effects. 
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CHAPTER 2: LITERATURE REVIEW 
Investigating Within and Between Neurocognitive Domain Variance 
It is recognized that developmental changes in neurocognitive functioning are diverse and 
sometimes widespread within older adults. Notably, executive functioning, attention, processing 
speed, episodic memory, and language abilities are the neurocognitive processes that have been 
proposed to be the most sensitive to age-related changes and to the early stages of AD 
(Weintraub et al., 2009). An important limitation within many studies to date is the lack of 
comprehensive neurocognitive evaluations in examining change over time in relation to relevant 
risk variables that have demonstrated significant interactions with one another (e.g., many have 
used gross screener measures of cognitive functioning, such as the Mini Mental State Exam: 
MMSE; Folstein et al., 2001). Relevantly, while measures such as the MMSE are useful in 
detecting stages of change within individuals with dementia, the MMSE has been found to lack 
sensitivity in detecting those with mild cognitive impairments (for review, see Mitchell, 2009). 
Furthermore, use of such measures can result in a lack of specificity in identifying the nature of 
cognitive impairments, as they are not capable of identifying which neurocognitive processes are 
first affected within individuals at risk for a dementia disorder.  
Another issue that arises is that there is significant variation within the amount and 
degree of neurocognitive changes that can occur with “normal” aging. Although there are some 
studies to suggest that older adults demonstrate significant neurocognitive impairment on 
neuropsychological tests compared to younger adults, other studies suggest that older adults’ 
neurocognitive functioning is generally well preserved; and, in some cases older adults have 
been shown to perform as well if not better, than younger adults on certain neuropsychological 
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tests (see Glisky, 2007). For instance, while language-processing deficits have been observed 
when older adults are faced with rapid speech rates, overall language abilities appear intact and 
oratory skills are frequently better within normal aging adults (for review, see Wingfield & 
Stine-Morrow, 2000). A review of the normative data from the Wechsler Adult Intelligence 
Scale – Third Edition (WAIS-III) suggests that over-learned “crystallized” skills (verbal 
comprehension index and arithmetic tests) appear to be the least affected by advanced age, while 
measures of fluid intelligence and processing speed (Digit Symbol) show the greatest age effects 
(Wechsler, 1997; as cited in Lezak, Howieson, & Loring, 2004). Taken together, language 
abilities and “over-learned material” appears to be relatively preserved within normal aging older 
adults; whereas, as will be discussed next, executive functioning, attention, and processing speed 
appear to be more impacted with advanced age.  
With respect to memory, the findings regarding memory and aging have been mixed. For 
the purpose of this study, we will specifically focus on two aspects of long-term explicit 
memory. There is evidence that there is an initially a steep decline in episodic memory (defined 
as the ability to deliberately recall contextual information for specific events and situations) that 
occurs with advanced age, whereas semantic memory (i.e., the ability to retain knowledge about 
facts and deeply learned materials and/or historical events, such as birth dates) appears to stable 
in non-diseased brains (Zacks, Hasher, & Li, 2002). Importantly, while both semantic and 
episodic processes generally recruit similar processes for encoding, there appears to be 
differences in their underlying neural storage systems that suggest that they are partially 
dissociable (see Vargha-Khadem et al., 1997). Furthermore, as will be discussed, successful 
memory recall with age also appears to differ as a function of individual differences in age-
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related shifts recruitment and neural resources. Finally, while memory declines have been noted 
as part of the normal aging process, there is longitudinal research that suggests significant 
impairment on tests of episodic and semantic memory is rare within healthy aging older adults 
(aged 65 to 94 years), and thus verbal memory declines are a potential indicator of early disease 
pathology (Hickman et al., 2000).  
Upon closer examination of respective neurocognitive processes, neuropsychological 
measures that are presumed to tap frontal and superior parietal lobe functioning in particular 
have demonstrated increased age-related decrements (see Raz, 2000; 2004). Specifically, 
working memory, attention, and executive functioning (e.g., tasks that require set-switching) 
appear to be substantially impacted with advanced age (for review, see Grady, 2012).  Here, it is 
worth noting that working memory deficits within older adults are still poorly understood, as it 
appears to have significant overlap with both executive function and attentional processes (Raz, 
2000). In this respect, the difficulty of the working memory task appears to play an important 
role in performance decrements in older adults. Accordingly, decreased attentional resources, 
deficits in information processing speed, and poor inhibitory control all have been posited to play 
a role in working memory deficits that have been observed within older adults 
neuropsychological test performance (Glisky, 2007). Furthermore, there is evidence to suggest 
that slower processing speed, poorer executive functioning and attention contribute to the age-
related decrements in other neurocognitive functions (see Salthouse, 2000; Salthouse, Atkinson, 
& Berish, 2003; Verhaeghen & Cerella, 2000). 
The relationship between processing speed, poorer executive functioning and attention 
with changes in other neurocognitive processes is not surprising, considering well-evidenced 
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information process models that have demonstrated attention and cognitive control of 
information selection is necessary for successful memory encoding and thus its subsequent 
storage and retrieval (Smith & Kosslyn, 2010). Still, to date, the majority of studies have been 
cross-sectional, so the degree to which these relationships actually reflect changes in 
neurocognitive functioning over time remains uncertain and there also is considerable 
heterogeneity within older adults’ neuropsychological test performance. In this regard, better 
understanding between neurocognitive-domain covariance (particularly between executive 
functioning and attention with language and memory functioning) within older adults in relation 
to factors that predict longitudinal changes within these processes remains an important area of 
study. 
Interplay between neurocognitive domains. Executive function, which appears to be 
compromised in elderly who exhibit early signs of MCI, has an inhibitory influence on attention 
and working memory processes (Grady et al., 2003; Heun et al., 2007; Morris et al., 2001). Of 
relevance, the relationship between executive function and other neurocognitive systems, 
particularly attention, appears to be bidirectional, in that intact executive functioning not only 
involves frontal lobe recruitment but also requires recruitment of non-frontal lobe regions (for 
review, see Alvarez & Eugene, 2006). For instance, a gold standard test of executive function 
(i.e., the Wisconsin Card Sorting Task: WCST) has been shown to activate numerous regions to 
include: the inferior parietal cortex, temporal-parietal association cortex, and occipito-temporal, 
temporal pole, and occipital cortices (see Alvarez & Eugene, 2006). Similarly, brain imaging 
studies have found that the Stroop, a test widely used to assess for frontal lobe dysfunction, has 
been associated with activation not only in its expected frontal lobe networks, but also activated 
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the middle frontal gyrus, parietal lobe regions, motor areas, and temporal lobe regions (see 
Alvarez & Eugene, 2006). Moreover, brain-imaging studies have found that phonemic tests of 
verbal fluency activate the parietal lobes, thalamus and temporal lobes, in addition to their 
hypothesized frontal lobe networks (see Alvarez & Eugene, 2006). Overall, these and other 
results indicate that executive function and attention processes have significant overlap in their 
underlying neural substrates, and that respective neurocognitive processes are reliant on one 
another for optimal functioning. All considered, taking a more fine-grained approach to 
understanding the interplay between specific neurocognitive processes in older adults may be 
fruitful in identifying which factors best predict risk for early neurocognitive decline in 
preclinical MCI/AD individuals.   
Relevantly, age-related variability in neurocognitive functioning may be explained by 
shifts in neural resources and individual differences in potential compensatory mechanisms (e.g., 
Cabeza et al., 2001, 2002, 2004; Grady et al., 2003). The next section(s) will build on these 
findings and provide evidence to support the hypothesis that a substantial amount of the variance 
found in higher-level cognitive processes within cognitively intact older adults may be explained 
by differences in compensatory mechanisms that are related to executive function and attention 
capacity (and posited underlying differences in neural and cognitive reserves).   
Individual differences in neurocognitive functioning with advanced age. There is a 
growing consensus that variability in normal age-related neurocognitive changes may be 
explained by shifts in neural resources and individual differences in potential compensatory 
mechanisms (e.g., Cabeza et al., 2001, 2002, 2004; Grady et al., 2003). Importantly, these neural 
changes are considered to be adaptive processes when they are connected to better 
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neurocognitive performance. For instance, a review of fMRI language studies suggests that, in 
healthy aging brains, older adults selectively recruit non-traditional language areas to 
compensate for age-related changes in the brain in order to maintain language stability 
(Wingfield & Grossman, 2006). Specifically, interconnected regions that are associated with 
attention and executive control (left dorsal inferior frontal and right temporal-parietal regions) 
appear to be upregulated in conjunction with reduced language center activation (left temporal-
parietal activation) in older adults who maintain good intact language comprehension 
performance as compared to younger adults (Wingfield & Grossman, 2006). These findings are 
in line with those who have argued that age-related decrements in language processing are a 
function of changes in working memory, attentional control and/or processing speed (see 
Wingfield & Stine-Morrow, 2000). Taken together, maintenance of language abilities appears to 
be reliant on the plasticity of neural networks, and the integrity of systems involved in attention 
and executive control. Thus, it may be that the rate of decline in attention or executive 
functioning processes would predict later declines in language abilities. 
 Similar to language functioning, memory functioning also appears to be highly reliant on 
the plasticity of neural systems. Older adults who demonstrate better neurocognitive performance 
on cognitively demanding memory source tests appear to display increased bilaterality within the 
PFC, as compared to older adults with poorer memory functioning who recruited similar regions 
as young adults (right lateralized PFC activation as measured by PET scans; Cabeza, Anderson, 
Locantore, & McIntosh, 2002). These authors suggest that this decreased lateralization in higher 
performing older adults is adaptive in that it serves to compensate for age-related neurocognitive 
decline. These findings are consistent with other studies that have found evidence of age-related 
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differences in bilateral compensation in prefrontal activation during memory recall tasks. For 
instance, while younger and older adults both demonstrate activation in left parietal and temporal 
regions during verbal memory tasks, during episodic memory retrieval and working memory 
tasks older adults show greater bilateral prefrontal activity as compared to younger adults who 
display lateralized prefrontal activity during the task (for review, see Grady & Craik, 2000). 
Additionally, evidence for differences in activations to working memory, visual attention and 
episodic retrieval tasks in younger versus older adults via fMRI has also been found (Cabeza et 
al., 2004). Across all three tasks the older adults showed weaker occipital activity along with 
stronger prefrontal and parietal activity than the younger adults. Behaviorally, older adults as 
compared to younger adults were as accurate but slower on the majority of neuropsychological 
tasks. Of further interest, although not anticipated, greater activation within parietal regions and 
decreased activation within the hippocampal formation was also found in older as compared 
younger adults within all three of the tasks. Of relevance, the reduction in occipital activity 
(which may be an indicator of sensory decline) and the increased parietal activity in tandem 
appears to suggest a compensatory age-related shift from ventral stream to dorsal stream 
processing (Cabeza et al., 2004). Overall, this research suggests that the dorsal stream pathway 
and frontoparietal network become increasingly important with age, as they may serve to 
compensate for declines in other neurocognitive processes that occur with advanced age.  
In sum, there is evidence to suggest that changes in executive functioning and attention 
could give rise to episodic memory and language dysfunctions, as memory retrieval and semantic 
knowledge requires intact frontal lobe function. Dementia in AD is cognitively characterized by 
vast dysfunctions in memory that are accompanied by deficits in language and semantic 
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knowledge, executive functions, attention, and constructional and visuospatial abilities (see 
Bondi et al., 2008). It is plausible that lowered executive function, attention, and processing 
speed abilities heralds difficulties in memory and language functioning in a subset of older adults 
with suspected dementia or AD pathology, whereas, in those without underlying vulnerabilities 
within the brain regions associated with these functions are able to successfully compensate for 
normal age-related shifts in neural resources.  
Neural regions affected in MCI/AD. Although memory impairments and temporal 
atrophy particularly within the hippocampus and the entorhinal cortex are considered a hallmark 
of AD pathology (Raz, 2000), there is increasing evidence that executive function and attention 
in addition to memory are disrupted early on in MCI/AD. A novel view is that the earlier stages 
of AD may be better predicted through examination of parietal lobe functioning and changes in 
its connectivity (for review, see Jacobs, Van Boxtel, Jolles, Verhey, & Uylings, 2012). As 
discussed, theories regarding AD suggest that beta-amyloids trigger a cascade of biological 
events and that amyloid accumulation is the predominating view of the biochemistry of AD. 
There is research to suggest that the posterior association cortices are the first to be affected by 
amyloid plaques in AD, and that observed hypometabolism within the medial parietal areas 
appears to be effective at discriminating AD patients from control participants (Jacobs et al., 
2012).  
Damage to the parietal lobe (particularly posterior regions) affects a wide range of 
functions to include attentional, memory retrieval, movement perception and visuospatial 
relationship judgment processes (Pinel, 2013). Grey matter loss in the posterior parietal cortex is 
found in patients with MCI (Jacobs et al., 2012). Atrophy of the posteromedial (precuneus) and 
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inferior parietal lobule have been consistently found within longitudinal studies that have 
investigated conversion rates to AD, and evidence for posterior parietal lobe involvement has 
been found in studies that have investigated individuals with neurocognitive decline without a 
diagnosis of MCI or AD (Jacobs et al., 2012). Loss of white matter integrity within tracts that 
innervate this region have also been found in patients with MCI, and although not consistently 
found there is also evidence for reductions in parietal white matter in MCI when compared to 
healthy controls (Jacobs et al., 2012). Parietal white matter hyperintensities are also pronounced 
in MCI patients (Jacobs et al., 2012). Notably, the composition of myelin within the parietal 
areas may be more vulnerable to toxicity and disease processes (for reviews, see Bartzokis 2011; 
Jacobs et al., 2012). It is also worth noting that APOE-e4 carriers have been shown to have lower 
myelin repair and maintenance capacities in the areas most affected by AD pathology, and lower 
white matter and gray matter volume within these regions (precuneus, posterior/middle 
cingulate, lateral temporal, and medial occipitotemporal regions) is evident as early as two 
months year old in infant carriers (for review, see Bartzokis 2011; Dean et al., 2014; Jacobs et 
al., 2012). In sum, there is evidence that factors other than temporal atrophy contribute to the 
early pathogenesis of MCI/AD. 
Behaviorally, dysfunction in frontoparietal functioning has been linked to worse 
executive attention performance on the Attention Network Test in individuals with MCI (Van 
Dam et al., 2013). In comparing relatively healthy aging adults to individuals with MCI, there is 
longitudinal research that suggests that identification of wide spread neurocognitive impairments 
on tests of executive function, processing speed, language, visuospatial, and attention is a better 
indicator of underlying neurodegenerative decline than memory alone (Johnson et al., 2012). 
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Similarly, another longitudinal study found that in addition to verbal memory, semantic/language 
processing (category fluency) and visuospatial construction tests were the best early behavioral 
markers of MCI in preclinical older adults over the age of 80 (Howieson et al., 2008); however, 
the sample mean age for this study was relatively restricted (Mean age at study entry = 83). 
Furthermore, a systematic review of preclinical AD provides evidence of subtle deficits in 
learning and memory, executive functioning, processing speed, attention, and semantic 
knowledge that are apparent on neuropsychological tests prior to disease states; relevantly, this 
study also indicated that specific impairments in episodic memory are a sensitive predictor in 
identifying those at higher risk for AD (Bondi et al., 2008). From interpretation of these and 
other findings (e.g., Albert, Moss, Tanzi, & Jones, 2001; Grober et al., 2008; Rapp & Reischies, 
2005), it would follow that executive function and attention processes, which have been shown 
to rely on frontal and frontoparietal network functioning (Koenigs, Barbey, Postle, & Grafman, 
2009), would be significantly affected in those with MCI, and dysfunction within this region may 
be evident prior to MCI diagnosis and visible impairments in other functions. 
All considered, as neurocognitive processes appear to somewhat rely on one another, 
observed deficits seen in typically spared processes within older adults may to some extent 
reflect difficulty in neural recruitment or connectivity within attention network and frontal lobe 
systems. Taken together, individuals with preexisting vulnerabilities within these neural regions 
would be expected to have a steeper age-related decline on neuropsychological tests that serve as 
proxies of functioning within these regions, and that over time more wide spread neurocognitive 
impairments in memory and language processing becomes evident as function of increased 
neurocognitive demands within the preclinical stages of MCI.  
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Cognitive Aging Theories: Compensation versus dedifferentiation of neurocognitive 
functioning. A challenge within the field is differentiating normal age-related changes from 
presumed disease related changes in neurocognitive functioning (e.g., determining the extent to 
which greater activations, particularly within left prefrontal cortex regions, represent successful 
compensatory mechanisms as compared to undifferentiated-diffuse activity). Important changes 
in neuroanatomical structures that occur with advanced age include decreases in white and gray 
matter1, loss of functional connectivity, irregularity in blood flow in various regions of the brain, 
changes in plasticity and neurogenesis as well as alterations in neurochemistry (see Raz, 2000; 
Cabeza, 2001, 2002). One theory is that vast age-related changes in non-diseased brains are 
indicative of neural/brain compensations (as evidenced by greater activations in regions other 
than would be expected by the task or greater bilateral activation) that occur throughout different 
regions of the brain in dynamic and complex ways that can serve to decrease age-related declines 
in neurocognitive functioning (Cabeza, 2001, 2002). However, there is some question as to 
whether or not neural compensations represent “successful” compensation or aberrant 
dedifferentiation of neural functioning in older adults (e.g., Li, Lindenberger, Frensch, 2000). In 
order to unravel this question, more longitudinal research on neural functioning and behavioral 
changes in neurocognitive functioning is needed across a broad range of cognitively intact older 
adults.  
 
                                                 
1 Decreased gray matter volume is believed to be more a function of neuronal shrinkage than  
neuronal loss within non-diseased aging brains. 
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Importantly, changes in neural recruitment and functional connectivity are seen as both 
part of the normal aging process and can also be related to disease pathology (e.g., aberrant 
plasticity; see Albers et al., 2014). The dedifferentiation hypothesis posits that heightened 
correlations observed between different neurocognitive domains with advanced age are evidence 
of a loss of specialization of functioning, rather than evidence of compensatory mechanisms 
(often referred to as “dedifferentiation” when the greater activation is paired with worse 
neurocognitive performance; see Grady & Craik, 2000). Notably, there is research to suggest that 
dedifferentiation and compensation theories are not mutually exclusive. As discussed, the 
maintenance of neurocognitive performance observed in Cabeza’s and others work may 
potentially reflect greater neural plasticity as indicated by the greater bilateral activation within 
the prefrontal and parietal regions within the relatively higher functioning older adults. Or 
alternatively, and not incompatible with the former, lower functioning older adults may have less 
cognitive reserves and/or greater neural vulnerability due to changes in their neurochemistry that 
affects functioning in the regions which may serve to compensate for normal age-related changes 
in brain functioning. Indeed, loss of efficiency in dopaminergic functioning and its associated 
pathways is tied to mild cognitive impairments with advanced age; and, as neural efficiency 
decreases neurocognitive impairment becomes more evident (Li, Duncan, Mcauley, Harmer, & 
Smolkowski, 2000; Li, Lindenberger, & Sikstrom, 2001). Thus, in preclinical stages of diseased 
brains, greater activations may be an indication of greater burden upon these processes. The later 
example is consistent with evidence that the early preclinical stage of MCI/AD is different from 
normal brain aging.  
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Scaffolding theory is somewhat integrative of these two theories in that it posits observed 
increased functional activity in older adults is due to the process of compensatory scaffolding, 
that is throughout the lifespan there is dedicated neural circuitry that helps individuals to acquire 
and learn new skills; once, skill acquisition occurs there are shifts in neural recruitment to the 
same cognitive task suggesting that the neural regions involved in the guiding learning are no 
longer recruited/required once cognitive demands are decreased (Park & Reuter-Lorenz, 2009; 
Petersen, Mier, Fiez, & Raichle, 1998). According to the scaffolding theory of aging and 
cognition (STAC), compensatory neural recruitment (particularly the PFC) occurs in response to 
increased cognitive demands in order to restore homeostatic cognitive functions within aging 
brains (Park & Reuter-Lorenz, 2009). Relevantly, scaffolding occurs in response to increased 
cognitive demands that are a function of age-related as well as pathology related declines in 
neural structures and their function. An important component to STAC, which is in accord with 
cognitive reserve models, is that it helps to account for the significant variability seen with 
advanced age in that the efficiency of scaffolding appears to be moderated by factors such as 
intelligence and education. STAC is also harmonious with the notion that overlearned skills, 
such as language processing, should not be as affected by normal age related changes in 
neurocognitive functioning.  
In relation to presumed MCI/AD pathology, there is evidence to suggest that greater 
activations may initially serve to help individuals compensate for neurological decline. For 
instance, increased activation in task positive regions and reduced deactivations in task negative 
regions are associated with better visual memory encoding within non-demented older adults 
with Aβ accumulation (Elman et al., 2014). These results (and others) support the notion that 
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increased activations, at least initially, serve as compensatory mechanisms in the face of 
pathological processes. However, as disease burden along with normal age-related decrements 
within parietal and frontal networks increase, wider spread neurocognitive deficits become more 
evident. This suggestion is also in relative accord with Bookheimer et al.’s (2002) finding that 
greater magnitudes of left hemisphere base-line brain activation predicted the degree of 
subsequent memory decline two-years later.  
As Park & Reuter-Lorenz (2009) discussed, in order to determine whether increases in 
neural activation and regions recruited are adaptive, one needs to assess the function for which 
these neural changes are compensating. In comparing neurocognitive profiles of patients with 
mild AD to cognitively intact older adults, who are in turn compared to younger adults – there 
are notable differences and similarities within the older adult groups (Sperling et al., 2003). 
Within AD patients, less bilateral activation in the hippocampal formation during encoding of 
complex visually presented stimuli (NvF condition) and less right hemisphere activation in the 
hippocampal formation during encoding of novel as compared to familiar (NvR condition) visual 
stimuli when the complexity was held constant was noted. However, bilateral activation in the 
medial parietal cortex (precuneus), the right posterior cingulate, and the superior frontal cortex 
regions during memory encoding of face-name associations when compared to cognitively intact 
older adults was also observed in patients with mild AD as compared to the cognitively intact 
older adults. Interestingly, in comparing these same relatively healthy older adults to younger 
adults, no differences in hippocampal activation during the NvF task were noted. Older adults 
also demonstrated greater activation in parietal regions, and less right but not left hippocampal 
activation as compared to younger adults during the NvR task. Furthermore, the non-AD older 
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adults demonstrated significantly less activation in both superior and inferior prefrontal cortices 
during memory encoding in the NvF when compared to the younger adults.  
Somewhat similar effects have been found in cognitively intact APOE-e4 allele carriers, 
in which APOE-e4 allele carriers as compared to APOE-e3 allele carriers demonstrate 
significantly greater activation within the left prefrontal and bilateral orbitofrontal, superior 
temporal, and inferior and superior parietal regions in response to memory recall tasks; these 
effects were not found during the resting or active-learning state (Bookheimer et al., 2000). 
Notably, this baseline measurement of increased left hemisphere activity (as measured by blood 
oxygen level-dependent: BOLD signal intensity) associated with subsequent memory decline at 
the two-year follow-up. Individuals with the APOE-e4 allele as compared to those with the 
APOE-e3 allele also displayed significantly worse delayed memory performance [as measured 
by Wechsler Memory Scale (WMS) Logical Memory Delayed Recall]. These authors concluded 
that this greater and less focal activation within the ROIs is an indication of greater cognitive 
load within the APOE-e4 allele carriers during the memory task; and, that this increased neural 
activity may be a result of neural compensatory mechanisms attempts to restore memory 
performance to normal levels.  
Relevantly, decreased activation in response to memory tasks in APOE-e4 carriers has 
also been found. In cognitively intact individuals with a family history of AD (at least one 
biological parent), decreased activity in the hippocampus and MTL in response to memory tasks 
was detected in APOE-e4 carriers as compared to non-carriers (Trivedi et al., 2006). Notably, 
within this study, greater left anterior MTL activation positively associated better encoding 
performance in the non-carriers but not in the APOE-e4 carriers. However, despite these 
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differences in activations the APOE-e4 carriers as compared to non-carriers did not differ in their 
neuropsychological task performance. Consequently, it could be argued that the greater 
activation could be interpreted as being an indicator of greater cognitive load within the non-
carriers – however, this explanation would not be harmonious with the finding of greater left 
MTL activation positively associating with better encoding performance within the non-carrier 
group. Thus, the authors concluded that the observed lower activity in APOE-e4 carriers is an 
indication of early biological changes within the MTL (e.g., disruption of the relationship 
between MTL and learning) that precede observable declines in neuropsychological test 
performance.  
Right-left asymmetrical differences (particularly within medial temporal lobe regions) 
have been reported in patients with AD, and a review of the imaging literature provides some 
support for APOE-e4 allele playing a role in asymmetrical damage to the left medial temporal 
lobe regions within AD patients that is also evident in cognitively intact APOE-e4 carriers (for 
review, see Lehtovirta, Laakso, Frisoni, & Soininen, 2000). In cognitively intact older adults and 
in patients with AD, the APOE-4 allele also appears to play a role in hemispheric asymmetry in a 
region of the medial temporal lobe that is believed to be first affected in AD (entorhinal cortex 
thickness right > left; Donix et al., 2013). Notably, the opposite effect has also been found, as 
there is evidence of a dose dependent effect of APOE-e4 on hippocampal volume asymmetry in 
patients with AD; such that, a reverse effect of greater left than right hippocampal volumes are 
found in homozygous APOE-e4 carriers, while in those with only one APOE-e4 allele 
asymmetry appears abolished and within non-carriers greater right than left asymmetry within 
the hippocampus appears disturbed (Geroldi et al., 2000). All considered, individual differences 
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in early asymmetrical hemisphere damage may at least to some extent explain both the greater 
activations within left hemisphere processes and reduced right hemisphere activations in mild 
AD and APOE-e4 carriers.  
Overall, these finding emphasize the need for more research on specific neurocognitive 
changes over time across a broad range of older adults with and without signs of neurocognitive 
impairment, before any solid conclusions on age-related changes in neural recruitment may be 
made. Problematically, differences found in regards to neural activations across studies could be 
related to a host of potential moderating factors (e.g., differences in genetic predispositions, 
health or demographic differences), different methodologies used and brain regions examined, 
and/or could potentially be reflective of individuals farther along on the continuum to MCI/AD 
pathology (see Grady, 2012). Thus, it is difficult to determine what differences in activations 
across studies means with any certainty. Notably, as deficits in any neurocognitive process can 
lead to impairments in functioning with widely different manifestations across individuals, 
research that longitudinally investigates within and between neurocognitive domain variance in 
relation to relevant risk factors in older non-demented adults is clearly needed.  
Relevant Predictors of Neurocognitive Functioning within Older Adults 
 Although there are mixed findings in regards to the APOE-e4 allele, there is clearly a link 
between neurocognitive functioning and APOE-e4 carrier status. There is research to suggest 
that APOE-e4 carrier status differentially associates with neurocognitive functioning in 
individuals with mild AD as well in relatively healthy older adults. Specifically, a cross-sectional 
study found a pattern of greater medial temporal lobe (MTL) atrophy was coupled to greater 
reported impairments in memory functioning within APOE-e4 carriers, whereas greater 
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frontoparietal atrophy was coupled to greater impairment on tests related to working memory, 
attention, executive control, and verbal fluency in non-carriers (Wolk et al., 2010). In non-
clinical older adults, longitudinal research on the effects of APOE-e4 suggests that it exerts its 
effects on memory early on, as APOE-e4 carriers’ memory functioning significantly diverges 
from non-carriers prior to the of age 60 (Casselli et al., 2009). Interestingly, within this study, 
worse visuospatial perception (as measured by Judgment of Line Orientation) also displayed a 
trend relationship with APOE-e4 carrier status, thereby indicating that right hemisphere 
dysfunction is evident early on. These results provide initial evidence that the underlying 
mechanism and the extent of memory and/or executive attention related deficits within mild AD 
might differ as a function of genetic risk, and suggest that there may be early identifiable 
subtypes of MCI/AD (with different trajectories of neurocognitive decline with corresponding 
neural networks). In this regard, research that increases our understanding of the interplay 
between memory, language, executive function, attention, processing speed, and working 
memory functioning over time in cognitively intact older adults may lead to better identification 
of individuals who are displaying early signs of cognitive decline prior to MCI/AD conversion.  
Genetic risk and its interaction with other risk factors for AD/MCI. Despite the 
APOE-e4 allele being the strongest known genetic risk factor for AD there is substantial 
variability within the findings that may be better understood through investigation in individual 
differences in demographic, cognitive reserve, and health related risk factors. To begin, while 
greater age remains a robust independent predictor of MCI/AD, the overall risk for AD appears 
to decrease after the age of 90 (Lautenschlager et al., 1997) and neither the APOE-e4 nor the 
APOE-e2 alleles are associated with incidence rates for dementia or AD in individuals aged 90 
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and older (Corrada, Paganini-Hill, Berlau, & Kawas, 2013). Additionally, as already discussed, 
there is evidence to suggest that the APOE-e4 allele exerts its effects early on prior to MCI or 
AD being present. Consistent with this notion, the odd risk of AD among APOE-e4 allele 
carriers appears to have a curvilinear relationship with age (Farrer et al., 1997). Furthermore, 
within this same large meta-analysis (k = 40) that assessed several demographics factors that 
might contribute to the considerable amount of mixed findings regarding APOE carrier status 
within the AD literature found that age, sex and race differentially influenced the relationship 
AD and APOE genotype (Farrer et al., 1997). Notably, the effect of sex (being female) was 
related to an increased risk of AD across genotypes as well as there being a significant 
interaction effect between APOE-e4 and sex (i.e., females with an e4 allele carried a 1.5 times 
greater risk) even after controlling for age. Race differences were also noted within this study, 
across a series of racially diverse studies representing African Americans, Caucasians, Hispanics, 
and Japanese, a significant relationship between APOE-e4 allele carriers and AD was found; 
however, this effect appeared to be somewhat weaker within African Americans as compared to 
Caucasian carriers and strongest within Japanese carriers (Farrer et al., 1997). The finding that 
genetic risk was somewhat weaker within African Americans as compared to Caucasian carriers 
is of particular interest considering the prevalence rate of AD/dementia disorders is 
approximately two times higher in African American as compared to Caucasian individuals 
(Alzheimer’s Association, 2014). 
Remarkably, women on average carry an inherently higher risk of AD than men (almost 
two-thirds of Americans with AD are women; see Alzheimer’s Association, 2014). Several 
studies indicate that females’ greater longevity when compared to males may be responsible for 
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the higher prevalence of AD in women (Alzheimer’s Association, 2014). However, there is 
research to suggest that females’ relatively longer life span cannot entirely explain the higher 
prevalence rate (Lautenschlager et al., 1995). Notably, within the oldest old, the APOE-e4 allele 
is significantly associated with increased prevalence of dementia and AD in females but not 
males, such that the odds ratio of female APOE-e4 allele carriers having dementia or AD was 
twice that of APOE-e3/ε3 carriers (Corrada et al, 2013). Altmann, Tian, Henderson, and Greicius 
(2014) also recently found that while the conversion risk from healthy to MCI and from MCI to 
AD was significantly greater in APOE e4carriers, overall the conferred genetic risk was 
substantially greater within women as compared to men. 
It is important to note that the relationship between sex and APOE-e4 carrier status on 
AD outcomes has been mixed. Some studies have failed to find a interaction between sex and 
carrier status (Combarros et al., 1998; Corder et al., 1995), while other studies have found that 
male as compared to female APOE-e4 allele carriers had twice the relative risk of AD (Qiu et al., 
2003) and, once age is adjusted, a greater relative risk of AD associated mortality (Dal Forno et 
al., 2002). It is also worth noting that Corrada et al. (2013) study found sex differences in regards 
to the protective effects of the APOE-e2 allele, in favor of women (i.e., male APOE-e2 carriers 
had an increased odds risk of dementia and AD, whereas female APOE-e2 carriers had decreased 
odds risk). In all these studies emphasize the need for a more comprehensive investigation of sex 
differences in relation to genetic risk and neurocognitive decline in older adults. 
On average the prevalence of AD is significantly higher in African Americans and 
Latino/as as compared to Caucasians (Alzheimer’s Association, 2014). While there is much 
debate regarding the factors underlying this heightened degree of risk in minority populations, 
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there is evidence that health-related risk factors (e.g., cardiovascular risk) and/or psychosocial 
factors (levels of education) contribute to this heightened risk for AD (see Chin, Negash, & 
Hamilton, 2011). Indeed, there is a considerable amount of research that indicates cardiovascular 
disease and diabetes is linked to a heightened AD risk (Alzheimer’s Association, 2014). Such 
findings are also consistent with research that has found that both health-related risk factors and 
levels of education are associated with an increased risk for MCI. A large population based study 
that followed older adults over a three-year period found that increased age, presence of genetic 
risk (APOE-e4 allele), and medicated hypertension all substantially increased risk for MCI; 
whereas, higher education was linked to a significantly lower risk of cognitive decline suggesting 
that it may exert a protective effect against age-related decline (Tervo et al., 2004). Furthermore, 
the combination of the APOE-e4 allele and cardiovascular disease had an additive non-
interacting effect such that odd ratio for conversion to MCI was 3.92 higher in those with both 
risk factors as compared to those without either of these risk factors. Similarly, another large 
longitudinal study that respectively examined predictors of MCI noted that the presence of the 
APOE-e4 allele, race differences (African American individuals having a higher rate of MCI 
than Caucasians), lower educational level, presence of health related risk factors (hypertension, 
diabetes mellitus, and depression) were unique predictors of MCI risk (Lopez et al., 2003). 
Additionally, poor neurocognitive test performance (MMSE and digit coding tests) and positive 
MRI findings (degree of atrophy, ventricular volume, white matter lesions, and infarcts) 
positively associated with MCI.   
Notably, the relationship between APOE-e4 carrier status and specific neurocognitive 
functions within the literature has been equivocal as indicated by a large meta-analysis (k = 38; 
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Small, Rosnick, Fratiglioni and Backman, 2004). While this cross-sectional meta-analysis found 
evidence of worse global cognitive functioning, episodic memory, and executive functioning in 
APOE-e4 carriers, the overall magnitude of APOE-e4 effects on neurocognition were small. 
Notably, potential moderators of sex, race, health, and education were not assessed within this 
meta-analysis. Here, it is worth noting that past research has found that the beneficial effects of 
education on age-related changes in neurocognition has been found to interact with APOE-e4 
allele, such that there is a steeper rate of decline in memory functioning in older adults (aged 70–
79) with an APOE-e4 allele whose educational obtainment is equivalent to or greater than ninth 
grade (Seeman et al., 2005). Furthermore, there is cross-sectional research that suggests that the 
effects of the APOE genotype on memory functioning and cognition in general disappear in non-
demented older adults - once the effects of age, sex and education are adjusted for (Welsh-
Bohmer et al., 2009). In sum, while there is research to suggest that APOE-e4 plays a specific 
role in neurocognitive decline within both mild AD and non-clinical older adult populations, 
studies that systematically assess longitudinal changes in neuropsychological test performance in 
relation to relevant predictors for MCI/AD are strongly needed in order to elucidate whether, the 
degree to which, and in whom, lower initial memory and/or executive function predicts 
subsequent declines in other neurocognitive processes. 
To review, there are substantial mixed findings in regards to the APOE-e4 allele; 
however, it clearly appears to be an important variable whose role in neurocognitive functioning 
needs to better defined. As discussed, the effects of the APOE-e4 and APOE-e2 allele appear to 
change with age, and the degree of risk for MCI or AD conferred from the APOE-e4 genotype 
might vary with race, age and sex. There is also evidence to suggest that older adults without a 
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significant history of health problems experience relatively little cognitive decline (Hickman et 
al., 2000), while cardio- and/or cerebrovasular events are strongly associated with impairments 
in executive function, attention and processing speed and higher rates of decline in language and 
memory functioning (e.g., Okonkwo et al., 2010; Weinstein et al., 2013). Furthermore, 
depression has been linked to a greater risk of MCI and there is research to suggest that 
depression precede memory decline rather than the converse (Zahodne, Stern, & Manly, 2014). 
Lastly, it is important to highlight that demographic, cognitive reserve, and health related risk 
factors appear to make unique contributions to MCI/AD pathology, as well as there being 
significant interactions amongst these factors with APOE-e4 carrier status.  
In summary, individual differences in demographic factors, cognitive reserve (higher 
levels of education and/or intelligence), as well as other health related biomarkers (e.g., high 
cholesterol) and neurocardiovascular risk (e.g., hypertension or history of stroke) appear to 
respectively account for individual differences in neurocognitive functioning. In this regard, 
investigating individual differences in risk variables and their potential interactions may help 
clarify “normal” age-related as compared to disease related decrements in neurocognitive 
functioning. Furthermore, comprehensive investigation of these factors may help explain the 
mixed findings within the literature on APOE genotype and functional outcomes, as these 
variables may act as moderating or potentially suppressor variable(s). All considered, increased 
understanding of the interplay between individual differences in risk factors and neurocognitive 
functioning may lead to improved assessment sensitivity that will allow for earlier detection and 
serve to inform preclinical models of MCI/AD, through providing indicators for potential 
treatment intervention points. 
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Validity Issues in Longitudinal Research 
Before proceeding to the study’s hypotheses, it is important to discuss validity issues that 
were anticipated to be present within this study. First, past research has found that certain 
neurocognitive tests are particularly susceptible to practice effects. Specifically, memory tests 
and/or tests that have a strong psychomotor component to them have been found to have 
substantial practice effects (for review, see Calamia, Markon, & Tranel, 2012; McCaffrey & 
Westervelt, 1995; Mitrushina & Satz, 1991). Consistent with this research, our group has 
previously reported practice effects in measures of memory and attention/processing speed in 
individuals without cognitive decline; of interest, in this same study a subset of participants 
defined as “cognitive decliners” did not benefit from previous exposures to testing and instead 
exhibited a performance decrement in these measures (MacAulay et al., 2014). Thus, while 
practice effects are a relevant concern, our work and others (e.g., Duff et al., 2007) also indicate 
that the failure to benefit from previous test exposure on tests that are susceptible to practice 
effects might serve as an indicator of a decline in that cognitive process. In considering these 
methodological limitations/concerns, the present study anticipated that there would be significant 
practice effects, particularly on tests of memory, and thus it was specifically hypothesized that 
those with lower initial memory functioning would demonstrate less benefit from previous test 
exposures.  
Instrumentation effects must be also considered. When the posited properties of a 
measurement changes with age (i.e., demonstrates factorial variance over time), the conclusions 
made regarding observed changes in such measures might lack validity (Little, 2013). Relatedly, 
another potential issue that can arise in longitudinal research involves the law of initial values – 
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that is, the higher or lower the initial level of functioning, the smaller the degree of change that 
can be produced (e.g., those with higher initial scores may demonstrate less gains over time due 
to their higher start point; Mosby’s online dictionary, n.d.). It is also possible that certain effects 
may be missed in those who are higher or lower functioning due to lack of measurement of 
sensitivity (e.g., pronounced ceiling or floor effects). To address these validity concerns, it is 
important to briefly mention measurement selection. The present study utilized a well-validated 
neuropsychological test battery established by the National Alzheimer’s Coordinating Center 
(NACC), which is frequently used within longitudinal research with older adults, that has proven 
to be sensitive measure of neurocognitive change. Previous confirmatory factor analyses (CFA) 
conducted on the factor structure of the NACC’s Uniform Data Set (UDS) neuropsychological 
test battery has demonstrated a good model fit for the proposed factor structure that is consistent 
with there being strict factorial invariance across a wide range of older adults with varying levels 
of cognitive functioning (e.g., Hayden et al., 2011; Weintraub et al., 2009). 
Study Summary with Aims and Hypotheses 
Of note, there are relatively few longitudinal studies that have concurrently examined 
relevant risk factors for MCI/AD in relation to neurocognitive functioning over time in relatively 
cognitively intact older adults. Using longitudinal data collected at three distinct time points 
spaced approximately a year apart in older adults, the purpose of this study was to help to 
disentangle the relationships between age-related declines in specific neurocognitive processes 
(using objective valid neuropsychological test measures) and theoretically important predictors 
of risk over time in order to better define “normal” as compared to potentially preclinical 
neurocognitive variability. By furthering our understanding of the interplay between these 
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processes, clinical models based on neurocognitive endophenotypes may be built in order to 
determine specific trajectories that increase risk so that individuals at risk for MCI/AD may be 
detected earlier on. Defining the functional relationships between changes in specific 
neurocognitive domains over time also has future research and treatment implications. For 
instance, specifying neurocognitive domains that are affected early on may indicate which 
neurotransmitter pathways are first impacted, which can help to inform future pharmacological 
treatment research (e.g., executive function/attention performance is modulated by dopamine 
functioning and dopamine dysfunction is believed to affect synaptic plasticity which can lead to 
structural changes within the brain). Hypothetically through preventing aberrant plasticity, 
interventions (both pharmacological and behavioral) that target systems involved in these earlier 
changes may slow or ideally impede propagation to other neural systems. Additionally, through 
better understanding the neurocognitive domains that are first affected novel behavioral and 
cognitive remediation techniques may be designed to target deficits within those showing early 
signs of dysfunction (e.g., cognitive remediation strategies to enhance attention allocation). In 
this regard, improved understanding of the interaction between risk factors and neurocognitive 
decline may lead to more effective interventions that can target pathological processes prior to 
AD conversion.  
 This study took a comprehensive approach to examining neurocognitive functioning over 
a three-year period in conjunction with theoretically important predictors of age-related decline 
(demographic, genetic, cognitive reserve, and health related risk factors). Specific aims and 
hypotheses for the study are presented next. 
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 Aim 1: Investigating within and between neurocognitive domain variance 
 Aim 1 sought to better understand the interrelationships between the specific 
neurocognitive processes of memory, executive function, attention, processing speed, language 
and working memory in older adults. Multivariate latent growth curve modeling methods were 
used to examine Memory, Executive Attention/Processing Speed, Language and Working 
Memory functioning over time (Year 1 to Year 3) and to assess whether changes in the 
respective growth trajectories differed as a function of within or between neurocognitive domain 
functioning. Specific goals and hypotheses for these analyses are as follows. 
Within-neurocognitive domain covariance. It was expected that Executive 
Attention/Processing Speed scores would on average demonstrate a decline from Year 1 to Year 
3 (as measured by a negative value for Mslope) within the non-demented older adults. Whereas, 
based on evidence that memory tests in particular are subject to significant practice effects, it 
was hypothesized that on average there would be an increase in memory scores from Year 1 to 
Year 3 as measured by the latent variable, Memory Mslope. Additionally, individuals with initially 
lower Executive Attention/Processing Speed scores would demonstrate a steeper rate of 
decrement than individuals who started with higher Executive Attention/Processing Speed scores 
at baseline (as measured by the within-domain covariance). Similarly, participants’ whose 
Memory performance was lowest as compared to those who were highest at baseline would 
demonstrate a slower rate of growth in memory over time (i.e., will benefit less from practice 
effects as evidenced by a significant within-domain covariance between Memory Mslope and 
Mintercept). Furthermore, based on prior research that has examined the preclinical profiles of 
those that have converted from preclinical to MCI stages (Howieson et al., 2008), it was also 
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expected that individuals with initially lower language performance would display a steeper rate 
of decrements in these functions over time (as evidenced by a significant within-domain 
covariance between Language Mslope and Mintercept). Given the previously discussed mixed 
findings with working memory, no specific hypotheses were made regarding this latent variable 
other than higher initial Working Memory scores were expected to positively associate with the 
other neurocognitive processes at baseline. 
Between-neurocognitive domains covariance at baseline. This set of analyses assessed 
the amount of interplay between neurocognitive domains at baseline. It was hypothesized that 
individuals with higher scores in one neurocognitive domain would on average also be higher in 
the other neurocognitive domains at baseline (and vice versa, those with lower neurocognitive 
functioning in one neurocognitive domain would generally have worse neurocognitive 
performance on all measures at baseline). Specifically, it was expected that individuals with 
initially lower Executive Attention/Processing Speed would concomitantly demonstrate poorer 
Memory and/or Language test scores than individuals with higher initial scores at baseline.  
Between-neurocognitive domains intercept and slope covariances. This set of 
analyses was specifically interested in the degree to which changes in Memory and Executive 
Attention/Processing Speed associates with changes in other neurocognitive processes over time. 
It was hypothesized that initially lower Executive Attention/Processing Speed scores would be 
shown to precede changes in other neurocognitive processes (as measured by the relationship 
between mean levels of Executive Attention/Processing Speed’s Mintercept with the other 
neurocognitive domains’ Mslopes). Exploratory analysis examined whether initial low memory 
functioning predicted steeper annual rate of declines in other neurocognitive processes. 
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Between-neurocognitive domains slope covariances. It was expected that on average as 
Executive Attention/Processing Speed demonstrated steeper decreases over time, so would 
memory and language scores (as measured by covariances between domains’ Mslope). 
Additionally, on average as Memory scores increase from Year 1 to Year 3, Executive 
Attention/Processing Speed and Language scores would increase in accord. Exploratory analysis 
investigated the remaining relationships between changes in neurocognitive domains in relation 
to one another from Year 1 to Year 3.  
Heterogeneity in neurocognitive functioning. It was expected that variance estimates 
(slope, intercept, and random measurement errors) for each of the neurocognitive domains would 
be statistically significant. Such findings would indicate that there were robust between 
individual differences in initial neurocognitive score values and rates of change from Year 1 
through Year 3, and thus provide support for the next set of analyses outlined in Aim 2. 
Competing models utilizing a global neurocognitive latent variable. In the interest of 
parsimony, prior to conducting Aim 2’s analyses, competing models (factor-of-curves and curve-
of-factor latent growth models; see Duncan, Duncan, & Strycker, 2006) utilized a global 
neurocognitive latent variable to determine whether a high order global neurocognitive latent 
factor could better explain the data. These models’ factor structures were contrary to the study’s 
posited four-factor model, in that they assume that the first-order factors (i.e., each respective 
neurocognitive domain) would be better explained by a higher order global neurocognitive latent 
variable’s intercept and slope. 
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Aim 2: Relevant predictors of neurocognitive functioning  
Given mixed findings within the literature in respect to demographic factors (age, race and 
sex), cognitive reserve (higher levels of education and estimated intelligence), health related risk 
factors (e.g., history of heart disease), and genetic risk for AD in relation to neurocognitive 
decline, Aim 2’s analyses were interested in whether, and to what degree, individual differences 
in these risk characteristics might explain heterogeneity within the present study’s posited model 
of neurocognitive functioning. This set of analyses was also interested in the amount of interplay 
between these variables and testing an etiological model of MCI. Thus, both specific (direct) and 
indirect effects of these factors were tested. Specific effects of these factors were modeled first in 
order to account for their respective influence on each of the growth parameters, as well as to 
assess for potential moderating or suppressor effects with their inclusion. Specific goals and 
hypotheses for these analyses are as follows. 
Demographic factors. Given strong evidence for their interrelationships within the 
literature, a goal of Aim 2 was to assess the degree to which age predicts neurocognitive 
functioning when sex and race are adjusted for in the model. It was posited that age would be a 
statistically significant predictor of initial neurocognitive scores at baseline and associate with a 
greater rate of memory and executive attention/processing speed decline from Year 1 to Year 3 
(even when age and sex were adjusted for in the model). Although no specific hypotheses were 
made in regards to race and sex, it was expected that these predictor variables would have a 
moderating influence on neurocognitive functioning. 
Cognitive reserve. While adjusting for the relevant demographic factors of age, race and 
sex, it was posited that the time invariant cognitive reserve variables (greater levels of education 
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and intelligence) would associate with higher neurocognitive functioning at baseline. 
Exploratory analyses also investigated these variables influence on rates of neurocognitive 
change over time. 
APOE-e4 carrier status. Based on previous research that has found that the APOE-e4 
allele preferentially associates with memory decline in MCI and mild AD patients, analyses 
investigated the influence of APOE genotype on specific neurocognitive domains. It was posited 
that while adjusting for relevant demographic factors (age, sex, and education), APOE-e4 
carriers as compared to non-carriers would demonstrate greater Memory impairment at baseline 
and a steeper rate of Memory decrement from Year 1 to Year 3. APOE-e4 carriers as compared 
to non-carriers were also expected to demonstrate a steeper rate of decline in Executive 
Attention/Processing Speed and Language scores over time. Exploratory analysis investigated 
APOE-e4’s relationship with the remaining neurocognitive domains mean levels at baseline and 
their incremental rates of change over the three-year period.  
Given mixed findings within the literature regarding the role of APOE-e4 genotype in 
respect to individual differences in age, race, education, sex, these factors relationship with 
neurocognitive functioning were systematically investigated in conjunction with APOE-e4 
carrier status. Once the relevant risk variables of age, sex, education and race were included 
within the model, it was expected that the effect of APOE-e4 on neurocognitive functioning 
would be attenuated. Sex was specifically expected to have a moderating effect on the 
relationship between APOE-e4 carrier status and neurocognition. No specific hypotheses were 
made in regards to race. 
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Health-related risk factors. There is substantial evidence that health related risk factors 
contribute to neurocognitive decline in older adults. The direct effect of Cardiovascular, 
Cerebrovascular, and Depression/Endocrine risk factors on Memory, Language, Executive 
Attention/Processing Speed, and Working Memory functioning was assessed while adjusting for 
potential moderating variables. It was expected that cardiovascular risk in particular would 
emerge as a strong predictor of neurocognitive functioning and would also associate with APOE-
e4 carrier status. It was also hypothesized that individual differences in demographic factors 
would contribute to the degree of health related risk factors. It was expected that: (1) advanced 
age would associate with a higher amount of health related risk factors, (2) sex and race 
differences would be found in the pattern of health related risk factors, and (3) cardiovascular 
risk in particular would be a strong predictor of neurocognitive functioning and would also 
associate with APOE-e4 carrier status. Exploratory analyses investigated the role of the cognitive 
reserve variables in this model. 
Etiological model of risk of cognitive decline. Based on Ritchie’s (2004) hypothetical 
model etiological model of MCI, the last set of analyses’ goal was to provide an etiological 
model of risk for cognitive decline in healthy older adults through testing the indirect effects of 
age, race, sex, and genetic risk on neurocognition through their impact on health related risk 
factors. According to Ritchie’s model, age-related brain changes predict overall vascular 
pathology/infarctions and MCI. Sex has direct effects on genetic predispositions and lipid 
metabolism, while genetic predispositions have both direct and indirect effects on development 
of MCI through its influence on lipid metabolism, as well as environmental and psychological 
factors (e.g., history of depression or trauma). Environmental and psychological factors, which 
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are influenced by educational and treatment intervention factors (e.g., antidepressants), are 
posited to have direct effects on MCI outcomes. Lipid metabolism is posited to predict 
cardiovascular risk factors (e.g., midlife hypertension) and overall vascular 
pathology/infarctions, which in turn are posited to predict MCI.  
Neurocardiovascular and depression health risk factors. As depression and 
neurocardiovascular factors have been shown to make independent contributions to MCI risk 
(Lopez et al., 2003), the present study was specifically interested in testing two paths of risk for 
neurocognitive decline. The first path of risk represented Neurocardiovascular pathology, while 
the second pathway represented a Depression/Endocrine pattern of neurocognitive risk. In accord 
with this hypothetical etiological model of MCI, within the present study: 
1. Sex, age, race, and genetic risk were presumed to be relevant individual difference factors 
that influence health related risk factors, which in turn a greater degree of health related 
risk factors would directly impact neurocognitive functioning.  
2. Furthermore, within this model, education and intelligence are posited to provide 
cognitive resiliency. Accordingly, the variables of education and intelligence served as 
cognitive reserve variables with specific effects on neurocognitive functioning that were 
adjusted for in the model, while examining the above described effects in Point 1.  
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CHAPTER 3: RESEARCH METHOD AND DESIGN 
Participants 
  This study utilized data collected between 2009-2013 from an on-going longitudinal 
study that investigates the effects of aging upon neurocognitive processes and daily living 
functioning in relatively healthy older adults, the Louisiana Aging Brain Study (LABrainS, PI: 
J.N. Keller). LABrainS is an open enrollment longitudinal study that has been following 
participants since 2009 (overall retention rate of 87%). Participants are recruited throughout 
Louisiana using traditional media sources (e.g., newspaper ads and television and newspaper 
press) as well regular community outreach efforts. Telephone screening procedures are used for 
initial enrollment. Age of enrollment is generally equivalent or greater than 60 years old; 
however, there are some participants who have been classified as higher-risk due to their familial 
status that have been admitted prior to their sixtieth birthday. Eligibility criteria for LABrainS 
requires that participants be willing to undergo annual neurocognitive assessment and have no 
existing diagnosis of dementia or neurocognitive impairment at the time of baseline screening. 
Participants are relatively healthy and cognitively intact (Mini-Mental Status Exam scores: 
MMSE > 25; Folstein et al., 2001) at time of enrollment. Initial (first visit) exclusion criteria for 
LABrainS includes: a Geriatric Depression Scale score ≥ 6 (15 item version; Sheikh & 
Yesavage, 1986), a recent history of cardiovascular, cerebrovascular or neurological (e.g., 
cerebrovascular disease and/or a traumatic brain injury within the past two years) or untreated 
health conditions (e.g., hypertension) that might cause neurocognitive impairment. Participants 
with a history of significant substance abuse or Parkinson’s disease are also excluded. All 
included participants have normal or corrected vision.  
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LABrainS is primarily conducted at the Pennington Biomedical Research Center’s 
Institute for Dementia Research and Prevention (IDRP) in Baton Rouge, LA. Study procedures 
are conducted by well trained, certified research assistants. Each year participants undergo 
informed consent followed by neuropsychological testing in a private testing suite. Participants 
had their blood drawn for APOE genotyping at the end of their visit after all other procedures 
had been completed. Oral and written informed consent were obtained from participants at each 
clinic visit. Pennington Biomedical Center’s Institutional Review Board and Ethics Committee 
approved of the longitudinal study and its data collected for use in research (Appendix B 
provides a copy of the most recent informed consent form).   
 The present study limited participants to age 60 and above. 59 participants under the age 
of 60 (Median = 56.00; range = 40-59; Skew Index = 3.95) were excluded from this study. 
Participants seen at satellite sites (e.g., nursing homes or doctor’s offices) were also excluded. As 
analyses were interested in predictors of cognitive decline, participants who were from families 
considered to be at a relatively higher risk for AD were included if they met all other study 
requirements. Due to a LABrainS protocol change in 2013, only new enrollees were 
administered the full UDS battery that year. In all, there were a total of 694 participants at Visit 
One, with a total N of 556 participants who had complete data on the primary variables of 
interest (with the exception of APOE genotype). Of these 556 individuals, 403 had participated 
in the APOE genotyping. Data analyses examined for potential attrition biases in those with 
incomplete datasets (i.e., study dropouts) and maximum likelihood estimates were compared to 
listwise deletion methods in handling the missing data (for further details on sample 
characteristics and missing data see the Results section).  
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Measures 
Neuropsychological test battery. The Uniform Data Set (UDS), a neuropsychological 
test battery established by the National Alzheimer’s Coordinating Center (NACC), was utilized 
for this study. The UDS test battery consists of brief measures of attention, processing speed, 
executive function, episodic memory, and language that were selected due to their sensitivity to 
detect neurocognitive change in the elderly (see Weintraub et al., 2009). The UDS specific tests 
include: a screener measure of global cognitive functioning (MMSE), Wechsler’s Memory 
Scale-Revised (WMS-R) Logical Memory Story-A Immediate and Delayed Recall, WMS-R 
Digit Span Forward and Backward tests, Category Fluency (Animals and Vegetables), Trails 
Making Test (TMT): Parts A and B, Wechsler’s Adult Intelligence Scale-Revised (WAIS-R) 
Digit Symbol, and the Boston Naming Test (BNT). In addition to the UDS neuropsychological 
test battery, the Clock Drawing Test (CDT) 18-point version was administered (see Babins, 
Slater, Whitehead, & Cherkow, 2008).  
Specific test descriptions follow: 
1. The MMSE is a widely used brief-screening measure for gross cognitive impairment that 
tests orientation, immediate and short-term memory recall, attention/concentration, 
language, and spatial construction. MMSE scores below 25 are believed to be suggestive 
of a dementia disorder. Given the lack of sensitivity of the MMSE in cognitively intact 
individuals, this measure only served as an exclusionary measure for participant selection 
(i.e., MMSE scores > 25 were required for participation). 
2. The WMS-R Logical Memory test assesses immediate and delayed episodic memory 
(Wechsler, 1987). The UDS version of the WMS-R Logical Memory consists of one 
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short vignette (“Story A”) that is read once to participants. Participants are then asked to 
recall the story twice: immediately after it is read, and following a twenty-minute delay 
with a brief story prompt. 
3. WMS-R Digit Span tests are widely used as measure of working memory and are also 
believed to involve attention processes (Wechsler, 1987). The Digit Span Forward test 
requires that participants repeat back a string of numbers in increasing length, while the 
Digit Span Backward test requires one to mentally manipulate the numbers’ order 
through having participants repeat the string of numbers read to them in backwards order. 
Participants receive one point for each string of numbers correctly repeated on these tests. 
Digit span tests are discontinued if the participant makes two consecutive errors at the 
same digit string length.  
4. Category Fluency tests are widely used measures of language fluency and semantic 
memory, however they also require intact retrieval ability and executive function 
(Goodglass & Kaplan, 1983). For the Category Fluency test, participants are given one 
minute to name as many words as they can for the two respectively given categories of 
“animals” and “vegetables”. They receive one point for each newly named item for each 
category test.  
5. The TMT (Trails A and B) is a complex visual scanning timed-task that assesses aspects 
of attention, processing speed and executive function (Reitan & Wolfson, 1993). The 
TMT is highly sensitive to cognitive decline and elderly persons who perform poorly on 
the TMT tend to also demonstrate significant deficits in their daily living skills (Lezak et 
al., 2004). A three (Trail A) and five (Trail B) minute time limit is imposed during the 
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TMT. A practice trial is always administered prior to each trail. For Trail A, participant 
are presented with a scattered array of 25 sequential numbers that appear inside small 
circles and are instructed to connect the numbers in ascending numerical sequence (e.g., 
1, 2, 3, etc.). For Trail B, participants are shown a form with an array of numbers and 
letters in circles and are instructed to connect the number to letters in a progressive order 
(e.g., 1-A-2-B-3-C, etc.). While Trail B is technically similar to Trail A, it involves 
greater cognitive control as the task requires the ability to shift response sets. 
6. In relatively healthy adults, the WAIS-R Digit Symbol (Weschler, 1981) test is largely a 
test of psychomotor speed that also requires sustained attention, processing speed, and 
visuomotor coordination (Lezak et al., 2004). Notably, it has proven to be one of the most 
sensitive (albeit non-specific) measures for brain damage; and has proven to be a good 
predictor of dementia progression (Lezak et al., 2004). The UDS version of the WAIS-R 
Digit Symbol test has slightly enlarged symbols meant for older adult population as 
compared to the standard WAIS-R test. For this task, participants are shown a form that 
has many rows with randomized numbers inside the boxes (“numbered boxes”), below 
these numbered box rows there are rows with blank boxes. At the very top of the page, 
there is a row with numbered boxes in sequential order (1-9) with a row of distinct 
meaningless symbols in boxes below each of the numbers. For the Digit Symbol test, 
participants are informed that each number at the top of the page has its own unique mark 
below it. They are then shown a line of boxes with marks with empty boxes below it and 
are instructed to put marks that correspond to the number above in the empty boxes 
during a practice trial. Following practice, they are instructed to notice the empty rows of 
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boxes with the numbers above them and that they are to put marks that correspond to the 
number above in the empty boxes. They are given 90 seconds to fill in as many boxes as 
they can without skipping any of the boxes. 
7. The BNT is a confrontational naming task that serves as a measure of language 
disturbance and word-retrieval deficits (Kaplan, Goodglass, & Weintraub, 1983). The 
BNT requires participants to verbally name line-drawn objects (e.g., a bed or giraffe). 
The UDS version is reduced to 30 odd-numbered items from the BNT.  
8. The CDT is an untimed test of visuospatial constructional ability that also involves intact 
auditory comprehension (responding to commands) and components of spatial planning  
and working memory (see Price et al., 2011). For this task, participants are required to 
draw a clock according to the following provided verbal instructions, “I want you to draw 
a face of a clock showing all the numbers. I want you to set the clocks hands to ten after 
eleven.” 
Demographic and cognitive reserve predictor variables. Baseline information collected 
regarding participants’ demographic (age, sex, race and education level) and estimated 
intelligence served as time invariant predictor variables. Demographic information was collected 
via clinical interview and the North American Adult Reading Test (NAART; Blair & Spreen, 
1989) was administered as an estimate of intelligence. The NAART is a widely accepted 
measure for estimating premorbid intelligence levels of English-speaking that has demonstrated 
acceptable convergence with other gold-star measures of intelligence (WAIS-Fourth Edition) and 
has been used to estimate intellectual functioning within patients with dementia (Uttl, 2002). It 
comprises 61 words assembled in four columns in order of increasing difficulty that participants 
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were requested to read aloud. NAART words are intentionally relatively short in order to avoid 
over complexity, and are “irregular” in their pronunciation rules to minimize phonemic decoding 
effects (Nelson & Wilson, 1991). Each incorrectly read word counts as an error. Estimated Full 
Scale IQ (FS-IQ) standardized scores are based on the number of correctly read words and 
adjusted age and education norms. 
Health-related risk predictor variables. The UDS Health History clinician administered 
interview form was used to collect information on the participants’ cardiovascular disease 
(CVD), cerebrovascular disease (CBD), neurological (e.g., seizures and/or traumatic brain 
injury), biological indicators of health (hypertension, hypercholesterolemia, diabetes, thyroid 
disease, B12 deficiency), and psychological history at baseline. Baseline information regarding 
participants’ UDS health history formed the time invariant health-related risk predictor variables. 
Health history variables on this measure are categorized as absent, active (defined as within the 
last two years), or remote/inactive (defined as greater than two years). Participants with untreated 
health conditions are excluded from the study. Remote and active health variables were collapsed 
given no significant between-group differences on these outcome variables. Factor analyses were 
used for data reduction purposes before proceeding to the primary analyses. Three health-related 
risk factors emerged from the UDS Health History data: (1) CVD factor (history of CVD loaded 
with biological indicators of hypertension, hypercholesterolemia, and diabetes), (2) 
Cerebrovascular factor (history of CBD loaded with seizures and/or traumatic brain injury), and 
(3) Depression/Endocrine factor (history of a psychiatric disorder loaded with thyroid disease 
and B12 deficiency).  
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 Deoxyribonucleic acid (DNA) extraction and genotyping procedure. The 
dichotomized variable of APOE-E4 carrier status served as a predictor within the Multivariate 
LGC model(s). Genomic deoxyribonucleic acid (DNA) was extracted from blood samples by a 
phlebotomist at Pennington Biomedical Research Center. APOE genotyping was performed 
by polymerase chain reaction (PCR) methodology (using recommended procedures described in 
Mufson et al., 2000). As expected, there were insufficient cases to examine homozygous  
APOE-e4 genotypes. Consistent with the relative frequencies of the APOE genotypes within the 
general population, the frequencies of homozygous APOE-e4 (n = 4) and APOE-e2 (n = 4) 
genotypes were rare (respective frequencies within sample equal 0.7%). Thus, as proposed, 
participants were dichotomized into two genotype groups: APOE-e4 carriers (defined as 
individuals with at least one copy of the APOE-E4 allele: e4/e4; e4/e3; e4/e2; N = 96) or non-
carriers (individuals without an APOE-e4 allele (e2/e2, e2/e3, e3/e3; N = 302).  
Analyses 
Data analyses were conducted over a multitude of steps. Prior to conducting the study’s 
primary analyses via LGC modeling, preliminary analyses examined variable distributions and 
sample characteristics. Next, potential confounds regarding attrition bias, demographic factors, 
and APOE-e4 carrier status were each systematically assessed. Subsequently, the relationship 
between baseline neurocognitive functioning and rates of change of change in Memory, 
Executive Attention/Processing Speed, Language and Working Memory factors were examined. 
Finally, the degree to which the individual differences in risk factors explained heterogeneity in 
neurocognitive function within the present sample was assessed. Specific descriptions for 
analyses undertaken are as follows. 
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Preliminary analyses. Preliminary analyses examined variable distributions and sample 
characteristics. Recommended guidelines for large samples (N > 200; Field, 2009 and Kline, 
2011) were followed in testing whether assumptions of normality were met for each 
neurocognitive variable. Data distributions for continuous variables were visually inspected, and 
index values for skewness and kurtosis were assessed (kurtosis defined as > 10 and skew defined 
as  > 3). To allow for ease of comparison, reaction time (RT) scores on the TMT were reflected 
using the formula [(X – Maximum Test Score +1) * -1] so that higher RT scores reflect lower 
values. Neuropsychological test scores were then converted into z-scores in order to assess for 
outliers within the dataset. Outlier neuropsychological test scores were defined based as per Field 
(2009; i.e., absolute value zs ± 3.29). As removal of outliers may remove true variance that 
introduces bias and retaining extreme outliers can introduce Heywood cases (Kline, 2011), 
Winsorized means (a more robust estimator of the population mean) were used for exceptionally 
extreme z-score values (i.e., extreme values of z ± 3.29 were replaced with the next closest 
observed value in the dataset). Once extreme z-scores were replaced, consistent with previous 
LGC modeling research methods (Johnson et al., 2012), neuropsychological test scores were 
converted to t-scores using the mean and standard deviation from the initial visit [t-score = 10 
(Raw Test Scoreindividual – MeanTime 1/Standard DeviationTime 1) + 50)]. This conversion allows for 
comparison of the parameters of interest and retains any longitudinal change over time. As this 
study was interested in the degree to which demographic factors contribute to the variance within 
the LGC model, neurocognitive test scores were standardized relative to the mean of the entire 
sample, rather than adjusting for age, education, etc.; thereby, allowing these demographic 
factors to be assessed as independent predictors within the LGC model(s).  
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 Potential confounds regarding attrition bias, demographic factors, and genotype were 
assessed via One-Way ANOVAs or chi-square tests prior to the SEM analyses. When Levene’s 
statistic indicated that assumptions of homogeneity were not met, Welch’s F test was used to 
adjust degrees of freedom. Chi-square tests of independence examined for differences in the 
categorical variables (sex, race and health factors). Two-tailed tests were used for all p-values. 
Given evidence of non-random attrition biases that could potentially affect the study outcomes, 
analyses were performed to investigate for differences in enrollees and dropouts on primary 
variables of interest and overall differences in model fit (further details are presented within the 
Result’s section).  
Latent growth curve (LGC) modeling. LGC modeling offers a dynamic and valid way 
of capturing linear changes in cognition over time (see Duncan et al., 2013; Li et al., 2000; 
McArdle & Anderson, 1990). LGC models are typically analyzed in two steps (Kline, 2011). The 
first level attempts to explain the covariances and variances of the repeated measure variables (in 
this case, the latent neurocognitive variables). This first level provides two latent growth 
parameters: intercept and slope (Byrne, 2011). For each respective neurocognitive domain within 
this study, the intercept parameter represents an individual’s level at baseline, while the slope 
parameter represents the rate of change over the three-year period (from visit one through visit 
three) within this domain. LGC model methodology also allows for the examination of variables 
(e.g., APOE genotype) that might explain heterogeneity within these individual growth 
trajectories. The prediction model(s) is also considered a multiple indicators and multiple causes 
(MIMIC) model because the latent factors have both effect and cause indicators (Kline, 2011). 
Another important advantage to LGC is that maximum likelihood methods allow missing data, 
  53
which is assumed to be missing completely at random (MCAR) or missing at random (MAR; 
i.e., missing data does not depend on the measured variables of interest), to be modeled based on 
available information to estimate values for the exogenous variables, rather than relying on more 
biased methods for handling missing data (e.g., pairwise deletion or mean imputation 
procedures; Allison, 2003; Arbuckle, 2013). A critical assumption in conducting SEM is that 
multivariate data are normally distributed (Byrne, 2010). Data that are multivariate kurtotic are 
particularly problematic to SEM analysis. Thus, prior to any analysis descriptive statistics were 
computed for all variables to determine that assumptions of normality were met. Multivariate 
normality was measured through the use of Mardia’s normalized estimate (Byrne, 2010). 
Mardia's coefficient was used to assess whether assumptions of multivariate normality were met.  
 Three fit indices were used to evaluate the goodness of a model’s fit to the data: Root 
Mean Square Error of Approximation (RMSEA), Comparative Fit Index (CFI), and Akaike’s 
Information Criterion (AIC). Each of these indices describes the model fit from a different 
perspective, and they are amongst the most widely reported within the SEM literature (Kline, 
2011). The CFI index is an incremental measure that represents the improvement in fit between 
the assumed model and the baseline model of uncorrelatedness (i.e., not varying together) 
between the observed variables, the RMSEA is an absolute measure of fit, and the AIC is a 
comparative measure of model fit. Recommended cut-off values for model fit vary from .90 to 
above (with close to .95 or above being more optimal) for CFI, while RMSEA values close to .06 
or less serve as indicators that the model(s) adequately fitted the data (Hu & Bentler, 1999). AIC 
was used for comparing fit of competing models, with lower AIC values indicating a better 
model fit (Duncan et al., 2006). Chi-square is reported but not used as measure of fitness, given 
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its over sensitivity to large sample sizes (Kline, 2011). Data analyses investigated for differences 
in parameter and goodness-of-fit estimates using non-corrected data as compared to bootstrap 
analyses. Parameter estimates and fit indices remained consistent across these different 
procedures. 
Aim 1 analyses. In order to test Aim 1’s hypotheses, a multivariate2 LGC model was 
used to fit the growth curve to the respective neurocognitive domain factor scores (also referred 
to as “curve-of-factors” latent growth model; see Duncan et al., 2006). To allow us to interpret 
the latent variables initial status values, parameters from each respective neurocognitive latent 
variable’s intercept to its observed indicator values were held constant (set to unity). Parameters 
from each respective neurocognitive latent variable’s slope were connected to their observed 
indicator measures and fixed at values reflecting each Time Point (Year 1 = 0, Year 2 = 1, Year 3 
= 2). The latent factors’ covariances were allowed to covary over time. Residuals of each 
indicator were freely estimated at each time point, and correlations amongst the corresponding 
residuals’ indicators were estimated. A scaling reference variable set to unity was used for each 
of the first common order factors, and consistent with strict temporal invariance the remaining 
common factor loadings for the non-referenced indicator measures to the respective latent 
constructs were constrained to be equal across time points. Model specification was theory 
driven. Specification searches were used to improve model when the original hypothesized 
model did not adequately fit the data, as indicated by fit indices. Once the measurement model 
was fit to the data, the structural model analyzed the associations among the neurocognitive 
variables.    
                                                 
2 Analyses used are also considered a parallel growth process as each neurocognitive process 
growth estimate is being measured separately 
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Two models were used to test whether a high order global neurocognitive latent factor 
could better explain the data. In the interest of parsimony, a factor-of-curves LGM was used to 
determine whether a higher order global neurocognitive latent factor could better explain the data 
(See Duncan et al., 2006). This model assumed that the factor covariances amongst the first-
order factors (i.e., each respective neurocognitive domain) are better explained by a higher order 
factor’s intercept and slope. Model procedures required that the covariances amongst the first-
order factors (Memory, Executive Attention/Processing Speed, Language and Working Memory) 
be restricted to be equal over time for each neurocognitive domain (through utilization of a 
reference variable and constraining remaining factor loadings for each respective factor between 
the first- and second order factors to be equal over time). The second model compared the 
posited four latent factor curve-of-factors model fit to a single neurocognitive latent factor curve-
of-factors model fit. To judge the different models’ fit, each model’s fit indicators (parameter 
estimates, CFI, and RMSEA) were inspected and their AIC values were compared.  
Aim 2 analyses. To test Aim 2’s hypotheses, separate analyses were conducted to 
examine the respective influence of relevant predictor variables on each of the neurocognitive 
domains. Predictor variables (demographic, cognitive reserve, health related risk factors, and 
genotype) were separately entered into the model in phases in order to detect the degree to which 
these variables respectively influenced neurocognitive functioning. Predictors were initially 
specified to have direct effects on both latent growth factors (i.e., the respective intercepts and 
slopes) for each neurocognitive domain. Within the predictor model(s), latent factor residuals 
(“disturbances”) serve as proxies for the Intercept and Slope factors each of the latent 
neurocognitive variables as these factors now represent endogenous factors; covariance between 
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these disturbances are used to reflect the assumption that the latent growth factors share common 
causes other than the respective predictors variables (Kline, 2011).  
Once provided with a well-fitted model of predictors of heterogeneity in neurocognitive 
functioning, two final models tested the proposed etiological model of MCI. Two separate sets of 
analyses were necessary to investigate the effect of race and genetics in relation to the other 
etiological factors for MCI. The first model examined race in conjunction with sex, age, and the 
cognitive reserve variables, while the second model examined APOE-e4 carrier status in 
conjunction with sex, age, and the cognitive reserve variables. In these respective models of race 
and genetic risk, sex, age, race and genetic risk were specified to have direct effects on the 
health-related risk factors, while Neurocardiovascular and Depression/Endocrine risk factors 
were specified to have direct effects on both latent growth factors (i.e., the respective intercepts 
and slopes) for each neurocognitive domain; the cognitive reserve variables of education and 
intelligence remained independent predictors of neurocognitive functioning within this model.  
Power analyses. In order to conduct a LGC model, data must be obtained from each 
individual on three or more occasions. The present study utilized three-years of consecutively 
obtained data. Second, in order to have sufficient power for LGC models, it is recommended that 
there is a minimum sample size of not less than 200 persons at each time point (Byrne, 2010; 
Kline, 2011), as anticipated this study far exceeded this minimal expectation. Third, an 
additional guideline for obtaining sufficient power in SEM is that that there be a minimum ratio 
of cases (N = 10 minimum with N = 20 being ideal) to the number of model parameters per each 
estimated parameter (i.e., the N:q ratio; Kline, 2011). For the present study, the degrees of 
freedom for all distinct parameters to be estimated, reached a highly desirable ratio that resulted 
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in all models having positive degrees of freedom to allow for respective rejection of each model 
(i.e., each specified model met the criteria of over identification). Details regarding the degrees 
of freedom for the estimated model(s) are provided within the results. 
Preliminary analyses for LGC models. AMOS (Version 22) was used to investigate the 
study’s aims via several LGC model(s). Neuropsychological test data scores collected from 
participants at Years 1, 2, and 3 were used to form the respective latent neurocognitive variables. 
Research suggests that age adjustment for neuropsychological test performance removes the 
variance that is associated with age-related changes in brain structure as evidenced by weaker 
relationships of neuropsychological test scores with MRI measured brain volumes; and, findings 
have been mixed regarding the influence of education-adjusted means on brain-test behavior 
relationships (Mungas, Reed, Farias, & DeCarli 2009). Thus, the present study chose to 
respectively assess demographic factors influence on neurocognition, rather than using norm 
based approaches to “control” for these factors. Binary variables were created for the predictor 
variables of sex (Male = 1 and Female = 2), APOE-E4 Carrier status (Non-carrier = 1 and 
Carrier = 2), and race (Caucasian/Latino = 1; African American = 2). Age was centered at its 
grand mean to aid in its interpretation. Prior to conducting Aim 2’s analyses, descriptive statistics 
were generated for the relevant study variables. When applicable to model(s), one-way ANOVAs 
or chi-square tests followed up on group differences in the predictor variables and are reported 
within the results. 
Mardia's coefficient indicated that assumptions of multivariate normality were violated, p  
< .001. Given that transformations alone are not very effective at normalizing multivariate 
distributions and that deleting outliers until the multivariate kurtosis index reaches an acceptable 
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level can be an effective method of handling multivariate non-normality (Gao, Mokhtarian, & 
Johnston, 2008), Mahalanobis Distance3 (D2) investigated for cases that significantly contributed 
to the multivariate non-normality. Three participants who were identified as extreme outliers 
(i.e., D2 distances were greater than three Standard Deviations from centroid) were removed from 
the primary analyses. Subsequent examination of Mardia’s coefficient indicated that removal of 
these participants substantially reduced but did not entirely eliminate multivariate non-normality. 
Therefore, bootstrap analyses were used to assess bias corrected confidence intervals. Bootstrap 
analyses were successfully performed on data and 500 usable bootstrap samples were obtained (0 
bootstrap samples were unused because of a singular covariance matrix or because a solution 
was not found). Parameter estimates for these analyses remained significant. 
Structural model. Building on prior research, four latent neurocognitive variables of 
Memory, Executive Attention/Processing Speed, Working Memory and Language were formed 
for each respective time point. The Memory factor was comprised of WMS-R’s Logical Memory 
immediate and the delayed subtest scores. The Executive Attention/Processing Speed factor was 
formed from the Digit Symbol Subtest and the Trails Making Test: Parts A and B, this measure 
was posited to reflect aspects of executive function, attention and processing speed. The 
Working Memory factor was compromised of the Digit Span Forward and Backward tests. 
Lastly, the Language factor was formed from the BNT and Category Fluency (Animals and 
Vegetables) test scores. All indicator variables with the exception of CDT demonstrated 
acceptable to excellent factor loadings (respective factor loadings ranged between .32 and .82 in 
standardized units) on each of the respective neurocognitive variables. Notably, a truncated score 
                                                 
3 D2; reflects in standardized units the squared distance from the centroid 
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range for CDT for each year suggested the presence of a ceiling effect for this measure. When 
allowed to load on the Working Memory factor, examination of the squared multiple correlation 
for the CDT (range: .15-.17) suggested that this measure had unacceptable reliability in its ability 
to measure this latent variable; similar poor reliability (range: .05-.18) was found in its ability to 
measure each of the other latent neurocognitive variables, and thus the CDT was discarded from 
any further analyses.  
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CHAPTER 4: RESULTS  
Attrition Analyses and Sample Characteristics 
 To determine whether there were potential predictors of attrition in those that dropped out 
of the study, One-Way ANOVAs and chi-square tests of independence examined for group 
differences in demographic factors (e.g., education and age), health related risk factors, estimated 
intelligence and neurocognitive test performance in those with 3-years of follow-up visits as 
compared to study dropouts. Results revealed significant between group differences in the 
predictor variables and in the neurocognitive test scores of study dropouts as compared to those 
with three consecutive visits from Year 1 to Year 3.  
 Missing Data. Analyses first examined patterns of missing values within the database in 
regards to participant attrition in relation to the neurocognitive test scores. There was a total of 
118 participants who either formally or informally dropped out (through non-response) from the 
study at Year 2 (n = 64) and Year 3 (n = 54). 6944 individuals invited to enroll between 2009 (n 
= 331) and 2010 (n = 363) were eligible for the present study. Of these 694 individuals enrolled 
at the IDRP, 72 formally withdrew from the study for a variety of reasons (e.g., transportation, 
not willing to participate, moving, caregiver status, etc.), 36 participants inactivity is not 
accounted for due to either inability to respond or refusal to respond, 20 participants were not 
administered the full UDS battery (i.e., only Digit Symbol Coding was administered), 7 died, and 
3 converted to presumed AD. Three participants with physical impairments were missing data on 
neuropsychological tests that required intact visual or motor functioning (i.e., the TMT-A and B, 
CDT, DC). Two visually impaired participants (mentioned previously) were also missing BNT 
                                                 
4 LABrainS has an initial inclusion rate of 82.9% 
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scores. Listwise deletion was used to remove these three participants from the primary set of 
LGC analyses. This decision was based on research that suggests that visual and/or motor 
impairments may precede decline in other cognitive processes (Albers et al., 2015), thus data 
could not be presumed to be missing at random as these dependent variables are dependent on 
intact vision and motor processes. This resulted in 553 participants with complete non-missing 
values in the dataset for Years 1 through 3. Of these 553 participants, 398 participants had 
completed APOE genotype analyses. 
 Sex was not related to the likelihood of dropping out from the study  [Χ2 (1, N = 694) = 
.979, p > .10] and enrolled participants (“enrollees”) and “dropouts” did not significantly differ 
in age, F(2, 693) = 0.618, p = .539.  There was a greater likelihood of attrition in African 
Americans (n = 14; expected count = 7) than Caucasians (n = 120; expected count = 127), Χ2 (2, 
N = 134) = 9.98, p = .019. Enrollees on average obtained 16.18 years of education as compared 
to dropouts who had on average 14.86 years of education, F(2, 693) = 15.01, p < .001. Enrollees 
(M = 1.15, SD = 1.02) and dropouts (M = 1.53, SD = 1.32) also significantly differed in the 
number of cardiovascular risk factors that were present, Welch’s F(1, 147.13) = 8.78, p = .04; no 
other significant differences in health related factors were found, all ps > .10.  
 Analyses next examined for potential differences in the neuropsychological 
characteristics in study dropouts as compared to those consecutively enrolled for three years. 
Enrollees had significantly higher estimated intelligence and baseline neurocognitive test scores 
than dropouts (See Table 1). These effects remained largely the same in those who completed 
two- but not three years of visits. In sum, the findings indicated that the attrition group was 
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significantly different than the enrolled participants on several of the predictor and dependent 
variables. 
 
 
Table 1. 
Neuropsychological Test Scores for Years 1 and 2 by Enrollment Status at Year 3 
Year 1 Test Scores  
M (SD) 
Dropouts 
(n = 118) 
Enrollees 
(n = 576) 
F = 
National Adult Reading Test † 105.08 (9.06) 109.17 (7.64) 186.70**
Mini Mental State Exam † 28.42 (1.52) 29.01 (1.19) 16.05** 
Logical Memory-I† 12.36 (4.00) 13.04 (3.25) 2.98* 
Logical Memory-II† 10.97 (4.11) 11.89 (3.47) 5.12* 
Digit Span Forward Total  8.42 (1.84) 9.17 (1.90) 15.00** 
Digit Span Backward Total  6.15 (2.15) 7.11 (2.11) 20.16** 
Category Fluency - Animals 18.65 (5.28) 21.29 (5.53) 22.59** 
Category Fluency Vegetables 13.96 (4.24) 15.40 (4.25) 11.37** 
Trails Making Test – Trail A 38.34 (14.04) 34.07 (11.98) 11.60** 
Trails Making Test – Trail B† 107.75 (61.70) 83.99 (37.38) 16.14** 
Digit symbol 43.23 (9.96) 48.13 (10.60) 21.06** 
Boston Naming Test† 26.54 (3.25) 27.57 (2.45) 10.52** 
Clock Drawing Test† 16.11 (2.01) 16.57 (1.57) 5.12** 
Year 2 Test Scores  
M (SD) 
Dropouts 
(n = 54) 
Enrollees 
(n = 576) 
F = 
Mini Mental State Exam † 28.63 (1.67) 28.93 (1.60) 1.64 
Logical Memory-I 12.81 (4.09) 14.03 (3.32) 4.48* 
Logical Memory-II 11.69 (4.45) 13.21 (3.53) 8.79** 
Digit Span Forward Total  8.57 (1.99) 9.13 (1.84) 4.41* 
Digit Span Backward Total  6.52 (2.16) 6.96 (2.21) 1.99 
Category Fluency - Animals 19.87 (6.14) 21.26 (5.48) 3.09† 
Category Fluency Vegetables 14.09 (4.54) 15.56 (4.52) 5.19* 
Trails Making Test – Trail A† 38.63 (14.15) 33.60 (12.38) 6.35* 
Trails Making Test – Trail B† 101.46 (57.62) 85.13 (40.92) 4.14* 
Digit symbol† 43.44 (9.02) 48.51 (10.89) 15.00** 
Boston Naming Test† 26.87 (3.27) 27.87 (2.38) 1.23 
Clock Drawing Test 16.60 (1.63) 16.84 (1.45) 8.79** 
Notes: Mean (M); Standard Deviation (SD); † denotes that Welch's F test was used due to 
violations in assumptions of homogeneity between groups. † p < .10; * p < .05; ** p < .01.  
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 Non-normality within the sample distribution was not amenable to transformations in the 
data set containing missing values for the study dropouts. Importantly, multiple imputations for 
missing values are not recommended when data is non-normally distributed and replacing 
missing values via MLE is problematic when the probability of attrition is related to later values 
on the dependent variables (Allison, 2003). Thus, listwise deletions methods were utilized for 
cases missing consecutive visits for Years 2 and/or 3. The decision to utilize listwise deletion 
methods for the primary analyses was based on the significant differences between the enrollees 
and dropouts on the dependent variables and the significant non-normality within the data set 
that contained the missing values.  
Notwithstanding the aforementioned limitations, for the interested reader, tables with 
supplementary analyses using MLE estimations for missing values are provided within Appendix 
C and D. Comparison of parameter estimates between complete and incomplete data sets and 
their respective fit indices were relatively close to one another. Thereby, further increasing our 
confidence in the identified latent neurocognitive constructs and their relationships with one 
another. Regarding the predictor model, MLE estimates were largely similar for the findings 
regarding age and sex; however, attempts to adjust for estimated intelligence in the model 
resulted in a non-positive covariance matrix and MLE estimated values regarding the 
relationship between race differences and neurocognitive functioning were substantially lower 
within the supplementary analyses. Given multivariate non-normality and group differences on 
these factors, it was outside the scope of this paper to provide further analyses that might allow 
for interpretation of the nature of these differences. Future studies intend to investigate the nature 
of these differences.  
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Descriptive Statistics for the Study Variables 
 Sample characteristics. The mean age of the final sample population was 68.62 (SD = 
6.45) with a total of 553 participants. There were a higher proportion of female participants 
(67.5% female vs. 32.5% male). The sample was primarily Caucasian participants (94.8%, 4% 
African American, and 1.2% Latino/a origins). Given the small number of Latino/a participants 
and no evidence of group differences on any of the variables of interest with Caucasians (all ps > 
.10), Latino/as were collapsed into the Caucasian group. Table 2 presents the descriptive 
statistics for the raw neurocognitive test scores for the participants who had complete datasets for 
three consecutive visits by year.  
 
 
Table 2. 
Neuropsychological Test Scores for the Primary Dataset by Year  
 
Neuropsychological Test: M (SD) Year 1 Year 2 Year 3 
Mini Mental State Exam † 29.03 (1.17) 28.99 (1.25) 29.10 (1.26) 
Logical Memory-I 13.03 (3.27) 14.00 (3.33) 14.09 (3.63) 
Logical Memory-II 11.88 (3.48) 13.22 (3.57) 13.48 (3.85) 
Digit Span Forward – Total Correct 9.17 (1.89) 9.13 (1.82) 9.10 (1.86) 
Digit Span Backward – Total Correct 7.12 (2.10) 6.95 (2.21) 6.89 (2.23) 
Category Fluency - Animals 21.22 (5.42) 21.28 (5.51) 21.31 (5.69) 
Category Fluency - Vegetables 15.36 (4.24) 15.51 (4.53) 15.71 (4.43) 
Trails Making Test – Trail A 34.01 (11.94) 33.69 (12.41) 32.86 (11.61) 
Trails Making Test – Trail B 84.00 (37.59) 84.90 (40.24) 83.48 (40.53) 
Digit Symbol Coding† 48.10 (10.58) 48.53 (10.92) 49.03 (11.16) 
Boston Naming Test† 27.58 (2.42) 27.85 (2.40) 28.07 (2.34) 
Clock Drawing Test 16.57 (1.57) 16.84 (1.46) 16.80 (1.62) 
Notes: Data presented are raw untransformed scores (values contain significant skew and 
kurtosis). Mean (M); Standard Deviation (SD); Lower scores on the TMT Trails A and B 
indicates better performance. 
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 Sex. On average male participants  (M = 69.85, SD = 6.85) were significantly older than 
females participants (M = 67.99, SD = 6.15), Welch’s F(1, 552) = 10.50, p = .001. Males on 
average obtained a higher level of education (M = 17.02, SD = 2.35) than females (M = 15.74, 
SD = 6.15), Welch’s F(1, 552) = 10.50, p = .001. Females as compared to males did not 
significantly differ in estimated intelligence but generally had higher neurocognitive test scores 
on measures of Memory, Language and attention/processing speed at each year with the 
exception of TMT-B, BNT, and Category Fluency “animal” test, all ps < .001.  
Race. No significant difference in age by race group was found, F(1, 552) = .021, p = 
.885. African American (n = 22) as compared to Caucasian/Latino5 participants (n = 531) had 
significantly higher levels of education (M = 17.32, SD = 2.34 vs. M = 16.13, SD = 2.44), F(1, 
552) = 5.02, p = .025. African Americans as compared to Caucasian participants had lower 
NAART scores (M = 100.36, SD = 6.74 vs. M = 109.52, SD = 7.50) and neurocognitive test 
scores on all measures at each year with the exception of CDT and Category Fluency tests, all ps 
< .001. Although African American participants significantly differed on neurocognitive test 
measures, similar to Caucasian participants all t-scores with the exception of the TMT fell within 
the average range, ps < .001.  
Cognitive Reserve. As noted prior, participants were generally well educated (M = 16.18 
years, SD = 2.45) and were of average estimated intelligence (FS-IQ: M = 109.16, SD = 7.68). 
As expected, education and estimated intelligence were highly correlated with one another even 
when sex and race were adjusted for in the model, r = .521, p < .001. 
  
                                                 
5 Given the small ratio of Latino/a participants within this group, this group will heretofore be 
referred to as the Caucasian group for simplicity.  
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 APOE Genotype. This study excluded cases that were missing genetic material from the 
primary APOE-e4 analyses, as use of MLE estimates for missing genotype values could have 
potentially resulted in inflated relationships between the APOE-e4 allele with the other study 
variables. Of the 553 participants, 398 participants had completed APOE genotype analyses 
(Carriers = 96 and Non-Carriers = 302). Those who were genotyped were significantly younger 
[M = 68.69, SD = 7.37 vs. M = 69.99, SD = 7.11, Welch’s F(1, 247.33) = 8.56, p = .004] and 
more likely to be African American than Caucasian [Χ2 (1) = 5.48, p = .019] than those without 
genotyping. They also were lower in cardiovascular risk [M = 1.06, SD = 1.02 vs. M = 1.46, SD 
= 1.00, Welch’s F(1, 285.60) = 13.28, p < .001] and cerebrovascular risk [M = .12, SD = .36 vs. 
M = .24, SD = .54, Welch’s F(1, 210.16) = 6.11, p = .014] factors. 
 The likelihood of being an APOE-e4 carrier did not differ between males and females, Χ2 
(1) = 0.72, p = .396. Male APOE-e4 carriers had lower estimated intelligence scores (M = 
106.62, SD = 7.37) than non-carriers (M = 110.65, SD = 7.36), F(1, 130) = 6.95, p = .009; 
whereas, female APOE-e4 carriers did not differ from non-carriers in estimated intelligence, p = 
.848. The likelihood of being an APOE-e4 carrier was significantly greater within African 
American (54.5%) as compared to Caucasian (23.3%) participants, Fisher’s Exact Test6, p = 
.027; however, the gross number of African American participants with APOE-e4 genotyping (n 
= 11) as compared to Caucasian participants (n = 387) prohibited examination of race effects in 
regards to APOE-e4 due to the significant skew and kurtosis of the race variable (SI = 5.76 and 
KI = 31.21, ps < .001). Thus, separate analyses were conducted to respectively investigate race 
and APOE-e4 carrier status in relationship to the other predictor variables. 
                                                 
6 Fisher's exact test was used as it is more accurate than the chi-square statistic when the 
expected numbers are small. 
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Aim 1 Results: Investigating within and between neurocognitive domain variance 
The following set of analyses aimed to elucidate the interplay between Memory, 
Executive Attention/Processing Speed, Language and Working Memory functioning in older 
adults over a three-year period through multivariate parallel process LGC modeling. A series of 
analyses systematically investigated: (1) individual differences in initial score values at baseline 
and the rate of change of each respective neurocognitive domain, (2) whether changes in the 
specific neurocognitive domains vary across participant as a consequence/function of different 
Memory and/or Executive Attention/Processing Speed intercepts and slopes, and (3) the 
interplay between neurocognitive process at baseline and rate of changes in the neurocognitive 
domains in relation to one another from Year 1 to Year 3. 
Model fit. Consistent with previous research on the UDS neuropsychological battery, the 
posited four-factor solution of Memory, Executive Attention/Processing Speed, Language and 
Working Memory provided an excellent fit for the data. However, contrary to expectations, the 
CDT was an unreliable predictor of working memory as well as other variables (see Preliminary 
Analyses for details). Fitting of the curve-of-factor model resulted in an excellent fit of the data 
once CDT was discarded, (Chi-square (df = 373) = 674.32, p < .001; CFI = .978; RMSEA = 
.037, 90% Confidence Interval = .032-.042). Provided with a well-fitting model, the structural 
model analyzed the associations among the latent neurocognitive domains.     
 Within-neurocognitive domain covariance. As expected, older adults demonstrated 
substantial heterogeneity in their neurocognitive functioning both at baseline and in their annual 
rate of change. Significant mean levels existed for all intercept parameters (MINT) and almost all 
slope parameters (MSlope reflects the on average year-to-year linear change). Table 3 presents the 
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results for the estimated values for each respective neurocognitive domain’s intercept and slope. 
The average score at baseline for Executive Attention/ Processing Speed was higher relative to 
all other neurocognitive domains. Memory, Language, and Working Memory performance had 
negligible differences from each other at baseline. As hypothesized, Memory scores on average 
significantly increased over time, while Executive Attention/Processing Speed performance 
demonstrated a decrease from Year 1 to Year 3. Interestingly, on average Language functioning 
demonstrated incremental improvements over time. Estimates for Working Memory MSlope failed 
to reach significance suggesting that on average there was limited change over time in working 
memory functioning.  
 
Table 3. 
Parameter Estimates for Intercept and Slope Means for Neurocognitive Domains 
 
 Variable Estimate Standard Error Critical Ratio p-values 
Memory Intercept 50.164 0.419 119.858 < .001 
Memory Slope 1.601 0.197 8.147 < .001 
EA/PS Intercept 53.406 2.687 19.876 < .001 
EA/PS Slope -.866 0.190 -4.545 < .001 
Language Intercept 50.044 0.411 121.803 < .001 
Language Slope 1.065 0.147 7.229 < .001 
WM Intercept 49.972 0.397 125.937 < .001 
WM Slope -0.161 0.185 -.873 0.261 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM).  
 
 
Next, the degree to which lower (or higher) initial neurocognitive functioning predicts 
change over time in each of the respective neurocognitive domains was examined. Table 4 
presents the descriptive statistics for each of the respective within-neurocognitive domain 
covariance estimates. As expected, the estimated within-domain covariance between Memory’s 
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intercept and slope was significant; however, contrary to assumptions, the negative value 
indicates that participants’ whose Memory scores were highest as compared to those with lower 
scores at baseline demonstrated a slower linear growth rate in Memory over time. Furthermore, 
the hypothesis that individuals with initially lower Executive Attention/Processing Speed scores 
as compared to higher scores would display greater decrements in Executive 
Attention/Processing Speed functioning over time was not supported. Similarly, the hypothesis 
that individuals with initially lower Language as compared to higher Language scores would 
display greater decrements in Language functions over time was not supported. Lastly, 
exploratory analysis found that the estimated within-domain covariance between Working 
Memory’s intercept and slope factor means was also non-significant. These results indicate that 
those who started with lower as compared to higher scores on each of these respective factors, 
with the exception of Memory, did not differ in their annual rate of change over time.  
 
 
Table 4. 
Parameter Estimates for Neurocognitive Functioning at Baseline in Relation to Within-
Neurocognitive Change Over Time 
 
Within-Domain Covariance Estimate Standard Error 
Critical 
Ratio p-values 
Memory Intercept <--> Memory Slope -8.253 1.527 -5.405 < .001 
EA/PS Intercept <--> EA/PS Slope -0.138 0.642 -0.215 0.830 
Language Intercept <--> Language Slope -0.837 0.680 -1.231 0.218 
WM Intercept <--> WM Slope 2.031 1.444 1.407 0.160 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
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 Neurocognitive domains at baseline. Examination of the between-neurocognitive 
domains associations at baseline supported the hypothesis that older adults who are initially 
higher functioning in one neurocognitive domain are also on average higher in the other 
neurocognitive domains, while those who are lower functioning in one neurocognitive domain 
generally have worse overall neurocognitive performance at baseline. Prior to examining the 
between-neurocognitive domain covariances, the three non-statistically significant within-
domain covariances for Executive Attention/Processing Speed, Language, and Working Memory 
were deleted from the model. Improvement to fit indices upon deletion of these factors was 
inappreciable (Change from AIC = 901.35 to AIC = 898.82). The between-domain covariance 
estimates for each of the respective neurocognitive domains intercepts in relation to one another 
were significant as predicted (See Table 5). Specifically, individuals with lower Memory, 
Language, Executive Attention/Processing Speed, and Working Memory test scores 
concomitantly had lower scores on each of the other neurocognitive latent variables.  
 
 
Table 5. 
Parameter Estimates for Between-Neurocognitive Domains Functioning at Baseline  
 
Variables Estimate Standard Error 
Critical 
Ratio p-values 
Memory Intercept <--> Language Intercept 27.287 3.161 8.632 < .001 
Memory Intercept <--> EA/PS Intercept 28.576 3.627 7.878 < .001 
Memory Intercept <--> WM Intercept 14.155 3.238 4.371 < .001 
EA/PS Intercept <--> Language Intercept 28.418 3.135 9.066 < .001 
EA/PS Intercept <--> WM Intercept 23.809 3.220 7.395 < .001 
WM Intercept <--> Language Intercept 14.625 2.454 5.959 < .001 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
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 Between-neurocognitive domains intercept and slope covariances. Analyses next 
investigated the degree to which baseline Memory and Executive Attention/Processing Speed 
functioning respectively predicted changes in the other neurocognitive processes (Table 6 
presents the descriptive statistics). Consistent with the study’s hypothesis that initial Executive 
Attention/Processing Speed scores would predict rates of changes in other neurocognitive 
processes over time, those with lower initial as compared to higher Executive 
Attention/Processing Speed scores demonstrated slower rates of increase in Memory scores from 
Year 1 to Year 3 (as indicated by the significant covariance between Executive 
Attention/Processing Speed MINT and Memory MSlope). Similarly, although to a lesser degree, 
those with lower as compared to higher Memory Scores at baseline demonstrated a slower rate of 
increase in Language scores over time (Memory MINT and Language MSlope). Notably, no other 
significant relationships between baseline estimates of Executive Attention/Processing Speed or 
Memory with rates of linear change in the other neurocognitive processes were found. 
 
 
Table 6. 
Parameter Estimates for Neurocognitive Change in Relation to Memory and Executive 
Attention/Processing Speed Functioning at Baseline 
 
Variables Estimate Standard Error 
Critical 
Ratio p-values 
Memory Intercept <--> Language Slope 1.520 0.776 1.960 0.050 
Memory Intercept <--> EA/PS Slope 0.837 0.695 1.203 0.229 
Memory Intercept <--> WM Slope 0.381 1.190 0.320 0.749 
EA/PS Intercept <--> Memory Slope 2.882 1.173 2.456 0.014 
EA/PS Intercept <--> Language Slope 0.517 0.646 0.799 0.424 
EA/PS Intercept <--> WM Slope -0.264 1.004 -0.263 0.793 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
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Between-neurocognitive domains slope covariances. This set of analyses was 
specifically interested in the degree to which changes in Memory and Executive 
Attention/Processing Speed associated with changes in other neurocognitive processes over time. 
Here (see Table 7), we see that on average as Memory scores increased over time, Executive 
Attention/Processing Speed and Language scores increased in accord. Similarly, the annual rate 
of change in Executive Attention/Processing Speed positively associated with the rate of change 
in Language scores. Next, exploratory analysis investigated the remaining relationships between 
changes in neurocognitive domains in relation to one another from Year 1 to Year 3. The annual 
rate of change in Working Memory was positively related to rates of change in Language, but 
not Memory or Executive Attention/Processing Speed changes from Year 1 to Year 3. 
 
 
Table 7. 
Parameter Estimates for Between-Neurocognitive Domains Slope Covariances  
 
Variables Estimate Standard Error 
Critical 
Ratio P-values 
Memory Slope <--> EA/PS Slope 0.894 0.339 2.637 0.008 
Memory Slope <--> Language Slope 1.622 0.361 4.486 < .001 
Memory Slope <--> WM Slope 0.656 0.540 1.213 0.225 
EA/PS Slope <--> Language Slope 0.451 0.174 2.594 0.009 
EA/PS Slope <--> WM Slope 0.296 0.271 1.095 0.274 
WM Slope <--> Language Slope 0.801 0.285 2.806 0.005 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
 
Heterogeneity in neurocognitive functioning. Lastly, in examining the variance 
estimates associated with the intercept and slopes for each neurocognitive domain, all variance 
estimates were significant (all ps < .05). These findings provide strong evidence for 
interindividual differences, and thus support investigation of factors that might account for this 
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substantial variability within neurocognitive functioning. See Appendix E for the standardized 
coefficients and variance estimates for the neuropsychological domains. 
Competing models using a global neurocognitive latent variable. While the posited 
curve-of-factors LGM had an excellent fit, in the interest of parsimony, a factors-of-curves LGM 
and curve-of-factors LGM utilizing a global neurocognitive latent factor was used to compare 
the fit of the posited model to these competing models. Fit indices for the competing factors-of-
curves (CFI = .833; RMSEA = .099) and the curve-of-factors LGM (CFI = .810; RMSEA = 
.107) models proved to be inadequate. Moreover, the substantially lower AIC value for the 
posited model (AIC = 898.83) as compared to the global neurocognitive latent variable’s factors-
of-curves (AIC = 2747.32) and curve-of-factors (AIC = 3053.25) values suggested that the 
present study’s hypothesized model was superior to both of these competing models. Thus, given 
confidence in our model fit and provided with evidence of significant interindividual differences, 
the next set of analyses investigated time-invariant predictors of neurocognitive functioning 
within the older adult sample.  
Aim 2 Results: Relevant predictors of neurocognitive functioning  
Based on previous research and theoretical speculation, multiple indicator parallel growth 
process LGC model(s) relating older adults neurocognitive performance to relevant predictors 
was conducted to answer the degree to which of Memory, Executive Attention/Processing Speed, 
Language and Working Memory differ as a function of these factors at baseline and individual 
differences in growth trajectories over time (Year 1 to Year 3). Demographic factors (sex, race, 
and age), APOE genotype (APOE-e4 carriers vs. non-carriers), indicators of cognitive reserve 
(education and FS-IQ scores) and health-related risk factors were respectively entered into the 
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model in different stages in order to account for their influence on neurocognitive functioning. 
First, the relationships between demographic factors and each neurocognitive growth trajectory 
(i.e., the respective Mint and Mslope) were examined. Next, cognitive reserve predictors followed 
by APOE genotype, and then health related risk factors were examined with relevant 
demographic predictors. The last set of analyses examined relevant predictors of heterogeneity in 
the intercepts and slopes of Memory, Executive Attention/Processing Speed, Language and 
Working Memory in a comprehensive etiological model. Significant parameter estimates of the 
respective predictors were retained at each stage of analysis, while non-significant parameters 
were discarded from subsequent analyses.  
 Demographic factors as predictor variables. This set of analyses assesses the degree to 
which age predicts neurocognitive functioning when sex and race are adjusted for in the model. 
Given strong evidence for their interrelationships within the literature that were also evident in 
the present sample, the time invariant variables of years of age (centered at its mean), sex, and 
race were simultaneously investigated within the first predictor model. Table 8 provides the 
parameter estimates with tests of significance for the demographic predictor model of 
neurocognitive functioning. Given significant between group differences, sex and age were 
allowed to covary within the model. This model provided an excellent fit for the data (Chi-square 
(df = 449) = 949.97, p < .001; CFI = .963; RMSEA = .045, 90% Confidence Interval = .041-
.049).  
Age and sex shared variance (estimate = -.42, SE = 0.13; CR = -3.18, p < .001) indicating 
that women on average were younger than men. When sex and race were adjusted for, greater 
age at baseline predicted worse initial functioning in each of the respective neurocognitive 
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domains, as well as older age associated with slower growth rates in Memory and Executive 
Attention/Processing Speed from Year 1 to Year 3, all ps < .10. As anticipated, differential 
effects for sex and race on neurocognitive functioning were found. In regards to race, Memory, 
Executive Attention/Processing Speed, Language, and Working Memory functioning on average 
appeared to be initially lower in African American as compared to Caucasian participants. Race 
did not predict annual rates of neurocognitive change in the model. Women generally had higher 
initial scores on Memory and Executive Attention/Processing Speed, while men on average 
demonstrated better Working Memory functioning at baseline. A trend relationship between 
better baseline Language and significantly greater incremental growth in Language functioning 
was found in women as compared to men. Lastly, a trend level sex difference in the average rate 
of linear increase in Memory scores over time was found. The effect sizes of age, race, and sex 
on neurocognitive functioning ranged from small to moderate (see Appendix E for standardized 
estimates).  
 
Table 8. 
Demographic Predictors of Neurocognitive Functioning at Baseline and Over Time 
 
 Variable Estimates Age Race Sex 
Memory Intercept -0.45** -6.98** 3.78** 
Memory Slope -0.07** 0.42 .577† 
EA/PS Intercept -0.63** -8.39** 1.38* 
EA/PS Slope -0.04** -0.51 -0.24 
Language Intercept -0.37** -3.037* 1.73† 
Language Slope -0.02 -0.14 1.93* 
WM Intercept -0.25** -5.32** -1.90* 
WM Slope 0.02 0.32 0.31 
Notes: Race (1 = Caucasian, 2 = African American); Sex (1 = Men, 2 = Women); Executive 
Attention/Processing Speed (EA/PS); Working Memory (WM); † p < .10; * p < .05; ** p < .01. 
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 Cognitive reserve as a predictor variable. A formative indicator approach attempted to 
form a latent Cognitive Reserve variable. Formative indicators differ in that the measurement 
variables are posited to “cause” the latent construct, rather than the factors “reflecting” the latent 
variable. In the case of the continuous variables of education (measured in years) and estimated 
intelligence (NAART standardized FS-IQ scores), this assumption is tenable, as research has 
suggested that greater levels of education and intelligence contribute to cognitive reserve. In this 
respect, cognitive resources may be created or enhanced by the degree of one’s education and 
intelligence. In doing so, the parameter estimates for the posited latent cognitive reserve variable 
failed to be identified. Similarly, a reflective Cognitive Reserve latent construct (with education 
and estimated intelligence as indicators) solution proved to be unacceptable even when the error 
variance for education was constrained to unity (Χ2(df = 3) = 4987.614, p < .001; NFI = 35.31; 
CFI = .000; RMSEA = 1.74). Thus, education and estimated intelligence were both entered as 
unique predictor variables into the model.  
Demographic predictor model with cognitive reserve variables on neurocognitive 
functioning. The analyses next turn towards investigating the effect of education and estimated 
intelligence on neurocognitive functioning. The significant predictors of age, sex and race were 
also included in this model. Given evidence of between group differences in education and 
estimated intelligences, education was set to covary with race and sex, while FS-IQ scores were 
set to covary with race. Inclusion of the cognitive reserve variables into the previous LGC model 
resulted in a well-fit model (Chi-square (df = 496) = 1053.489, p < .001; CFI = .960 RMSEA = 
.045, 90% Confidence Interval = .041-.049). As expected, the covariances between predictor 
variables were all statistically significant, all ps < .001. The significant covariances found reflect: 
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(1) the higher education levels found in African American participants and men when 
respectively compared to Caucasian participants and women, and (2) the lower estimated FS-IQ 
scores found in African American as compared to Caucasian participants. 
Results from this model indicated that once the predictor variables of education and 
estimated intelligence were taken into account, the effect of age on neurocognitive functioning 
remained stable (as indicated by only marginal changes in its estimated Mint and Mslope values); 
whereas, changes to some of the previous statistically significant relationships with sex and race 
on neurocognitive functioning were noted (See Table 9). Specifically, the previously reported 
effects of race on initial Working Memory and Language functioning were both no longer 
significant; conversely, the effect of sex on Memory, Executive Attention/Processing Speed, 
Language, and Working Memory function appeared to be strengthened by their inclusion in the 
model. As hypothesized, higher levels of estimated intelligence predicted higher initial 
neurocognitive functioning within each domain at baseline, while greater years of education 
predicted both higher initial Memory and Language functioning. Education levels were not 
predictive of initial differences in Executive Attention/Processing Speed or Working Memory 
performance. Speculative analysis found that higher levels of estimated intelligence predicted 
modestly steeper rates of increase in Memory and Executive Attention/Processing Speed scores 
from Year 1 to Year 3. Obtained education was not related to rates of change in neurocognitive 
functioning over time. 
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Table 9. 
Effects of Demographic and Cognitive Reserve Predictors on Estimates for Neurocognitive 
Functioning at Baseline and Over Time 
 
 Variable Estimates Age Race Sex Ed FS-IQ 
Memory Intercept -0.41** -4.95** 4.48** 0.40* 0.28** 
Memory Slope -0.07** 0.94 .480 -0.11 0.04† 
EA/PS Intercept -0.60** -6.44** 1.67** 0.14 0.24** 
EA/PS Slope -0.03* -0.30 -.24 -0.01 0.02† 
Language Intercept -0.35** -0.91 1.41** 0.31* 0.32** 
Language Slope -0.02 -0.27 0.44* 0.03 -0.01 
WM Intercept -0.20** -1.57 -1.60* 0.06 0.42** 
WM Slope 0.02 0.26 0.36 0.04 0.00 
Notes: Education (Ed); Race (1 = Caucasian, 2 = African American); Sex (1 = Men, 2 = 
Women); Executive Attention/Processing Speed (EA/PS); Working Memory (WM); † p < .10; * 
p < .05; ** p < .01. 
 
 
 APOE-e4 carrier status as a predictor variable. Analyses next investigated the effect 
of APOE-e4 allele on neurocognitive functioning. Prior to presenting the results for differences 
in APOE-e4 carriers as compared to non-carriers, it is important to emphasize that these findings 
are not directly comparable with the prior analyses as this analysis was conducted on a subset of 
the sample population. It is possible that those who were genotyped may represent a different 
sample population and there was also a decrease in power to detect effects due to the reduced 
sample size. Furthermore, as noted previously, race effects in conjunction with APOE-e4 carrier 
status was not conducted due to the low number of African American participants within the 
present sample.  
Effects of APOE-e4 on neurocognitive function adjusting for demographic factors 
and cognitive reserve. Given significant interactions between sex, age, and education with 
APOE-e4 carrier status within the literature, the next model investigated the degree to which 
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APOE-e4 predicts neurocognitive functioning when these variables are adjusted for in the model. 
APOE genotype was initially allowed to covary with age, sex and education; however, given 
non-significance these paths were removed. Sex was allowed to covary with age and education. 
Testing of this model resulted in a good fit (Χ2 (481, N = 398) = 918.55, p < .001; CFI = .953; 
RMSEA = .048, 90% Confidence Interval = .043-.053). As hypothesized, APOE-e4 carriers’ 
initial Memory functioning was significantly lower than non-carriers at baseline, even when the 
direct effects of sex, age, and education were included within the model. The hypothesis that sex 
would have a moderating effect on the relationship between APOE-e4 status and neurocognitive 
functioning was not supported. Results indicated that APOE-e4 carrier status did not covary with 
sex, education or age, all ps > .10. Overall, the predictors of age, sex, and education relationships 
with neurocognitive functioning remained largely unchanged from the prior set analyses (see 
Table 10 for descriptive statistics). 
 
Table 10. 
Effects of Genotype with Demographic and Cognitive Reserve Predictors on Neurocognitive 
Functioning at Baseline and Over Time 
 
 Variable Estimates Age Sex Ed APOE Genotype 
Memory Intercept -0.48** 4.65** 0.46* -1.98* 
Memory Slope -0.04 0.59 -0.11 -0.06 
EA/PS Intercept -0.65** 1.09 0.14 -0.62 
EA/PS Slope -0.03* -0.18 -0.01 -0.35 
Language Intercept -0.38** 1.17* 0.47* -0.50 
Language Slope -0.02 0.36† 0.03 -0.28 
WM Intercept -0.20** -1.76* 0.06 -1.44 
WM Slope 0.02 0.14 0.04 -0.12 
Notes: Education (Ed); APOE Genotype (1 = non-carrier 2 = e4 carrier); Sex (1 = Men, 2 = 
Women); Executive Attention/Processing Speed (EA/PS); Working Memory (WM); † p < .10; * 
p < .05; ** p < .01. 
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Lastly, exploratory analyses examined the influence of estimated intelligence within the 
model, in which its inclusion revealed a trend relationship between FS-IQ and APOE-e4 carriers 
status (Estimate: -.254, SE = .14, CR = -1.78, p = .075), as well as its inclusion attenuated the 
significant effect between Memory and APOE-e4 (Estimate: -1.53, SE = .93, CR = -1.64, p = 
.10). No other notable changes in the model’s parameters were noted. 
Zygosity. Next, as the APOE-e2 allele has been posited to have protective effects, 
follow-up analysis excluded e2 allele carriers, to test whether e3/e3 as compared to e3/e4 allele 
carriers differed in neurocognitive functioning (N = 337). Here, again baseline Memory was on 
average lower in carriers (Estimate: -1.84, SE = .914, CR = -2.01, p = .044) and a strong trend 
relationship between steeper growth rates in Executive Attention/Processing Speed in non-
carriers as compared to APOE-e4 carriers was revealed (Estimate: -.473, SE = .996, CR = -1.95, 
p = .052). No other exploratory relationships with APOE-e4 carrier status and neurocognitive 
functioning were found, all ps > .10. These results potentially indicate the APOE-e2 exerts a 
protective effect on in Executive Attention/Processing Speed; however, further study is required. 
Post-hoc MLE for missing APOE-e4 values. Men and women did not differ in their 
likelihood of being genotyped; however, those who consented to genotyping were significantly 
younger than non-genotyped participants (Mean difference in years = 1.90; Cohen’s d = .30). 
Thus, follow-up analysis used MLE methods for replacing missing APOE-e47 values to test 
whether the found effects remained similar in the larger study sample. Consistent with the 
previous analysis, even when age, sex, and education were adjusted for, significantly worse 
initial Memory functioning (Estimate: -1.63 SE = .81, CR = -2.02, p = .044) was noted in APOE-
                                                 
7 This study excluded subjects who were missing genetic material from the APOE-e4 analyses to 
avoid potential inflation errors in the phenotypic expressions (Xu & Vogl, 2000).  
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e4 carriers as compared to non-carriers - thereby, increasing our confidence in these findings. A 
trend relationship with slower annual growth in Executive Attention/Processing Speed was also 
found (Estimate: -.395, SE = .22 CR = -1.80, p = .072). The effect of age on the linear rate of 
change in Memory, Executive Attention/Processing Speed and Language remained statistically 
significant (all ps <. 10). Similar to the prior analysis, sex differences in initial Working Memory 
functioning were no longer significant when APOE-e4 carrier status was included in the model, 
p = .22. Overall, the post-hoc analysis supports the relationship between memory and APOE-e4 
carrier status, and potentially indicates that Executive Attention/Processing Speed and Working 
Memory functioning are also influenced by APOE-e4. 
 Health related risk factors as predictor variables. The present set of analyses was 
specifically interested in testing the specific effects of Cardiovascular, Cerebrovascular and 
Depression/Endocrine risk on Memory, Language, Executive Attention/Processing Speed, and 
Working Memory functioning once individual differences in race, sex, genetics were adjusted 
for. Direct effects of each predictor variable were simultaneously modeled in order to account for 
their respective influence on each of the growth parameters, as well as to account for their 
potential moderating or suppressor effects on the relationship between health and neurocognitive 
functioning. 
Direct effects of health related risk on neurocognitive functioning. Adjusting for the 
previously found effects of age, sex, and race on neurocognitive variables, each health related 
risk factor was to set to directly predict the respective neurocognitive domain’s intercept and 
slope factors. Covariances between the predictor variables were based on previous analyses and 
all statistically significant parameters remained the same within this model with the exception of 
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cognitive reserve variables that were entered in a second step. Additionally, age, sex and race 
were allowed to covary with the health related risk factors. Testing of this model had little 
change on the model’s fit, which remained good (CFI = .962; RMSEA = .042, 90% CI= .038-
.046). Table 11 presents the results between the covariance estimates and predictor variables: (1) 
greater age associated with a higher amount of Cardiovascular and Cerebrovascular risk factors. 
(2) men were higher in Cardiovascular and Cerebrovascular risk factors than women, (3) women 
were more likely to have a history of Depression/Endocrine factors, and (4) African American as 
compared to Caucasian participants had a higher amount of Cardiovascular risk factors. 
 
Table 11. 
Covariance Estimates Between the Predictor Variables  
 
Variables (N = 553)  Estimate  S.E.  C.R. p ≤ 
Cardiovascular   <--> Age 0.94 0.28 3.34 0.001 
Cardiovascular <--> Race 0.02 0.01 3.05 0.002 
Cardiovascular <--> Sex -0.10 0.02 -5.06 0.001 
Cerebrovascular <--> Age 0.23 0.11 2.04 0.041 
Cerebrovascular  <-->  Sex 0.00 0.00 -0.99 0.323 
Cerebrovascular <-->  Race -0.03 0.01 -3.54 0.001 
Depression/Endocrine <--> Age -0.06 0.17 -0.33 0.741 
Depression/Endocrine <--> Sex -0.01 0.01 -1.57 0.117 
Depression/Endocrine <--> Race 0.08 0.01 6.53 0.001 
Notes: Race (Caucasian = 1, African American = 2); Sex (1 = Men, 2 = Women).  
 
In relation to neurocognitive functioning, Cardiovascular and Depression/Endocrine risk 
factors were both significant predictors of worse Executive Attention/Processing Speed and 
Language functioning at baseline, and there was trend relationship between greater 
Cerebrovascular risk factors predicting slower annual growth rates in Working Memory 
functioning from Year 1 to Year 3 (See Table 12).  
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Table 12. 
Direct Effects of Health Related Risk on Neurocognitive Functioning Adjusting for Age, Sex, 
and Race 
 
Variables Cardiovascular Cerebrovascular Depression/Endocrine
Memory Intercept -0.23 0.68 -0.59 
Memory Slope -0.04 -0.47 0.13 
EA/PS Intercept -0.68* -0.94 -1.35** 
EA/PS Slope 0.02 -0.03 -0.09 
Language Intercept -0.45† -0.56 -1.22** 
Language Slope -0.07 -0.28 0.06 
WM Intercept -0.25 0.43 -0.67 
WM Slope -0.23 -0.64† -0.08 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM).  
† p < .10; * p < .05; ** p < .01. 
 
Lastly, the significant paths for the respective cognitive reserve variables were entered 
into the model. Notably, the inclusion of education and estimated intelligence significantly 
attenuated Cardiovascular risk’s effect on Language functioning (estimate = -.19, SE = 0.25; CR 
= -0.76, p = .448) at baseline. The relationship between Depression/Endocrine risk factors with 
worse initial Executive Attention/Processing Speed and Language functioning remained 
significant, and there were no notable changes in the relationship between Working Memory and 
Cerebrovascular risk with inclusion of the cognitive reserve variables.  
Direct effects of health related risk on neurocognitive functioning while adjusting 
for age, sex, and APOE-e4 carrier status. The next set of analyses examined health-related risk 
factors effect on neurocognition in conjunction with genetic risk. All parameters for the model 
remained the same as described previously with the exception of race as a predictor being 
removed and APOE-e4 carrier status as a predictor of health related risk factors was added to the 
model. Given that race was a significant predictor within the previous models, groups were 
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stratified into a Caucasian and collapsed race groups in order to examine whether there were 
differences in the parameter estimates for these two groups. Results indicated that these two 
models’ fit and parameters estimates obtained were largely similar (AIC Change was negligible 
= 1268.78 vs. 1240.89) and both were considerably better than the Independence Model (AIC = 
9780.53). Thus, the reported analyses used the collapsed race group. Testing of this model had 
resulted in little change to the model’s fit, which remained good (CFI = .958; RMSEA = .043, 
90% Confidence Interval = .039-.048).  
 Within this model (see Table 13), APOE-e4 carrier status associated with 
Depression/Endocrine risk, but not as hypothesized Cardiovascular or Cerebrovascular risk. The 
independent covariance estimates between age with Cardiovascular and Cerebrovascular risk 
were not significant within this set of analyses; however, this may potentially reflect individual 
differences in the characteristics of those genotyped from those not genotyped. Similar to 
previous analyses, sex remained a significant predictor of Cardiovascular and 
Depression/Endocrine risk factors within this model; such that, men had a greater amount of 
Cardiovascular risk factors, while women on average had a greater amount of 
Depression/Endocrine health risk factors. Cardiovascular risk significantly associated with worse 
baseline Executive Attention/Processing speed. Depression/Endocrine risk significantly 
associated with worse language functioning and had a trend relationship worse baseline 
Executive Attention/Processing speed (See Appendix F for the statistically significant parameter 
estimates). 
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Table 13. 
Covariance Estimates Between the Predictor Variables with APOE-e4 
 
Variables (N = 398)  Estimate  S.E.  C.R. p ≤ 
Cardiovascular   <--> APOE-e4 0.02 0.02 1.11 0.269 
Cardiovascular <--> Age 0.46 0.31 1.47 0.142 
Cardiovascular <--> Sex -0.10 0.02 -4.16 0.001 
Cerebrovascular <--> APOE-e4 -0.01 0.01 -1.02 0.307 
Cerebrovascular  <-->  Age 0.13 0.11 1.20 0.231 
Cerebrovascular <-->  Sex -0.01 0.01 -1.12 0.265 
Depression/Endocrine <--> APOE-e4 0.03 0.01 2.03 0.042 
Depression/Endocrine <--> Age 0.03 0.19 0.15 0.883 
Depression/Endocrine <--> Sex 0.09 0.02 6.26 0.001 
Age  <--> Sex -0.37 0.14 -2.53 0.012 
Notes: APOE-e4 (1 = Non-carrier, 2 = carrier); Sex (1 = Men, 2 = Women);   
Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
 
 
Final Etiological Model of Risk of Cognitive Decline 
Provided with a well-fitted model of predictors of heterogeneity in neurocognitive 
functioning, a modified version of Ritchie’s (2004) hypothesized etiological model of MCI was 
conducted. In this model, demographic factors and genetic risk are presumed to be relevant 
factors that influence health related risk factors, which in turn impact neurocognitive functioning. 
Furthermore, within this model, education and intelligence are posited to have direct effects upon 
neurocognitive functioning. As depression and vascular risk factors have been shown to make 
independent contributions to MCI, the present study was specifically interested in testing two 
paths of risk for cognitive decline: Neurocardiovascular (combined cardio- and cerebrovascular 
risk factors) and Depression/Endocrine risk. 
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 Two separate sets of analyses were necessary in order to investigate the effect of race and 
genetics in relation to the other etiological factors for MCI. Model 1 examined race in 
conjunction with sex, age, and the cognitive reserve variables, while Model 2 examined APOE-
e4 carrier status in conjunction with sex, age, and the cognitive reserve variables. Results were 
largely similar for the two models and the respective models’ fit remained good (Model 1: CFI = 
.957; RMSEA = .042, 90% Confidence Interval = .039-.046 and Model 2: CFI = .954; RMSEA = 
.043, 90% Confidence Interval = .038-.047). Given the corresponding patterns between the race 
and APOE-e4 models, their results are jointly discussed.   
 The addition of the latent health variables to the model elucidated the interplay between 
the respective predictor variables on neurocognitive functioning. As hypothesized, the 
Neurocardiovascular and Depression/Endocrine latent variables associated with worse 
neurocognitive functioning in those with a greater number of risk factors and vice versa (see 
Table 14). The creation of the Neurocardiovascular latent variable representing cardio- and 
cerebrovascular risk factors significantly strengthened the relationship between neurocognitive 
functioning and vascular risk. Specifically, Neurocardiovascular risk when predicted by age, sex 
and race differences significantly associated with worse neurocognitive performance within each 
domain at baseline, as well as those with a higher amount of Neurocardiovascular risk factors 
generally demonstrated slower growth rates in neurocognitive performance from Year 1 to Year 
3 (i.e., less practice effects/learning). In assessing the specific effects of sex and APOE-e4 as 
predictors of Depression/Endocrine risk, Depression/Endocrine risk predicted worse baseline 
Executive Attention/Processing Speed and Language functioning.  
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Table 14. 
Etiological Model of Neurocardiovascular and Depression/Endocrine Risk Factors Effect on 
Neurocognitive Functioning at Baseline and Over Time 
 
Variables Neurocardiovascular Depression/Endocrine 
Model 1: Predicted by Age, Sex, and Race with Cognitive Reserve (N = 553) 
Memory Intercept -14.31** -.13 
Memory Slope -2.02** <.01 
EA/PS Intercept -17.14** -1.74** 
EA/PS Slope -.64† -.12 
Language Intercept -10.44** -1.40** 
Language Slope -.85* -.07 
WM Intercept -3.69* -.78 
WM Slope .20 -.09 
Model 2: Predicted by Age, Sex, and APOE-e4 with Cognitive Reserve (N = 398) 
Memory Intercept -22.21** .23 
Memory Slope -1.50 .28 
EA/PS Intercept -25.42** -1.37* 
EA/PS Slope -.44 -.12 
Language Intercept -15.45** -1.01* 
Language Slope -.10 .16 
WM Intercept -5.21† -.60 
WM Slope 2.28* .08 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM).  
† p < .10; * p < .05; ** p < .01. 
  
 As expected there was considerable interplay between the predictor variables (as 
indicated by the significant covariances between these variables). Appendix G and H presents the 
final models’ parameters with standardized estimates. Evidence for both direct and indirect 
effects on neurocognition indicated that these factors at the very least play a moderating role in 
the relationship between health-related risk factors and neurocognitive decline. These results 
bolster the argument that APOE genotype, age, sex, race, and health-related risk factors act as 
independent predictors but also share common variance in their effect on neurocognitive 
functioning. Figure 1 provides a combined schematic of the final etiological model(s).  
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Figure 1. Schematic of Neurocardiovascular (NCV) and Depression/Endocrine Risk Effect on 
Neurocognitive Functioning. Dashed lines indicate significant path coefficients. Bold lines 
indicate significant covariance between the predictor variables. The direct effects of education 
and estimated intelligence on neurocognition are not depicted in the figure for simplicity. 
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CHAPTER 5: DISCUSSION 
The results of this longitudinal study provide insight into the interplay between Memory, 
Language, Executive Attention/Processing Speed, and Working Memory functioning in older 
adults. The current study adds to the literature as it provides a detailed description of the 
relationship between neurocognitive changes in relation to baseline functioning within non-
demented older adults and relevant risk factors that have been associated with MCI/AD. 
Consistent with past evidence, significant decrements over time in neuropsychological test 
measures of executive function and attention/processing speed were found in cognitively intact 
older adults. Whereas, episodic memory and language performance on average improved over 
time within the present sample – thus, suggesting that these functions are relatively stable in 
healthy aging adults and that practice effects are also occurring in the majority of participants. 
All considered, these results are consistent with research that suggests intact frontal lobe 
functioning (as evidenced by performance on tests of executive function and attention/processing 
speed) is important to maintaining language and memory functioning with advanced age.  
Within the present study, several factors appeared to have moderating (and potentially 
mediating) effects on neurocognitive functioning. As hypothesized, age, race, sex, education, 
estimated intelligence, health and genetic risk were all significant predictors of neurocognitive 
functioning; such that, on average older participants, African Americans, men, less education and 
lower estimated intelligence, APOE-e4 carriers, and the presence of health risk factors associated 
with worse baseline neuropsychological test performance and differences in the estimated 
growth trajectories. Furthermore, there was a significant amount of interplay between the 
individual difference variables and evidence of different patterns of cognitive profiles in relation 
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to individual differences in the predictor variables. Overall, results indicate that there was 
substantial heterogeneity within neurocognitive functioning that might be explained by 
individual differences in the degree of risk variables. 
The sections that follow provide a discussion on the present study’s findings with their 
potential implications integrated into each section. To begin, the interplay between 
neurocognitive functions as measured by the latent variables of Memory, Executive 
Attention/Processing Speed, Language and Working Memory are discussed within the context of 
Aim 1’s hypotheses and goals. Following the presentation of the structural model’s results, the 
effects of the respective predictor variables on these neurocognitive functions in older adults are 
discussed and integrated into an etiological model of risk for cognitive decline. Subsequently, 
potential implications of study attrition and differences between demographic groups in relation 
to neurocognitive functioning are considered and study limitations are presented. A brief 
summary of the main findings with future research directions concludes the discussion section. 
Within and Between Neurocognitive Domain Variance in Older Adults 
 Aim 1 sought to elucidate the interplay between Memory, Executive 
Attention/Processing Speed, Language and Working Memory functioning in older adults through 
systematically investigating relationships between baseline neuropsychological performance and 
linear changes in these processes over a three-year period via multivariate LGC modeling. 
Consistent with previous research on the UDS neuropsychological battery, the posited four-
factor solution provided an excellent fit for the data. Analyses were designed to avoid over-
parameterization of the model and to ensure that a more parsimonious model of global cognition 
did not better explain the data. The covariances placed between the neurocognitive domain 
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intercepts was soundly based on the well-accepted notion that Memory, Executive 
Attention/Processing Speed, Language, and Working Memory all, to some degree, share 
cognitive resources yet have specialized functions. Relatedly, although it was posited that there 
would be shared variance between these factors, it was not expected that a global second-order 
neurocognitive factor would better explain the data. Indeed, it was the case that the four-factor 
model of neurocognition had an excellent fit as compared to the competing global common 
process models. Furthermore, the expectation of shared variance was supported, as each 
covariance between the different neurocognitive domains intercept means were significant at 
baseline.  
Provided with an excellent fitting model, Aim 1’s analyses assessed baseline 
neurocognitive functioning and the degree to which specific neurocognitive processes changed 
over time in relatively healthy older adults. In accord with past research and the present study’s 
hypotheses, individuals with initially lower Memory, Language, Executive Attention/Processing 
Speed, and Working Memory performance concomitantly had lower scores on each of the other 
neurocognitive latent variables at baseline. There was also evidence of practice effects as 
indicated by the linear growth rate in Memory scores from Year 1 to Year 3, and although not 
hypothesized performance enhancement was noted on the Language factor over time. There were 
no notable changes in the Working Memory factor over time suggesting that verbal working 
memory/auditory attention is relatively stable within normal aging. As hypothesized Executive 
Attention/Processing Speed performance declined over the three-year period. This finding is 
consistent with Raz et al.’s (2000, 2004) suggestion that neuropsychological test measures 
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presumed to tap frontal and superior parietal lobe functioning show a significant decrement over 
time even in cognitively intact older adults.  
Contrary to the study’s posited directionality, but consistent with the law of initial values, 
initially higher Memory functioning associated with a slower annual growth rate in memory. The 
hypothesis that lower baseline Executive Attention/Processing Speed would predict steeper 
annual rates of decline in Executive Attention/Processing Speed was not supported. Exploratory 
analyses indicated that initial differences in baseline Language and Working Memory 
functioning did not respectively predict within-neurocognitive domain incremental annual 
changes in these processes.  
As expected, there was considerable interplay between the neurocognitive processes in 
relation to linear changes over the three-year period. Consistent with the study’s hypotheses,, 
older adults who demonstrated higher initial Executive Attention/Processing Speed functioning 
at baseline demonstrated greater incremental increases in Memory performance over time. In 
turn, higher initial Memory functioning predicted greater incremental increases in Language 
performance over time. Although the relationship between baseline episodic memory and 
incremental language change was not anticipated, these findings are of interest, considering 
verbal fluency in conjunction with memory functioning has been posited to be the best predictor 
of MCI/AD (Howieson et al., 2008). The hypothesis that incremental changes in Language 
functioning would be predicted by baseline Executive Attention/Processing Speed performance 
was not supported.  
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In analyzing the degree to which annual rates of neurocognitive change associated with 
one another, results indicated that on average as Memory, Language, and Executive 
Attention/Processing Speed scores increased over time, there were respective increases in each 
of the other processes with the exception of Working Memory. Notably, incremental increases in 
Language functioning from Year 1 to Year 3 was the only neurocognitive process to associate 
with gradual increases in Working Memory functioning. Lastly, as expected, there was 
consistently large variability in these processes across individuals.  
 Aim 1 summary and future directions. In all, these results indicate that there is 
substantial heterogeneity in older adults in their initial levels of cognitive functioning and in 
linear changes in these processes over time. Subtle declines in executive function and attention 
processes over the three-year period were found, while on average memory and language 
performance improved with repeated testing within the cognitively intact older adults. As 
expected, lower executive function and attention performance at baseline predicted less 
incremental growth rates in memory. In turn, higher initial memory functioning associated with 
incremental improvements in language from Year 1 to Year 3. Improvement in language 
functioning did not associate with measures of executive function and attention/processing speed 
at baseline; this may partially due to the different nature of the language tasks (verbal fluency vs. 
confrontation naming). 
 Mechanistically efficient semantic knowledge retrieval (particularly verbal fluency) is 
believed to involve frontal lobe processes as well as language systems, while deficits in 
confrontational naming tasks (BNT) in older adults has been linked to damage in memory 
regions (left hippocampal damage, see Lezak et al., 2004). There is also research that suggests 
  94
that the posterior parietal cortex plays an intermediary role in extending long-term memory 
processes through its interconnections with both the frontal lobe and the medial temporal lobe 
(see Shannon & Buckner, 2004). Thus, in light of these findings, it may be that language tasks 
(which are believed to involve frontal and parietal cortices in addition to language systems) 
recruit similar compensatory processes as episodic memory to preserve cognitive functioning 
with advanced age. This suggestion, although highly speculative, seems consistent with the 
evidence that has thus been presented.  
 The above conceptualization is consistent with previous research that indicates that 
decrements in executive function and attention (accompanied by slower processing speed) are 
common within “normally” aging older adults. Relevantly, brain imaging studies indicate that 
the regions of the brain (e.g., frontal and frontoparietal areas) that are primarily responsible for 
these neurocognitive processes serve to compensate for age-related decline in more posterior 
regions of the brain that support memory and language functioning (e.g., the hippocampus and 
medial temporal lobe). Furthermore, as evidenced by activations during older adults’ successful 
memory recall, there appears to be an age-related shift in neural recruitment that indicates that 
frontal and the posterior parietal regions become increasingly involved in memory functioning 
within older adults. Putting it all together, older adults who have preexisting vulnerabilities 
within any one of these regions (as evidenced by neurocognitive test performance and/or 
imaging studies) are at greater risk of moving closer to MCI/AD disease threshold as a function 
of age-related shifts in neural resources. Importantly, more longitudinal research integrating 
brain imaging with neuropsychological assessment is needed to reconcile that the brain regions 
(frontal and superior parietal areas) posited to compensate for declines in other neural processes 
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are also believed to be amongst the first to decline with age (Raz, 2000). Further research is also 
needed to shed light on the relationship between episodic memory and changes in language 
processes in cognitively intact older adults. 
Practice Effects 
The nature of the present study design was that participants had equal exposure to tests, 
and thus, theoretically could equally benefit from previous test exposures. It was posited that 
failure to benefit from practice effects would be linked to neurocognitive decline. Indeed, the 
present study found several notable relationships that were suggestive of individual differences 
in practice effects that may serve as useful indicators of cognitive decline.  
First, as noted previously, memory functioning improved over time with additional 
exposures, providing support for the hypothesis that there would be practice effects on the 
memory measures. However, inconsistent with expectations, those with higher initial Memory 
functioning did not demonstrate a steeper increase in these scores over time. Rather, those with 
lower initial Memory functioning demonstrated greater gains in these abilities from Year 1 to 
Year 3. These results could be interpreted as those with higher initial Memory functioning 
demonstrated a slower rate of improvement due to their initial higher values (i.e., less to gain) or 
conversely higher functioning individuals did not experience practice effects (suggesting 
cognitive decline within these individuals). Relevantly, as discussed, a problem that can arise 
with interpretation of longitudinal research involves the law of initial values, which suggests that 
the degree of change produced is dependent on initial values. In considering these alternative 
explanations as to why participants did not equally benefit from previous test exposures, it is 
important to note that while there did not appear to be evidence of ceiling effects on the episodic 
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memory tests (as indicated by significant skew or a truncated range at any time point), test 
sensitivity alone does not rule out the law of initial values. Thus, it is important to consider the 
overall pattern of results, that is, those with higher memory functioning at baseline 
concomitantly demonstrated higher performance across each of the other neurocognitive 
domains. Furthermore, higher initial Memory functioning was predictive of subsequent annual 
gains on the language measure. Taken together, these findings argue against those with higher 
baseline as compared to lower baseline memory performance demonstrating memory decline.  
Secondly, these results may indicate that in order to optimally benefit from previous test 
exposures executive function and attention processes need to be intact, as those who started with 
higher executive function and attention/processing speed functioning at baseline demonstrated a 
steeper rate of growth in memory functioning over time. This suggestion is somewhat consistent 
with scaffolding theories that suggest that the neural networks believed to underlie executive 
function and attention processes play a vital role in learning processes that increase overall 
neurocognitive efficiency. As Petersen et al.’s (1998) seminal work on the functional anatomy of 
skill acquisition cogently argued, the systems involved in practice effects are not entirely task-
specific, as novel verbal generation tasks require effort and thus employ top-down cognitive 
control to effectively cope with cognitive demands. However, once learning processes have 
occurred (as suggested by greater proficiency at task), the task becomes more automatic and no 
longer requires higher cognitive control. While this evidence on the anatomical basis of practice 
effects was cross-sectional in its nature, others have noted that practice effects appear to be 
enduring and are evident across neuropsychological domains.  
 
  97
Determining the true nature of potential practice effect differences within this study is 
difficult in that there was a significant interplay between the neurocognitive domains and there 
was also consistently large variability in these processes across individuals. Furthermore, in 
regards to memory performance, the amount of material recalled at any given time point may be 
limited by factors other than memory functioning (e.g., initial test anxiety could lower baseline 
memory scores). Indeed, as will be discussed, the rate of change in memory over time was 
influenced by other factors (e.g., age and estimated intelligence). Thus, these findings will be 
further discussed in the context of the predictor variables. 
Relevant Predictors of Neurocognitive Functioning in Older Adults 
While subtle changes in neurocognitive functioning occur as part of the normal aging 
process, there is considerable variability in the degree to which older adults experience cognitive 
impairments. Based on previous research and theoretical speculation, multiple indicator parallel 
growth process LGC model(s) relating older adults neurocognitive performance to relevant 
predictors were conducted to answer the degree to which of Memory, Executive 
Attention/Processing Speed, Language and Working Memory at baseline and changes over time 
(Year 1 to Year 3) differ as a function of these factors.  
Age. The first set of analyses was specifically interested in the degree to which age 
impacts neurocognitive functioning when sex and race are adjusted for in the model. As 
hypothesized, greater age at baseline predicted worse initial functioning in each of the respective 
neurocognitive domains. Consistent with past research (see Calamia et al., 2012), older age 
associated with slower growth rates in Memory, Executive Attention/Processing Speed, and 
Language functioning from Year 1 to Year 3. The finding that older adults benefited less from 
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previous test exposures (as evidenced by older adults’ slower annual growth rate) may indicate 
an age-related vulnerability in the cognitive processes involved in procedural test learning (i.e., 
failure to benefit from practice effects).  
Race. Consistent with previous research, differential effects for race on neurocognitive 
functioning and the degree of risk factors for cognitive decline were found. African American as 
compared to Caucasian participants had a higher rate of cardiovascular risk factors and the 
likelihood of being an APOE-e4 carrier was also significantly greater within African American 
(54.5%) as compared to Caucasian/Latino (23.3%) participants. On average Memory, Executive 
Attention/Processing Speed, Language, and Working Memory functioning appeared to be 
initially lower in African American as compared to Caucasian participants; however, race was 
not related to the annual rate of growth or decline in neurocognitive functioning. For cognitive 
reserve factors, African American participants on average obtained higher levels in education but 
were lower in estimated intelligence than Caucasian participants. The addition of the cognitive 
reserve variables attenuated the relationship between race with Language and Working Memory 
functioning – however, significant effects remained between race with Memory and Executive 
Attention/Processing Speed even when these factors were adjusted for in the model.  
In discussing the findings in regards to race it is important to note that the NAART word 
reading test might be a biased indicator of intellectual functioning within African Americans. 
Research indicates that educational quality and/or ethnic differences in pronunciation can 
contribute to race/ethnic performance differences on word reading tests (See Lezak et al., 2004). 
Of interest, a study that conceptualized the original version of the NAART (i.e., the National 
Adult Reading Test that has not been modified for North American pronunciations) as a measure 
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of educational quality found that word reading scores was the only the factor to explain race 
differences in episodic memory functioning within older adults (Fyffe et al., 2011). Similar to the 
present study, African American participants were higher in education than Caucasian 
participants; however, this study did not investigate relevant genetic risk in relationship to race 
differences in episodic memory. Relevantly, the present study (and others) have found 
associations between APOE-e4 with episodic memory. In addition, the present study found 
NAART scores associated with APOE-e4 and predicted both baseline and incremental growth in 
episodic memory functioning (indicative of learning/practice effects). Considering the higher 
ratio of APOE-e4 carriers in African Americans along with the pattern of findings within the 
present study, it is possible that lower cognitive reserve as a function of genetic risk may 
potentially explain the relationship between NAART and episodic memory. Collectively, these 
results suggest that improving education quality, particularly in reading abilities may lend 
cognitive resilience in older adults. In this respect, albeit a controversial measure of estimated 
intelligence, the NAART overall appears to be a useful predictor of cognitive reserve. 
Finally, it worth noting this study is a Deep South cohort. From a biopsychosocial 
perspective it is important to acknowledge the potential contribution of racial disparities and 
prejudice that may increase daily life stress – which, both psychologically and biologically (e.g., 
chronic psychosocial stress activation of the hypothalamic-pituitary-adrenal axis) would be 
expected to impact neurocognitive functioning and overall cardiovascular health. It is also 
conceivable that the higher proportion of APOE-e4 allele carriers and lower neurocognitive 
functioning within the African American participants within the present sample could be 
indicative of a selection bias, that is African Americans on average participated in the study due 
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to having greater concerns regarding their cognitive functioning. Overall, these findings 
emphasize the need for more ethnically and racially diverse sample populations, before any 
conclusions on racial differences be made (see study limitations for further discussion). 
Sex. Despite women having higher rates of AD, research suggests that within the oldest-
old women overall outperform men on cognitive tests despite their lower education levels (Van 
Exel et al., 2001). Similarly, normative research on the NACC’s UDS neuropsychological test 
battery found that older adult women as compared to men perform significantly better on all its 
measures with the exception of digit span and category fluency (animal) tests (Weintraub et al., 
2009). Consistent with previous research, within the present study on average women had higher 
initial scores on Memory, Executive Attention/Processing Speed, and Language measures than 
men, while men generally demonstrated better Working Memory functioning than women at 
baseline. Women when compared to men also demonstrated overall greater gains in their 
language scores over time. In addition to sex differences in neurocognitive performance, women 
with the present sample were on average younger than men, had less cardiovascular risk factors 
but greater depression/endocrine risk factors, and were lower in years of education. These results 
provide further evidence that on average women demonstrate greater resilience to age-related 
cognitive decline than men (McCarrey et al., 2016), which may potentially be explained by 
differences in health risk factors. 
Cognitive reserve. In the present study, while levels of education and estimated 
intelligence were correlated with one another, attempts to form a common latent variable from 
these factors failed. Thus, indicating that they may make unique contributions to neurocognitive 
functioning. Consistent with this notion, estimated intelligence as compared to education levels 
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demonstrated both common and unique relationships with neurocognitive functioning. 
Specifically, while both higher levels of education and estimated intelligence predicted higher 
initial Memory and Language functioning, only estimated intelligence associated with better 
Executive Attention/Processing Speed and Working Memory performance at baseline. 
Additionally, higher levels of estimated intelligence predicted modest annual increases in 
Memory and Executive Attention/Processing Speed latent factor scores; whereas, education level 
was not related to linear changes in neurocognitive functioning over time. Of further interest, 
after adjusting for the influence of education and intelligence within the model, the previously 
reported effects of race on initial working memory and language functioning were both no longer 
significant. Conversely, sex differences were strengthened by inclusion of the cognitive reserve 
variables. Notably, significant sex differences predicted Memory, Executive 
Attention/Processing Speed, Language, and Working Memory functioning. Considering women 
on average obtained lower education levels as compared to men, yet demonstrated better overall 
neurocognitive performance (with the exception of working memory), these enhanced effects 
were not surprising. In sum, these factors appeared to have a moderating effect on observed race 
and sex differences in neurocognitive performance. 
Genetic risk. Given significant interactions between sex, age, and education with APOE-
e4 carrier status within the literature, the degree to which the presence of APOE-e4 predicted 
neurocognitive functioning when these variables are adjusted for in the model was investigated. 
Those who were genotyped were more likely to be younger, African American, with less 
cardiovascular and cerebrovascular risk factors. The shared covariance between race and APOE-
e4 carrier status indicated that African American participants had a higher ratio of APOE-e4 
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carriers than Caucasians. However, due to the limited African American participants with 
genotyping within the present sample, examination of race differences would not have been 
statistically valid given the skewed sample distribution. Importantly, the hypothesized sex 
difference in APOE-e4 carrier status was not found. Furthermore, results within the present 
sample indicated that APOE-e4 carrier status did not covary with sex, education or age. 
Consistent with previous research, memory functioning was significantly lower in APOE-e4 
carriers as compared to non-carriers – this effect remained even when sex, age, and education 
were adjusted for in the model.  
Next, exploratory analyses examined the influence of estimated intelligence within the 
model. Notably, inclusion of estimated intelligence revealed a trend relationship between lower 
intelligence in APOE-e4 carriers, and attenuated the significant effect of APOE-e4 on baseline 
memory functioning. Although not part of the original hypotheses, the relationship between 
APOE-e4 and estimated intelligence is compatible with evidence that the APOE-e4 exert its 
effects on neurocognition earlier on prior to the onset of significant disease pathology. Or 
alternatively, lower estimated intelligence scores within APOE-e4 carriers may be an indication 
of cognitive deterioration as evidenced by its significant relationship with lower neurocognitive 
functioning; however, this suggestion is less consistent with research that has demonstrated that 
the NAART is a relatively robust measure of estimated intelligence in cognitively intact adults. 
NAART scores have demonstrated strong intraindividual correlations across the life span (age 
eleven to seventy-seven, r = .77) and word reading tests have been found to be fairly resistant to 
brain insult within healthy aging adults (See Strauss, Sherman, Spreen, 2006). Furthermore, 
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word reading deterioration is usually not evident until the later stages of dementia and overall 
word reading scores tend to improve with age (Strauss et al., 2006).  
Exploratory analyses that excluded individuals with a copy of the e2 allele, found that 
e3/e4 carriers as compared to e3/e3 carriers demonstrated both worse baseline memory 
functioning and slower growth rates in executive function and attention/processing speed from 
Year 1 to Year 3. This finding is worthy of future investigation, as it is possible that a copy of the 
e2 allele has protective effects on the underlying processes involved in executive function and 
attention/processing speed declines. In line with this notion, dose-related responses of reduced 
parietal activation within cognitively intact homozygous as compared to heterozygous APOE-e4 
carriers has been found (Lind et al., 2006). Notably, these differences were found in absence of 
cognitive differences, thus, suggesting that changes in task-related brain responses may be 
evident prior to behavioral manifestations. Future studies will also need to assess zygosity effects 
on neurocognitive functioning in relation to relevant risk variables, as there is research to suggest 
that older healthy adult e3/e4 as compared to e3/e3 carriers demonstrate worse memory 
functioning that is linked to structural brain differences (reduced gray matter density in the right 
MTL, bilateral PFC, temporal cortex, and cerebellum) even in the absence of differences in 
demographic factors and estimated intelligence (Wishart et al., 2006). All considered, more 
longitudinal studies that incorporate imaging techniques in relation to APOE-e4 zygosity and 
risk variables are needed to further substantiate neurocognitive endophenotypes for MCI/AD. 
Health related risk factors: Etiological model of neurocognitive decline. Supporting 
the study’s etiological model(s) of neurocognitive decline, the predictor variables of sex, age, 
race and genetic risk had direct effects on neurocognitive functioning and were also significant 
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predictors of health-related risk factors. Inclusion of the direct effects of predictor variables on 
the latent health variables and combining the cardiovascular and cerebrovascular risk factors into 
a common latent variable significantly strengthened the relationship between health-related risk 
and neurocognitive functioning.  
Review of the standardized estimates indicated that age specifically accounted for 37% of 
the variance in Neurocardiovascular risk, sex accounted for 18% of the variance, and race 
accounted for 11% in Neurocardiovascular risk. 16.3% of the variance in Depression/Endocrine 
risk was accounted for by sex, while APOE genotype accounted for approximately 5%. Overall, 
estimated intelligence was an important predictor of neurocognitive functioning, while the 
effects for education and APOE-e4 on neurocognitive functioning were minimal.  
Within the final model(s), sex, age, and race predicted Neurocardiovascular risk, while 
sex and APOE-e4 carrier status were significant predictors of Depression/Endocrine risk. Greater 
age associated with a higher amount of Neurocardiovascular risk factors but not 
Depression/Endocrine risk factors. Men and African American participants were significantly 
more likely to have a history of Neurocardiovascular conditions, while women on average had a 
greater history of Depression/Endocrine risk factors. Neurocardiovascular risk was directly 
associated with worse neurocognitive performance across domains and accounted for the largest 
amount of variance in cognitive function. Consistent with previous research, 
Neurocardiovascular history was a significant predictor of not only lower Executive 
Attention/Processing Speed but also of Language and Memory functioning at baseline. 
Neurocardiovascular risk factors also predicted a slower growth curve in neurocognitive 
performance across domains from Year 1 to Year 3. Adjusting for the cognitive reserve variables 
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in the model significantly attenuated the relationship between Neurocardiovascular risk and 
Language functioning. A history of Depression/Endocrine risk predicted worse Executive 
Attention/Processing Speed and Language functioning at baseline; this relationship appeared to 
be strengthened by the inclusion of sex and APOE-e4 as predictors of Depression/Endocrine risk. 
Aim 2 summary and future directions. Several important findings emerged from this 
study. First, despite significant relationships between the predictor variables and neurocognitive 
functioning, overall the effect sizes in relation to neurocognitive functioning were relatively 
small. Notably, there was considerable interplay between the predictor variables with health risk 
on neurocognitive functioning, thus suggesting that these factors at the very least play a 
moderating role in the relationship between health-related risk factors and neurocognitive 
decline. Second, there was no evidence of shared variance between sex, education or age with 
APOE-e4 carrier status within the present sample. Age was an important predictor of 
neurocognitive performance and the degree of neurocardiovasular risk. With respect to race, the 
findings within the present study are consistent with previous research that suggests that race 
differences in cognitive decline are moderated by several other factors, most notably being 
cardiovascular and genetic risk factors. However, given the low number of African American 
participants and possible selection bias, results regarding race within the present study must be 
interpreted with caution. Higher levels of education and estimated intelligence did indeed appear 
to provide cognitive resiliency, as these variables were both associated with better 
neurocognitive performance. 
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 Consistent with past research, the presence of APOE-e4 was associated with worse 
memory functioning even when age, sex and education were adjusted for. Interestingly, lower 
estimated intelligence was linked to APOE-e4 and inclusion of intelligence attenuated the effect 
of APOE-e4 on memory functioning. Sex (women) and APOE-e4 predicted a greater history of 
Depression/Endocrine risk factors that, in turn, associated with worse Executive 
Attention/Processing Speed and Language functioning at baseline. Differences in sex (men), race 
(African Americans) and greater age were all significant predictors of the degree of 
neurocardiovascular risk. Neurocardiovascular risk in turn predicted lower neurocognitive 
functioning across domains.  
These findings are consistent with prospective cohort studies that suggest preclinical 
cognitive impairments of vascular origin associate with more broad cognitive changes than 
preclinical AD phases (e.g., Ingles et al., 2007).  Notably, research also indicates that vascular 
factors accelerate the pathological processes of AD (Sadowski et al., 2004); thereby, further 
increasing risk for cognitive decline. In sum, these findings are strongly suggestive of there being 
additive and interactive effects between risk factors influence on neurocognitive functioning and 
are consistent with past research that suggests heterogeneity in neurocognitive functioning within 
older adults is multifaceted. Lastly, the pattern of sex related differences in health-related risk 
factors and neurocognitive functioning could potentially indicate that men and women might on 
average differ in their risk profiles for a dementia disorder. 
On a final note, the finding that genetic predisposition for AD was related to a history of 
depression and endocrine dysfunction is worthy of further discussion, considering the potential 
implications of heightened inflammatory responses (e.g., via dysregulation of the hypothalamic-
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pituitary-adrenal axis) and/or catecholamine dysregulation that are common in depression. This 
is not the first study to link APOE-e4 to depression symptoms. In a large study conducted with 
323 AD patients, 72% of depressed AD patients with depression carried at least one copy of the 
ε4 allele, as compared to 58% of non-depressed patients (Delano-Wood et al., 2008). 
Remarkably, this associated risk was four times higher within females, while APOE-e4 status did 
not predict depression among men. While there is evidence that depressive symptoms predict 
subsequent memory decline (when age, sex, education, race, ethnicity, and vascular disease are 
adjusted for in the model, Zahodne et al, 2014), there is also research that has demonstrated that 
cognitive symptoms precede depressive symptoms in older community dwelling Latina/o adults 
with on average lower education (Perrino, Mason, Brown, Spokane, & Szapocznik, 2008). The 
latter results potentially indicate that biopsychosocial factors that are associated with less 
education or cognitive reserve play a role in the relationship between late-life depression and 
neurocognitive decline. Although the directionality of the relationship between memory and 
depressive symptoms in late life is unclear, these results appear to suggest that depression may 
be an important indicator of prodromal stages of cognitive decline and/or might be an underlying 
etiological factor in MCI/AD pathology. Indeed, Johnson et al. (2013) have proposed a 
depressive endophenotype of MCI and AD. In this respect, more research is needed to 
investigate the underlying mechanisms between depression and cognitive changes in older 
adults.  
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Implications for Clinical Practice and Future Research 
Given our increasing knowledge of the reciprocal interplay between risk factors that also 
are presumed to have a biological basis, it is recommended that future research uniformly assess 
for individual difference factors that have been shown to influence functional outcomes in older 
adults. In clinical practice, medical and psychological comorbidities appear to be the rule rather 
than the exception. In line with this, the present study demonstrated that there is significant 
interplay between demographic and health-related risk factors, and that their inclusion is 
clinically relevant in interpreting findings regarding neurocognitive functioning. Disentangling 
the relationship between risk factors and neurocognitive decline will require more studies that 
examine a broader spectrum of clinical characteristics (e.g., inclusion of individuals with 
depression) within cognitively intact older adults. 
From a treatment perspective, currently diagnosis of MCI/AD generally remains divorced 
from interventions that are non-pharmacological. Given this fact, it is important that research not 
only continues to improve the sensitivity and specificity of measures used to detect MCI, but also 
that clinical recommendations be developed for suspected preclinical stages of MCI/AD. The 
present data indicates that there are important modifiable factors that influence neurocognitive 
decline. Even to the layperson, the implications are obvious – psychological and physical health 
impacts neurocognitive functioning. Further, the majority of individuals are aware of the 
ramifications of health behaviors and that they likely need to eat better, exercise more, and so on. 
It is also important to consider the negative effect that declines in cognitive functioning can have 
on psychological and physical health (e.g., decreased activities of daily living).  
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In light of these considerations and the enormous burden of AD, there is a present need to 
develop and improve upon applied behavioral interventions effectiveness so that people 
experiencing early symptoms of neurocognitive decline may benefit from intervention prior to 
substantial neurodegenerative processes are incurred. Within other neurological conditions, there 
is some initial support that early interventions at sensorimotor levels can improve neural 
functioning (e.g., neural feedback and mental simulation tasks have been shown to have 
rehabilitative effects) as well as changes in health-related behaviors have been shown to modify 
courses of diseases that are linked to cognitive decline. However, to my knowledge, research on 
applied cognitive behavioral interventions that target these factors in conjunction with cognitive 
remediation strategies within older adults has been sparse if not non-existent.  
Study Attrition and Missing Data 
 Consistent with a previous cognitive aging study that investigated predictors of attrition 
over a three-year period (Van Beijsterveldt et al., 2001), individuals that dropped out obtained 
lower educational levels, had a greater number of cardiovascular risk factors, and demonstrated 
worse performance on neuropsychological tests at baseline; however, unlike Van Beijsterveldt et 
al. age and sex (women) were not linked to differences in attrition rates. In addition, African 
American participants on average had a greater attrition rate than Caucasian participants within 
the present sample. 
 In considering patterns of attrition rates on the findings within the present sample, it is 
important to discuss the sample characteristics. Women within our sample were younger than 
men, generally performed better on the neurocognitive tests, and the relative frequency of 
genetic risk was lower in women (i.e., a trend towards men having a greater likelihood of 
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carrying an APOE-e4 allele). Women were higher in factors that are associated with lower 
attrition rates, while African American participants tended to be higher on risk factors associated 
with greater attrition rates (e.g., lower neuropsychological test performance and greater 
cardiovascular risk factors). In assessing the cognitive reserve variables influence on study 
attrition outcomes, it is important to emphasize that even though the study dropouts were 
significantly lower in years of education and estimated intelligence, their estimated intelligence 
still fell well within the average range and they had obtained on average three years of college 
education. Furthermore, while neuropsychological test scores in dropouts as compared to 
enrollees were comparatively lower, the majority of dropouts’ scores remained within normal 
ranges on the UDS standardized test measures. Finally, in addition to there being between race 
and sex group differences, socio-demographic factors were also highly correlated with one 
another suggesting that there are significant interactions between these variables. Determining 
the directionality and reciprocity of these relationships in relation to attrition is important in that 
individuals that tend to dropout of studies are also more prone to belong to groups at higher risk 
for a dementia disorder. 
From a statistical standpoint, when attrition is associated with potentially predictable 
reasons (e.g., education, health, or race), and when these factors are measured, MLE methods 
tend to be fairly effective at recovering missing data for these cases (Little, 2013). However, 
given strong evidence for group differences in the dependent variables, a cautionary approach 
was taken in the model analyses, such that complete datasets (using listwise deletion methods) 
were used for the primary analyses and supplementary analyses were conducted using MLE 
methods to estimate missing values for Aim 1’s and 2’s final models. Comparison of parameter 
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estimates between the complete and incomplete data set models and their respective fit indices 
were relatively close to one another - thereby, further increasing our confidence in the identified 
constructs and their interrelationships.  
These findings are consistent with others who have reported that attrition has little effect 
on longitudinal estimates of cognitive change, even in the presence of individual differences 
neurocognitive, demographic and educational characteristics (Beijsterveldt et al., 2001; 
Salthouse, 2014). Regarding the predictor model, MLE methods for the missing value dataset 
resulted in a non-positive covariance matrix when estimated intelligence was adjusted for in the 
model. It was the outside of the scope this study to further investigate the nature of theses 
difference, however given the strong evidence for group differences between enrollees and 
dropouts on many of these factors, future research intends to further investigate these patterns of 
missing data in those that dropped out and those with three-years of follow-up visits (e.g., testing 
cross-sectional factorial invariance across groups). 
Finally, while it is attempting to conclude that differences in neuropsychological test 
performance at baseline predicted study attrition, as with all cross sectional research participant’s 
test performance may be influenced by other extraneous variables such as stereotype threat bias, 
test anxiety or simply a poor night’s sleep. Furthermore, it is important to consider the role of 
motivational factors, as it possible that group differences between enrollees and dropouts are 
related to environmental and/or stable individual differences in factors related to task persistence 
(e.g., the majority of study dropouts had attended college but had not completed their degree). In 
this respect, inclusion of effort measures to assess for low motivation in future cognitive aging 
studies is recommended. 
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These results and others emphasize that as we attempt to understand change in cognition 
with advanced age, we must also improve methods of retaining participants who may be more 
vulnerable to study attrition and/or cognitive decline. Notably, there was a truncated range in 
education levels and individuals with less education were more likely to dropout from the present 
study. It is possible that the lack of educational range in this study sample is related to practical 
issues - such as, those with higher education tend to have greater resources (e.g., available 
transportation and greater flexibility in their schedules) that enhance their ability to participate in 
research. Suggestions for broadening sample demographics in future studies include having more 
flexible study hours (e.g., weekend hours), and/or provision of transportation or conducting 
mobile assessments. Future investigation into the role of motivation on study attrition and 
neurocognitive decline in older adults is also warranted. 
Study Limitations 
As discussed above, although potentially more costly and less “convenient”, there is a 
strong need for study protocols that implement recruitment and retention strategies to increase 
sample diversity in cognitive aging research. LABrainS participants are generally college 
educated, predominantly white, with a higher proportion of females than male, which may limit 
the generalizability of these findings. Lack of educational range is also relevant considering that 
sample populations with similar characteristics of higher in education tend to exhibit greater 
health related behaviors that can influence cognitive trajectories (Welsh-Bohmer et al., 2009). 
Unfortunately, these limitations are not specific to this study, as lack of demographic diversity is 
a common issue within geriatric research, if not research in general. Overall, these findings and 
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others clearly demonstrate the need to enhance both recruitment and retention strategies for 
obtaining broader demographic samples in cognitive aging research.  
Other potential limitations within the present study arise from decisions regarding 
statistical choices and measurement selection. To begin, in order to simplify an already 
complicated analyses, time-invariant measures were used for all predictor variables. It is possible 
that different results would have emerged for age and health related risk factors had they been 
studied dynamically. Secondly, although accepted statistical procedures were used to handle 
non-normally distributed variables and in the definition of outliers, a question always remains the 
degree to which results were affected by such procedures. For instance, it is possible that cases 
removed due to multivariate non-normality are part of the population of interest. For this reason, 
this study specifically chose to use Winsorized means as opposed to case deletions to assist in 
normalizing data distributions, as we wanted to retain as many extreme cases as these 
participants were posited to be part of the population of interest. Of further interest, qualitative 
analysis of the few cases that were deleted due to significant multivariate heterogeneity that was 
not amenable to transformations across the neuropsychological variables (as indicated by D2) 
indicated that two of the deleted cases had a significant familial history of AD in their first-
degree relatives. I believe that this qualitative example serves as a reminder that it is also critical 
that we attempt to understand “extreme cases” – as it is easily conceivable that multivariate 
heterogeneity within performance is an important indicator of cognitive decline. In this regard, 
case studies remain an important although often overlooked contribution to the field. 
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A goal of this project was to provide a comprehensive investigation of the relationship 
between neurocognitive functioning within non-demented older adults and relevant risk factors 
that have been associated with MCI/AD.  In doing so, many exploratory relationships were 
tested. Although these relationships tested were based on prior evidence within the literature and 
all tests were two-tailed, there is the possibility that Type I errors were increased with the use of 
multiple comparisons. Future research designed to replicate these results is highly encouraged.  
The present study was based on archived data utilized from the NACC’s UDS 
neuropsychological test battery, and while the UDS battery has considerable empirical support 
for its sensitivity in detecting cognitive change in older adults, a more comprehensive assessment 
of each of the neurocognitive domains, particularly in regards to executive function and memory 
functioning is recommended for future research. Additionally, the present study lacked an 
adequate measure of visuospatial functioning. The CDT was a poor indicator of 
visuospatial/working memory functioning within the present sample, and was thusly discarded 
due to its poor reliability. Despite these potential methodological limitations, the longitudinal 
information obtained from use of the UDS neurocognitive test battery in the present study is 
important in guiding future studies that utilize the NACC’s database for research. For instance, 
as previously discussed, this study adds to the body of research that recognizes the effect of 
previous test exposure to future test performance. As expected, there were considerable 
indications of practice effects on the UDS neuropsychological test battery. In this respect, these 
results have important implications for the handling of cross-sectional analyses of the NACC’s 
UDS database – in that, collapsing different annual cohorts’ data for cross-sectional analyses 
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should be strongly discouraged given strong evidence of practice effects on many of the 
neuropsychological study measures.  
Finally, in considering the lifespan, three years is not a very long period to observe 
neurocognitive change. Participants will need to be followed for a more extended duration of 
time to better delineate the nature and magnitude of declines in neurocognitive functioning in 
relation to genetic, demographic, and health risk factors.  
Study Summary 
Improving measures to detect preclinical AD is a vital research direction, as earlier 
interventions may prove more efficacious in altering the disease’s trajectory. Preclinical AD 
patients often present with an array of neurocognitive symptoms as well as subtle impairments in 
visual, motor and auditory sensory systems. Research regarding which neurocognitive 
function(s) best predicts cognitive decline has been mixed. While some studies suggest that 
memory functioning is the best predictor of pre-MCI/AD disease states in older adults, other 
studies have indicated that wider spread neurocognitive impairments may be the best predictor 
for distinguishing normal aging adults from those with MCI. Endophenotype models are useful 
in that they help to identify individuals at high risk for MCI/AD, through linking genetic risk to 
cognitive functioning prior to disease states. 
Within the present study, executive attention/processing speed was the only 
neurocognitive domain to demonstrate a significant decrement over the three-year period across 
a broad age range of older adults. Conversely, both memory and language performance on 
average improved over time, indicating that these processes benefited from practice effects 
within normally aging adults. As expected, lower executive function and attention/processing 
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speed performance at baseline predicted less incremental growth rates in memory. Furthermore, 
APOE-e4 specifically associated with worse baseline memory functioning supporting episodic 
memory’s role as a neurocognitive endophenotype for AD. Of notable interest, lower initial 
memory functioning predicted slower language growth rates. These findings are consistent with 
research that suggests intact executive function and attention processes are important to 
preserving memory and languages functioning in older adults. Results are also compatible with 
indications that neuropathological changes involved in neurocognitive decline are at least to 
some degree associated with aging processes (Jack et al., 2015) and that cognitive inefficiency in 
older adults appears to some extent reflect decrements in attention network systems.  
Overall, these results provide further evidence that failure to benefit from prior test 
exposures may serve as useful heuristic of neurocognitive decline and support the notion that 
deficits seen in typically spared processes on formal neuropsychological testing, such as 
semantic knowledge and language functioning, within older adults may reflect early diseased 
related pathology. As such, declines in language and/or memory functioning in older adults 
needs to be considered in conjunction with executive function and attention processes in order to 
understand the nature of the cognitive decrement.  
An important limitation within many cognitive aging studies to date is the lack of 
comprehensive neurocognitive evaluations in examining change over time in relation to relevant 
risk variables that have demonstrated significant interactions with one another. It is becoming 
increasingly evident that there are important group differences between sex and races in relation 
to functional outcomes with age, which appear to be both psychosocial and biological in their 
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nature. Still to date, the majority of biomedical research has not acknowledged the important role 
that these factors can play on disease and health outcomes.  
The present study provided a systematic investigation of the role of APOE-e4 in 
neurocognitive functioning in conjunction with the potential confounding factors of age, race, 
sex, and indicators of cognitive reserve and health risk. Both direct and indirect effects on 
neurocognitive functioning were found amongst the predictor variables, suggesting that these 
factors should not be studied in isolation, as there is a significant amount of interplay between 
them. Furthermore, unique patterns were found between education and estimated intelligence on 
the different neurocognitive domains growth parameters indicating that they play a role in 
cognitive stability with age. These results support conceptual models that suggest individual 
differences in sex, genetic risk, cognitive reserve, medical and mental health comorbidities in 
combination influence trajectories of cognitive decline. Future research intends to investigate for 
potential mediation and moderation between the health risk factors and demographic factors on 
neurocognitive functioning, as well as testing the measurement model’s equivalence across sex.  
  118
REFERENCES 
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., ... & Zhang, 
 L. I. (2015). At the interface of sensory and motor dysfunctions and Alzheimer's disease. 
 Alzheimer's & Dementia, 11, 70-98. doi: 10.1016/j.jalz.2014. 04.514 
Albert, M. S., Moss, M. B., Tanzi, R., & Jones, K. (2001). Preclinical prediction of AD using 
 neuropsychological tests. Journal of the International Neuropsychological Society, 7(05), 
 631-639. 
Allison, P. D. (2003). Missing data techniques for structural equation modeling. Journal of 
 Abnormal Psychology, 112(4), 545-557.  
Altmann, A., Tian, L., Henderson, V. W., & Greicius, M. D. (2014). Sex modifies the APOE-
 related risk of developing Alzheimer disease. Annals of Neurology, 75(4), 563-573. 
Alzheimer's Association. (2014). 2014 Alzheimer's disease facts and figures. Retrieved from: 
 http://www.alz.org/downloads/Facts_Figures_2014.pdf on October 10, 2014. 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders  
 (5th ed.). Arlington, VA: American Psychiatric Publishing.  
Arbuckle, J. L. (2013). IBM® SPSS® Amos™ 22 User’s Guide. Chicago, IL: IBM. 
Babins, L., Slater, M. E., Whitehead, V., & Chertkow, H. (2008). Can an 18-point clock-
 drawing scoring system predict dementia in elderly individuals with mild cognitive 
 impairment? Journal of Clinical and Experimental Neuropsychology, 30(2), 173-186. 
Bartzokis, G. (2011). Alzheimer's disease as homeostatic responses to age- related myelin 
 breakdown. Neurobiology of Aging, 32(8), 1341-1371.  
Blair, J. R., & Spreen, O. (1989). Predicting premorbid IQ: A revision of the National Adult 
 Reading Test. The Clinical Neuropsychologist, 3(2), 129-136. 
  119
Bondi, M. W., Jak, A. J., Delano-Wood, L., Jacobson, M. W., Delis, D. C., & Salmon, D. P.  
(2008). Neuropsychological contributions to the early identification of Alzheimer’s 
disease. Neuropsychology Review, 18(1), 73-90. 
Bondi, M. W., & Smith, G. E. (2014). Mild cognitive impairment: A concept and diagnostic 
 entity in need of input from neuropsychology. Journal of the International 
 Neuropsychological Society, 20(02), 129-134.  
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., 
 Mazziotta, J. C., & Small, G. W. (2000). Patterns of brain activation in people at risk for 
 Alzheimer's disease. New England journal of medicine, 343(7), 450-456. 
Byrne, B. M. (2010). Structural equation modeling with AMOS: Basic concepts, applications, 
 and programming. 2nd edition. New York, NY: Routledge. 
Cabeza, R. (2001). Cognitive neuroscience of aging: contributions of functional neuroimaging. 
 Scandinavian Journal of Psychology, 42(3), 277-286. 
Cabeza, R., Anderson, N. D., Locantore, J. K., & McIntosh, A. R. (2002). Aging gracefully: 
 compensatory brain activity in high-performing older adults. Neuroimage, 17(3), 1394-
 1402. 
Cabeza, R., Daselaar, S. M., Dolcos, F., Prince, S. E., Budde, M., & Nyberg, L. (2004). Task-
 independent and task-specific age effects on brain activity during working memory, 
 visual attention and episodic retrieval. Cerebral Cortex, 14(4), 364-375.  
Calamia, M., Markon, K., & Tranel, D. (2012). Scoring higher the second time around:  
Meta-analyses of practice effects in neuropsychological assessment. The Clinical 
Neuropsychologist, 26(4), 543-570. 
  120
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., ... & 
 Reiman, E. M. (2009). Longitudinal growth modeling of cognitive aging and the APOE 
 e4 effect. The New England Journal of Medicine, 361(3), 255-263. 
Centers for Disease Control and Prevention. (2014).  Alzheimer's Disease. Retrieved 
 from http://www.cdc.gov/aging/aginginfo/alzheimers.htm#burden on October 10, 2014. 
Chin, A. L., Negash, S., & Hamilton, R. (2011). Diversity and disparity in dementia: The impact  
of ethnoracial differences in Alzheimer’s disease. Alzheimer Disease and Associated 
Disorders, 25(3), 187-195. 
Combarros, O., Leno, C., Oterino, A., Berciano, J., Fernandez‐Luna, J. L., Fernandez‐Viadero, 
 C., ... & Delgado, M. (1998). Gender effect on apolipoprotein E 84 allele‐associated risk 
 for sporadic Alzheimer's disease. Acta Neurologica Scandinavica, 97(1), 68-71.  
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., 
 ... & Pericak-Vance, M. A. (1994). Protective effect of apolipoprotein E type 2 allele for 
 late onset Alzheimer disease. Nature Genetics, 7(2), 180-184.  
Corder, E. H., Small, G. W., Haines, J. L., Saunders, A. M., Strittmatter, W. J., Schmechel, D. 
 E., ... & Pericak-Vance, M. A. (1995). The apolipoprotein E E4 allele and sex-specific 
 risk of Alzheimer's disease. JAMA, 273(5), 373-374.  
Corrada, M. M., Paganini-Hill, A., Berlau, D. J., & Kawas, C. H. (2013). Apolipoprotein E 
 genotype, dementia, and mortality in the oldest old: the 90+ Study. Alzheimer's & 
 Dementia, 9(1), 12-18.  
  121
Dal Forno, G., Carson, K. A., Brookmeyer, R., Troncoso, J., Kawas, C. H., & Brandt, J. (2002). 
 APOE genotype and survival in men and women with Alzheimer’s disease. Neurology, 
 58(7), 1045-1050. 
Davis, S. W., Dennis, N. A., Daselaar, S. M., Fleck, M. S., & Cabeza, R. (2008). Que PASA? 
 The posterior–anterior shift in aging. Cerebral Cortex, 18(5), 1201-1209. 
Dean, D. C., Jerskey, B. A., Chen, K., Protas, H., Thiyyagura, P., Roontiva, A., ... & Reiman, E. 
 M. (2014). Brain differences in infants at differential genetic risk for late-onset 
 Alzheimer disease: a cross-sectional imaging study. JAMA Neurology, 71(1), 11-22. 
Delano‐Wood, L., Houston, W. S., Emond, J. A., Marchant, N. L., Salmon, D. P.,  Jeste, D. V., ... 
 & Bondi, M. W. (2008). APOE genotype predicts depression in women with 
 Alzheimer's disease: a retrospective study. International Journal of Geriatric 
 Psychiatry, 23(6), 632-636. 
Donix, M., Burggren, A. C., Scharf, M., Marschner, K., Suthana, N. A., Siddarth, P., ... &  
Bookheimer, S. Y. (2013). APOE associated hemispheric asymmetry of entorhinal 
cortical thickness in aging and Alzheimer's disease. Psychiatry Research: Neuroimaging, 
214(3), 212-220. 
Elman, J. A., Oh, H., Madison, C. M., Baker, S. L., Vogel, J. W., Marks, S. M., ... & Jagust, W.  
J. (2014). Neural compensation in older people with brain amyloid-[beta] deposition. 
Nature Neuroscience, 11(10), 1316–1318. doi:10.1038/nn.3806.  
Duff, K., Beglinger, L. J., Schultz, S. K., Moser, D. J., McCaffrey, R. J., Haase, R. F., ... &  
  122
Huntington's Study Group. (2007). Practice effects in the prediction of long-term 
cognitive outcome in three patient samples: A novel prognostic index. Archives of 
Clinical Neuropsychology, 22(1), 15-24. 
Duncan, T. E., Duncan, S. C., & Strycker, L. A. (2013). An introduction to latent variable 
 growth curve modeling: Concepts, issues, and application. Mahwah, New Jersey: 
 Routledge Academic.  
Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000). The 
 preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham 
 Cohort. Archives of neurology, 57(6), 808-813. 
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., ... & van 
 Duijn, C. M. (1997). Effects of age, sex, and ethnicity on the association between 
 apolipoprotein E genotype and Alzheimer disease: a meta-analysis. Jama, 278(16), 1349-
 1356. 
Field, A. (2009). Discovering statistics using SPSS. Sage publications. London, UK. 
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-Mental State Examination. 
 PsycTESTS Dataset. doi:10.1037/t07757-000 
Fyffe, D. C., Mukherjee, S., Barnes, L. L., Manly, J. J., Bennett, D. A., & Crane, P. K. (2011).  
Explaining differences in episodic memory performance among older African Americans 
and whites: The roles of factors related to cognitive reserve and test bias. Journal of the 
International Neuropsychological Society, 17(04), 625-638. 
  123
Gao, S., Mokhtarian, P. L., & Johnston, R. A. (2008). Nonnormality of data in structural 
 equation models. Transportation Research Record: Journal of the transportation 
 research board, 2082(1), 116-124.  
Geroldi, C., Laakso, M. P., DeCarli, C., Beltramello, A., Bianchetti, A., Soininen, H., ... &  
Frisoni, G. B. (2000). Apolipoprotein E genotype and hippocampal asymmetry in 
Alzheimer's disease: a volumetric MRI study. Journal of Neurology, Neurosurgery & 
Psychiatry, 68(1), 93-96.  
Glisky, E. L. (2007). Changes in cognitive function  in human aging. Brain aging: Models, 
 methods, and mechanisms, 3-20. 
Goodglass, H. & Kaplan, E. (1983). Boston Diagnostic Aphasia Examination Booklet, III, ORAL 
 EXPRESSION, J. Animal Naming (Fluency in Controlled Association). Philadelphia, 
 PA: Lea & Febiger.  
Grady, C. (2012). The cognitive neuroscience of ageing. Nature Reviews Neuroscience, 13(7), 
 491-505. 
Grady, C. L., & Craik, F. I. (2000). Changes in memory processing with age. Current Opinion In 
 Neurobiology, 10(2), 224-231. 
Grady, C. L., McIntosh, A. R., & Craik, F. I. (2003). Age related differences in the 
 functional connectivity of the hippocampus during memory encoding. Hippocampus, 
 13(5), 572-586.  
Grober, E., Hall, C. B., Lipton, R. B., Zonderman, A. B., Resnick, S. M., & Kawas, C. (2008). 
 Memory impairment, executive dysfunction, and intellectual decline in preclinical 
  124
 Alzheimer's disease. Journal of the International Neuropsychological Society, 14(02), 
 266-278. 
Hayden, K. M., Jones, R. N., Zimmer, C., Plassman, B. L., Browndyke, J. N., Pieper, C., ... &  
Welsh-Bohmer, K. A. (2011). Factor structure of the National Alzheimer’s Coordinating 
Centers uniform dataset neuropsychological battery: an evaluation of invariance between 
and within groups over time. Alzheimer Disease and Associated Disorders, 25(2), 128-
137. 
Heun, R., Freymann, K., Erb, M., Leube, D. T., Jessen, F., Kircher, T. T., & Grodd, W. (2007). 
 Mild cognitive impairment (MCI) and actual retrieval performance affect cerebral 
 activation in the elderly. Neurobiology of Aging, 28(3), 404-413. 
Hickman, S. E., Howieson, D. B., Dame, A., Sexton, G., & Kaye, J. (2000). Longitudinal  
analysis of the effects of the aging process on neuropsychological test performance in the 
healthy young-old and oldest-old. Developmental neuropsychology, 17(3), 323-337. 
Howieson, D. B., Carlson, N. E., Moore, M. M., Wasserman, D., Abendroth, C. D., Payne-
 Murphy, J., & Kaye, J. A. (2008). Trajectory of mild cognitive impairment onset. Journal 
 of the International Neuropsychological Society, 14(02), 192-198. 
Hu, L. T., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis:  
Conventional criteria versus new alternatives. Structural equation modeling: a 
multidisciplinary journal, 6(1), 1-55.  
Hyman, B. T. (2011). Amyloid-dependent and amyloid-independent stages of Alzheimer disease. 
 Archives of neurology, 68(8), 1062-1064.  
  125
Ingles, J. L., Boulton, D. C., Fisk, J. D., & Rockwood, K. (2007). Preclinical Vascular Cognitive 
 Impairment and Alzheimer Disease Neuropsychological Test Performance 5 Years 
 Before Diagnosis. Stroke, 38(4), 1148-1153. 
Jacobs, H. I., Van Boxtel, M. P., Jolles, J., Verhey, F. R., & Uylings, H. (2012).  Parietal cortex 
 matters in Alzheimer's disease: an overview of structural, functional and metabolic 
 findings. Neuroscience & Biobehavioral Reviews, 36(1), 297-309. 
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Vemuri, P., Mielke, M. M., ... & 
 Gregg, B. E. (2015). Age, sex, and APOE ε4 effects on memory, brain structure, and β-
 amyloid across the adult life span. JAMA neurology, 72(5), 511-519. 
Johnson, J. K., Gross, A. L., Pa, J., McLaren, D. G., Park, L. Q., Manly, J. J., & Alzheimer’s  
Disease Neuroimaging Initiative. (2012). Longitudinal change in neuropsychological 
performance using latent growth models: a study of mild cognitive impairment. Brain 
Imaging and Behavior, 6(4), 540-550. 
Johnson, L. A., Hall, J. R., & O’Bryant, S. E. (2013). A depressive endophenotype of mild 
 cognitive impairment and Alzheimer’s disease. PloS one, 8(7), e68848.  
Johnson, J. K., McCleary, R., Oshita, M. H., & Cotman, C. W. (1998). Initiation and propagation 
 stages of beta-amyloid are associated with distinctive apolipoprotein e, age, and gender 
 profiles. Brain Research, 798(1-2):18-24. 
Kaplan, E., Goodglass, H., & Weintraub, S. (1983). Boston Naming Test scoring booklet. 
 Philadelphia, PA: Lea & Febiger. 
Kline, R. B. (2011). Principles and practice of structural equation modeling. New York, NY: 
 Guilford press. 
  126
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., ... & 
 Petersen, R. C. (2013). Brain injury biomarkers are not dependent on β-amyloid in 
 normal elderly. Annals of Neurology, 73(4), 472-480. 
Koenigs, M., Barbey, A. K., Postle, B. R., & Grafman, J. (2009). Superior parietal cortex is  
critical for the manipulation of information in working memory. The Journal of 
Neuroscience, 29(47), 14980-14986. 
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., ... &  
Larson, E. B. (2002). Dementia and Alzheimer disease incidence: A prospective cohort 
study. Archives of neurology, 59(11), 1737-1746. 
Lautenschlager, N. T., Cupples, L. A., Rao, V. S., Auerbach, S. A., Becker, R., Burke, J., ... & 
 Farrer, L. A. (1996). Risk of dementia among relatives of Alzheimer's disease patients in 
 the MIRAGE study: What is in store for the oldest old? Neurology, 46(3), 641-650.  
Lehtovirta, M., Laakso, M. P., Frisoni, G. B., & Soininen, H. (2000). How does the 
 apolipoprotein E genotype modulate the brain in aging and in Alzheimer’s disease? A 
 review of neuroimaging studies. Neurobiology of aging, 21(2), 293-300.  
Lezak, M.D., Howieson, D.B., & Loring, D.W. (2004). A compendium of tests and assessment 
 techniques. Lezak, M.D (Eds). In Neuropsychological Assessment. New York, New 
 York. Oxford University Press. 
Li, F., Duncan, T. E., Mcauley, E., Harmer, P., & Smolkowski, K. (2000). A didactic example of 
 latent curve analysis applicable to the study of aging. Journal of Aging and Health, 12(3), 
 388-425. 
Li, S., Lindenberger, U., Frensch, P., 2000. Unifying cognitive aging: From neuromodulation to  
  127
representation to cognition. Neurocomputing 32-33, 879-890. Li, S., Lindenberger, U.,  
 Sikström, S., 2001. Aging cognition: From neuromodulation to representation. Trends in  
 Cognitive Sciences 5, 479-486.  
Lind, J., Persson, J., Ingvar, M., Larsson, A., Cruts, M., Van Broeckhoven, C., ... & Nyberg, L.  
(2006). Reduced functional brain activity response in cognitively intact apolipoprotein E 
ε4 carriers. Brain, 129(5), 1240-1248. 
Little, T. D. (2013). Longitudinal structural equation modeling. New York, New York. Guilford  
 Press. 
Lopez, O. L., Jagust, W. J., Dulberg, C., Becker, J. T., DeKosky, S. T., Fitzpatrick, A., ... &  
Kuller, L. H. (2003). Risk factors for mild cognitive impairment in the Cardiovascular 
Health Study Cognition Study: Part 2. Archives of Neurology, 60(10), 1394-1399. 
MacAulay, R. K., Brouillette, R. M., Foil, H. C., Bruce-Keller, A. J., & Keller, J. N. (2014). A 
 Longitudinal Study on Dual-Tasking Effects on Gait: Cognitive Change Predicts Gait 
 Variance in the Elderly. PLoS ONE, 9(6), e99436. doi:10.1371/journal.pone.0099436. 
McArdle, J. J., & Anderson, E. (1990). Latent variable growth models for research on aging. 
 Handbook of the psychology of aging, 2, 21-44. 
McCarrey, A. C., An, Y., Kitner-Triolo, M. H., Ferrucci, L., & Resnick, S. M. (2016). Sex 
 Differences in Cognitive Trajectories in Clinically Normal Older Adults. Psychology and 
 aging.  
Mitchell, A. J. (2009). A meta-analysis of the accuracy of the mini-mental state examination in 
 the detection of dementia and mild cognitive impairment. Journal of psychiatric 
 research, 43(4), 411-431. 
  128
Mitrushina, M., & Satz, P. (1991). Effect of repeated administration of a neuropsychological 
 battery in the elderly. Journal of Clinical Psychology, 47, 790–801. 
Mufson, E. J., Ma, S. Y., Cochran, E. J., Bennett, D. A., Beckett, L. A., Jaffar, S., ... &  
Kordower, J. H. (2000). Loss of nucleus basalis neurons containing trkA 
immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's 
disease. Journal of Comparative Neurology, 427(1), 19-30.  
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. 
 (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Archives of 
 Neurology, 58(3), 397-405. 
Law of initial value. (n.d.). In Mosby's Online Medical Dictionary, 8th edition. (2009). Retrieved  
 May 21, 2015 from http://medicaldictionary.thefreedictionary.com/law+of+initial+value. 
Mungas, D., Reed, B. R., Farias, S. T., & DeCarli, C. (2009). Age and education effects on 
 relationships of cognitive test scores with brain structure in demographically diverse 
 older persons. Psychology and Aging, 24(1), 116-128. 
National Institute on Aging (2013). 2013-2014 Alzheimer's Disease Progress Report. Retrieved 
 on July 28, 2014 from: http://www.nia.nih.gov/alzheimers/publication/2013-2014-
 alzheimers-disease-progress-report/identifying-genetics-alzheimers. 
Nelson, H. E., & Willison, J. (1991). National Adult Reading Test (NART). Retrieved from 
 http://www.academia.edu/2515150/National_Adult_Reading_Test_NART_test_manual_
 Part_1 on October 14, 2014. 
Qiu, C., Kivipelto, M., Agüero-Torres, H., Winblad, B., & Fratiglioni, L. (2004). Risk and 
 protective effects of the APOE gene towards Alzheimer’s disease in the Kungsholmen 
  129
 project: variation by age and sex. Journal of Neurology, Neurosurgery & Psychiatry, 
 75(6), 828-833.  
Okonkwo, O. C., Cohen, R. A., Gunstad, J., Tremont, G., Alosco, M. L., & Poppas, A. (2010). 
 Longitudinal trajectories of cognitive decline among older adults with cardiovascular 
 disease. Cerebrovascular Diseases, 30(4), 362-373. 
Park, D.C., Reuter-Lorenz, P. (2009). The adaptive brain: aging and neurocognitive scaffolding.  
Annual Review of Psychology, 60, 173-96.  
Perrino, T., Mason, C. A., Brown, S. C., Spokane, A., & Szapocznik, J. (2008). Longitudinal  
relationships between cognitive functioning and depressive symptoms among Hispanic 
older adults. The Journals of Gerontology Series B: Psychological Sciences and Social 
Sciences, 63(5), P309-P317. 
Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of internal 
 medicine, 256(3), 183-194.  
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). 
 Mild cognitive impairment: clinical characterization and outcome. Archives of 
 neurology, 56(3), 303-308. 
Petersen, S. E., Van Mier, H., Fiez, J. A., & Raichle, M. E. (1998). The effects of  practice on the 
 functional anatomy of task performance. Proceedings of the National Academy of 
 Sciences, 95(3), 853-860. 
Pinel, J. P. (2013). Biopsychology. Upper Saddle River, New Jersey: Pearson Higher Education. 
Price, C. C., Cunningham, H., Coronado, N., Freedland, A., Cosentino, S., Penney, D. L., ... &  
  130
Libon, D. J. (2011). Clock drawing in the Montreal Cognitive Assessment: 
recommendations for dementia assessment. Dementia and geriatric cognitive disorders, 
31(3), 179-187.  
Rapp, M. A., & Reischies, F. M. (2005). Attention and executive control predict Alzheimer 
 disease in late life: results from the Berlin Aging Study (BASE). The American Journal 
 of Geriatric Psychiatry, 13(2), 134-141. 
Raz, N. (2000). Aging of the brain and its impact on cognitive performance: Integration of 
 structural and functional findings. In F. I. M. Craik & T. A. Salthouse (Eds.), Handbook 
 of aging and cognition (2nd ed., pp. 1–90). Mahwah, NJ: Erlbaum. 
Raz, A. (2004). Anatomy of attentional networks. The Anatomical Record Part B: The New 
 Anatomist, 281(1), 21-36.  
Reitan, R. M., & Wolfson, D. (1993). The Halstead–Reitan Neuropsychological Test Battery: 
 Theory and clinical interpretation (2nd ed.). Tucson, AZ: Neuropsychology Press. 
Ritchie, K. (2004). Mild cognitive impairment: an epidemiological perspective. Dialogues in 
 Clinical Neuroscience, 6(4), 401-408. 
Roberts, J. S., Karlawish, J. H., Uhlmann, W. R., Petersen, R. C., & Green, R. C.  (2010). Mild 
 cognitive impairment in clinical care: A survey of American Academy of Neurology 
 members. Neurology, 75(5), 425-431. 
Sadowski, M., Pankiewicz, J., Scholtzova, H., Li, Y.S., Quartermain, D., Duff, K. and 
 Wisniewski, T., 2004. Links between the pathology of Alzheimer's disease and vascular 
 dementia. Neurochemical research, 29(6), pp.1257-1266. 
  131
Salthouse, T. A. (2000). Aging and measures of processing speed. Biological psychology, 54(1), 
 35-54. 
Salthouse, T.A. (2014). Selectivity of attrition in longitudinal studies of cognitive functioning.  
Journals of Gerontology, Series B: Psychological Sciences and Social Sciences, 69(4), 
567–574, doi:10.1093/geronb/gbt046.  
Salthouse TA, Atkinson TM, & Berish DE (2003). Executive functioning as a potential mediator  
 of age-related cognitive decline in normal adults. Journal of Experimental Psychology 
 General, 132, 566–594.  
Seeman, T. E., Huang, M. H., Bretsky, P., Crimmins, E., Launer, L., & Guralnik, J. M. (2005). 
 Education and APOE-e4 in longitudinal cognitive decline: MacArthur Studies of 
 Successful Aging. The Journals of Gerontology Series B: Psychological sciences and 
 social sciences, 60(2), 74-83. 
Shannon, B. J., & Buckner, R. L. (2004). Functional-anatomic correlates of memory retrieval 
 that suggest nontraditional processing roles for multiple distinct regions within posterior 
 parietal cortex. The Journal of Neuroscience, 24(45), 10084-10092.  
Sheikh, J. I., & Yesavage, J. A. (1986). Geriatric Depression Scale (GDS): Recent evidence and 
 development of a shorter version. Clinical Gerontologist, 5, 165–173. 
Small, S. A., Perera, G. M., DeLaPaz, R., Mayeux, R., & Stern, Y. (1999). Differential regional 
 dysfunction of the hippocampal formation among elderly with memory decline and 
 Alzheimer's disease. Annals of Neurology, 45(4), 466-472.  
Smith, E. E., & Kosslyn, S. M. (2006). Attention. Cognitive psychology: Mind and Brain  
(pp. 103-146). Upper Saddle River, NJ: Pearson Prentice Hall.  
  132
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., ... & 
 Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer’s disease: 
 Recommendations from the National Institute on Aging-Alzheimer's Association 
 workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 
 7(3), 280-292. 
Sperling, R. A., Bates, J. F., Chua, E. F., Cocchiarella, A. J., Rentz, D. M., Rosen, B. R., ... & 
 Albert, M. S. (2003). fMRI studies of associative encoding in young and elderly controls 
 and mild Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 74(1), 
 44-50. 
Stern, Y. (2002). What is cognitive reserve? Theory and research application of the reserve 
 concept. Journal of the International Neuropsychological Society, 8(03), 448-460. 
Stern, Y. (2006). Cognitive reserve and Alzheimer disease. Alzheimer Disease & Associated 
 Disorders, 20(2), 112-117. 
Stern, Y. (2009). Cognitive reserve. Neuropsychologia, 47(10), 2015-2028. 
Strauss, E., Sherman, E. M., & Spreen, O. (2006). General Cognitive Functioning, 
 Neuropsychological Batteries, and Assessment of Premorbid Intelligence. In Strauss, E., 
 Sherman, E. M., & Spreen, (Eds.), (3rd ed., pp. 189–200). A compendium of 
 neuropsychological tests: Administration, norms, and commentary. New York, NY: 
 Oxford University Press. 
Tervo, S., Kivipelto, M., Hänninen, T., Vanhanen, M., Hallikainen, M., Mannermaa, A., & 
 Soininen, H. (2004). Incidence and risk factors for mild cognitive impairment: A
  133
 population-based three-year follow-up study of cognitively healthy elderly 
 subjects. Dementia and Geriatric Cognitive Disorders, 17(3), 196-203. 
 Trivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., ...  
& Johnson, S. C. (2006). Reduced hippocampal activation during episodic encoding in 
middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study. 
BMC medicine, 4(1), 1. doi:10.1186/1741-7015-4-1. 
Uranga, R. M., & Keller, J. N. (2010). Diet and age interactions with regards to cholesterol 
 regulation and brain pathogenesis. Current Gerontology and Geriatrics Research, 2010. 
Uttl, B. (2002). North American Adult Reading Test: age norms, reliability, and validity. Journal  
of Clinical and Experimental Neuropsychology, 24(8), 1123-1137. 
Van Beijsterveldt, C. E. M., Van Boxtel, M. P. J., Bosma, H., Houx, P. J., Buntinx, F., & Jolles,  
J. (2002). Predictors of attrition in a longitudinal cognitive aging study: The Maastricht 
Aging Study (MAAS). Journal of clinical epidemiology, 55(3), 216-223.  
Van Dam, N. T., Sano, M., Mitsis, E. M., Grossman, H. T., Gu, X., Park, Y., ... & Fan, J. (2013). 
 Functional neural correlates of attentional deficits in amnestic mild cognitive impairment. 
 PloS One, 8(1), e54035. 
Van Exel, E., Gussekloo, J., De Craen, A. J. M., Bootsma-Van der Wiel, A., Houx, P., Knook, D.  
L., & Westendorp, R. G. J. (2001). Cognitive function in the oldest old: women perform 
better than men. Journal of Neurology, Neurosurgery & Psychiatry, 71(1), 29-32.  
Vargha-Khadem, F., Gadian, D. G., Watkins, K. E., Connelly, A., Van Paesschen, W., &  
Mishkin, M. (1997). Differential effects of early hippocampal pathology on episodic and 
semantic memory. Science, 277(5324), 376-380.  
  134
Verhaeghen,P. & Cerella, J.(2002). Aging, executive control, and attention: A review of meta-
 analyses. Neurosciences and Biobehavioral Reviews, 26, 849–857. 
Waldstein, S. R. (2000). Health effects on cognitive aging. The Aging Mind: Opportunities in 
 cognitive research, 189-217. 
Wechsler, D. (1981). Manual: Wechsler Adult Intelligence Scale-Revised.  
 New York, NY. Psychological Corporation.  
Wechsler, D. (1987). Manual: Wechsler Memory Scale-Revised. San Antonio, Texas: 
 Psychological Corporation.  
Weinstein, G., Beiser, A. S., DeCarli, C., Au, R., Wolf, P. A., & Seshadri, S. (2013). Brain 
 imaging and cognitive predictors of stroke and Alzheimer disease in the Framingham 
 Heart Study. Stroke, 44(10), 2787-2794. 
Weintraub, S., Salmon, D., Mercaldo, N., Ferris, S., Graff-Radford, N. R., Chui, H., ... & Morris, 
 J. C. (2009). The Alzheimer’s disease centers’ uniform data set (UDS): The 
 neuropsychological test battery. Alzheimer Disease and Associated Disorders, 23(2): 91-
 101. 
Welsh-Bohmer, K. A., Østbye, T., Sanders, L., Pieper, C. F., Hayden, K. M., Tschanz, J. T., ... &  
Cache Country Study Group. (2009). Neuropsychological performance in advanced age: 
influences of demographic factors and apolipoprotein E: findings from the Cache County 
Memory Study. The Clinical Neuropsychologist, 23(1), 77-99. 
Wilkosz, P. A., Seltman, H. J., Devlin, B., Weamer, E. A., Lopez, O. L., DeKosky, S. T., & 
 Sweet, R. A. (2010). Trajectories of cognitive decline in Alzheimer's disease. 
 International Psychogeriatrics, 22(02), 281-290.  
  135
Wingfield, A. & Grossman, M. (2006). Language and the aging brain: patterns of neural 
 compensation revealed by functional brain imaging. Journal of Neurophysiology, 96(6), 
 2830-2839. 
Wingfield,A. & Stine-Morrow, E. (2000). Language and speech. In Craik, Fergus I. M. & 
 Salthouse, T.A. (Ed). The handbook of aging and cognition (2nd ed.). pp. 359-416. 
 Mahwah, NJ: Lawrence Erlbaum Associates, Inc. Publishers. 
Wishart, H. A., Saykin, A. J., McAllister, T. W., Rabin, L. A., McDonald, B. C., Flashman, L.  
A., ... & Rhodes, C. H. (2006). Regional brain atrophy in cognitively intact adults with a 
 single APOE ε4 allele. Neurology, 67(7), 1221-1224. 
Wolk, D. A., Dickerson, B. C., Weiner, M., Aiello, M., Aisen, P., Albert, M. S., ... & Diaz-
 Arrastia, R. (2010). Apolipoprotein E (APOE) genotype has dissociable effects on 
 memory and attentional–executive network function in Alzheimer’s disease. Proceedings 
 of the National Academy of Sciences, 107(22), 10256-10261.  
Xu, S., & Vogl, C. (2000). Maximum likelihood analysis of quantitative trait loci under selective 
 genotyping. Heredity, 84(5), 525-537. 
Zacks, Hasher, & Li (2000). Human Memory. In F. I. M. Craik & T. A. Salthouse (Eds.),  
 Handbook of aging and cognition (2nd ed., pp. 293-357). Mahwah, NJ: Erlbaum. 
Zahodne, L. B., Stern, Y., & Manly, J. J. (2014). Depressive symptoms precede memory  
decline, but not vice versa, in non‐demented older adults. Journal of the American 
Geriatrics Society, 62(1), 130-134. 
 
 
  136
APPENDIX A 
INSTITUTIONAL REVIEW BOARD APPROVAL SHEET 
A copy of the approval sheet from the Institutional Review Board for the “Louisiana Aging 
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APPENDIX B 
INSTITUTIONAL REVIEW BOARD CONSENT FORM 
 
PBRC29007  Full Approval by IRB Received 1-7-14 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
FOR AN ADULT 
INFORMED CONSENT - PART I 
Title of Study: 
 
Louisiana Aging Brain Study (LABrainS)  
 
What you should know about a research study 
  
 We give you this consent form so that you may read about the purpose, risks and benefits of 
this research study. 
 The main goal of research studies is to gain knowledge that may help future patients. 
 You have the right to refuse to take part, or agree to take part now and change your mind 
later on. 
 Please review this consent form carefully and ask any questions before you make a decision. 
 Your participation is voluntary. 
 By signing this consent form, you agree to participate in the study as it is described. 
 
1- Who is doing the study? 
     Investigator Information:  
  
Principal Investigator: Jeffrey N. Keller, Ph.D.  
 225-763-3190 
  
Medical Investigator: Frank Greenway, M.D. 
 Day Phone: 225-763-2576 
 24-hr. Emergency Phone Nos.:   
 225-763-2632 (Weekdays 7:00 a.m - 4:30 p.m.)  
 225-765-4644 (After 4:30 p.m. and Weekends)  
   
Co-Investigators: Robert M. Brouillette, M.S., Heather C. Foil, B.S., Leslie G. 
Jackson, B.A., Stephanie L. Fontenot, M.S.  
  
Dr. Keller directs this study, which is under the medical supervision of Dr. Frank Greenway.  We 
expect to enroll up to 5,000 participants.  The study will take place over a period of years.  Your 
expected time in this study will be 2 hours per year for as long as you are enrolled in the study.  
This is a study being done by researchers at the Pennington Biomedical Research Center in 
Baton Rouge, LA. 
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2- Where is the study being conducted?  
The study takes place at the Institute for Dementia Research and Prevention (IDRP) testing suite 
located on the second floor of the PBRC Outpatient Clinic Building, the St. James Place 
Retirement Community, the Residence of the Retirement Community of the Sisters of St. Joseph, 
St. Paul the Apostle Catholic Church, Baton Rouge, LA, and the Diamondhead Community 
Church in Diamondhead, MS.  
 
3- What is the purpose of this study? 
The purpose of this research study is to establish a registry of aging individuals in Louisiana who 
receive annual cognitive evaluations.  This allows for both the collection of “normal” data to be 
used for comparison in other studies and the earliest possible detection of disease onset and the 
factors leading up to it. 
 
Additionally, this research allows for the investigation of the relationships between cognitive 
decline, mobility, activity level and fall risk.  
 
4- Who is eligible to participate in the study?  Who is ineligible? 
   
 Inclusion Criteria  
You are eligible of inclusion in the study if: 
 
 You are a man or woman > 60 years of age 
 You have no exclusionary health problems as outlined in the exclusion criteria 
below and measured by the UDS Form A5:  Subject Health History and have no 
awareness of significant cognitive decline 
 You have a score of > 25  on the Mini Mental Status Examination (MMSE)  
 You are not currently under treatment for any form of dementia  
 Exclusion Criteria 
You are not eligible for inclusion in the study if: 
 You have been diagnosed, or have a suspected diagnosis of dementia of any kind 
or are taking medications for the treatment of memory loss 
 You have a history of brain injury 
 You have a history of cerebrovascular disease (Stroke or Transient Ischemic 
Attack) 
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 You have a history of Parkinson’s disease  
 You have a history of seizure disorder 
 You have a history of B12 deficiency 
 You have a history of untreated and/or severe Thyroid Disease. 
 You have a history of substance abuse or alcoholism within the past 5 years. 
 You have a history of significant psychiatric disorder that would interfere with the 
subject’s ability to complete the study. 
 You show symptoms of acute depression as measured by the UDS Form B6: 
Behavioral Assessment – Geriatric Depression Scale (GDS) (Raw > 6) 
5- What will happen to you if you take part in the study? 
Your participation will consist of an annual two hour visit.  At your initial visit, you will be 
interviewed by IDRP clinicians to collect basic information about you, your health history, and 
possible risk factors.  You will perform screening tests of your thinking and mood.  If your 
performance on these measures results in exclusion from the study, you will be informed at that 
time.   If you meet the inclusion criteria you will undergo the following: 
 
 Cognitive Testing 
You will undergo more extensive cognitive testing to assess your performance in the 
areas of memory, language, attention/concentration and reasoning. 
 
 Anthropometric Measures. 
During this visit, we will measure your height and weight.  
 
 Questionnaires  
You will be asked to fill out multiple questionnaires to assess your family history of 
dementia and cancer, your community mobility and general health history.  
 
 Short Physical Performance Battery 
You will then be asked to complete a short physical performance (SPPB) test. The 
physical performance test has three parts:  
1. You will be asked to walk a short distance (about 13 feet) 
2. You will be asked to stand up from a chair 5 times without using your arms 
3. You will be asked to stand in 3 different positions while keeping your balance 
 GAITRite Assessment 
You will be asked to walk across a short computerized mat which will measure your 
length of stride, posture and gait.  You will be asked to perform this measure both 
normally and while completing a cognitively distracting task. 
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This process will be repeated annually for as long as you continue to meet criteria for 
inclusion/continuation. 
 
Additionally you may choose to participate in two optional aspects of the study.  Participation in 
the following is not necessary for enrollment in the study. 
 
 Optional Blood Draw  
You will have blood drawn from an arm vein.  The two samples taken will be used for 
the following: genetic genotyping and storage of sample for future studies related to 
dementia.  This collection will be completed only once and is not repeated annually. The 
possible benefits of research from your blood and/or DNA samples include learning more 
about what biomarkers in the blood may be related to the onset of Alzheimer’s disease 
and other dementias.  
 
Genetic Genotyping 
You will have blood (about one teaspoon) drawn from an arm vein for studying a gene, 
ApoE.  Your DNA will be taken from your blood, and a test will be done to find out your ApoE 
status.  Any sample left over after this test will be destroyed.  Your sample will not be saved for 
future testing.  These results are for research only.  Since these tests are exploratory research 
only, they will have no clear implications about you or your family medical conditions.  The 
results of the testing will not be returned to you. 
 
I give permission to have my DNA collected for ApoE genotyping as explained above.  Please 
initial next to your choice below. 
 
                                                Yes                                        No 
 
 Optional Activity Monitors 
Your participation will consist of wearing a combination of two activity monitors for a 
period of seven consecutive days.  You will be given oral and written instructions 
regarding the proper wearing of the monitors and asked to return the monitors to the front 
desk of the PBRC Clinic Building at the end of the seven day period.  You will also be 
asked to keep a simple log of wearing activities. 
 
 Subjects agreeing to enrollment in this ancillary study will receive the following in 
addition to their annual cognitive screens: 
 Physical Activity Monitor: 7 days - After completion of annual cognitive 
assessments, you will be fitted with a combination of two activity monitors 
(GT3X+ accelerometer, pedometer) and will be asked to wear the activity 
monitors for  7 consecutive days, except while showering/bathing. The 
accelerometer is to be worn while sleeping and awake whereas the pedometer is 
to be worn only when awake.  You will be asked to complete brief records of your 
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daily wearing time, the number of steps you take (displayed on the pedometer), 
and activities you engaged in during the day. 
 
 Activity Monitor Descriptions 
 
Pedometer 
This monitor is small (approximately the size of a matchbox) and is worn at the waist when 
awake. 
 
GT3X+ 
This monitor is small (approximately the size of a matchbox) and is worn at the waist on an 
elasticized belt while sleeping and awake. 
o I agree to wear the activity monitors for a period of seven days as outlined above. 
 
______ Yes               ______ No                   __________ Initials 
 
6- What are the possible risks and discomforts? 
The risks associated with a study such as this are minimal.   
 
Cognitive Testing 
The procedures used for cognitive testing are completely non-invasive and painless.  Some 
subjects may experience mild performance anxiety associated with taking the tests or experience 
mental fatigue during or after completion of the evaluation.  
 
Risk of Falling:  
There is a risk of losing your balance and falling associated with the physical performance-based 
testing (e.g., balance tests, rising from a chair).  We will minimize this risk by:  
o safely escorting you to chairs  
o following you at a close distance when walking 
o being at your side should you need assistance 
 
Optional Blood Draw:  
There is the possibility of pain and bruising at the vein on your arm where the needle is inserted. 
Aseptic (sterile) technique and trained personnel minimize these risks.  
 
Optional Genetic Testing:  
Although we have made every effort to protect your identity, there is a small risk of loss of 
confidentiality.  If the results of these studies of your genetic makeup were to be accidentally 
released, it might be possible that the information we will gather about you as part of this study 
could become available to an insurer, an employer, a relative or someone else outside the study. 
Even though there are discrimination protections in Louisiana state law, there is still a small 
chance that you could be harmed if a release occurred. 
o A new federal law, called the Genetic Information Nondiscrimination Act 
(GINA), generally makes it illegal for health insurance companies, group health 
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plans, and most employers to discriminate against you based on your genetic 
information.  Be aware that this new federal law does not protect you against 
genetic discrimination by companies that sell life insurance, disability insurance, 
or long-term care insurance.  GINA also does not protect you against 
discrimination if you have already been diagnosed with the genetic disease being 
tested. 
 
Optional Activity Monitors:  
 
Precautions 
The devices should not be exposed to water so you should remove them when showering/bathing 
and secure them back onto your body after drying off.  You will be asked to note the time of day 
when the devices are removed to shower/bathe or for any other reason. 
 
Risks 
All devices may cause some mild discomfort while initially getting used to wearing the devices.   
 
 You will be allowed to refuse or terminate any procedures that cause you distress. 
 
7- What are the possible benefits? 
We cannot promise any benefits from your being in the study.  However, your participation will 
help researchers and health care practitioners better understand the process of normal aging and 
identify factors which could potentially cause the process to become accelerated (dementia).  By 
your participation in this study you insure the earliest possible detection of a Dementia process 
for yourself, which is very important to maximize treatment of the illness.  If, during the course 
of screening or evaluation, you are found to exhibit cognitive symptoms indicative of dementia, 
you will be encouraged to seek medical attention from you primary care physician, as soon as 
possible for further evaluation.  Additionally, your participation in this study will afford you the 
collection of baseline cognitive data, which can prove vital to your physicians in diagnosis and 
care of future disease states. These records will be made available to personal physicians upon 
request. 
8- If you do not want to take part in the study, are there other choices?  
 You have the choice at any time not to participate in this research study.  If you choose not to 
participate, any health benefits to which you are entitled will not be affected in any way. 
 
9- If you have any questions or problems, whom can you call? 
If you have any questions about your rights as a research volunteer, you should call the 
Institutional Review Board Office at 225/763-2693 or the Executive Director of PBRC at 
225/763-2513.  If you have any questions about the research study, contact Dr. Jeffrey Keller at 
225/763-3190.  If you think you have a research-related injury or medical illness, you should call 
Dr. Frank Greenway at 225/763-2576 during regular working hours.  After working hours and on 
weekends, you should call the answering service at 225/765-4644.  The on-call physician will 
respond to your call. 
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10- What information will be kept private? 
Every effort will be made to maintain the confidentiality of your study records.  However, 
someone from the Food and Drug Administration, the National Institutes of Health, the 
Pennington Biomedical Research Center, and the Institute for Dementia Research and Prevention 
may inspect and/or copy the medical records related to the study.  Results of the study may be 
published; however, we will keep your name and other identifying information private.  Other 
than as set forth above, your identity will remain confidential unless disclosure is required by 
law. 
 
11- Can your taking part in the study end early? 
Dr. Keller can withdraw you from the study for any reason or for no reason.  You may withdraw 
from the study at any time without penalty; however, all data Pennington Biomedical has 
previously collected cannot be removed from the study.  Possible reasons for withdrawal include 
conversion from a normal aging state to one suggestive of a dementia process or development of 
medical conditions which are listed in the exclusion criteria.  
 
12- What if information becomes available that might affect your decision to stay 
in the study? 
During the course of this study there may be new findings from this or other research 
which may affect your willingness to continue participation.  Information concerning any such 
new findings will be provided to you. 
 
13- What charges will you have to pay? 
None 
 
14- What payment will you receive? 
None 
 
15- Will you be compensated for a study-related injury or medical illness? 
No form of compensation for medical treatment or for other damages (i.e., lost wages, time lost 
from work, etc.) is available from the Pennington Biomedical Research Center. In the event of 
injury or medical illness resulting from the research procedures in which you participate, you 
will be referred to a treatment facility.  Medical treatment may be provided at your expense or at 
the expense of your health care insurer (e.g., Medicare, Medicaid, Blue Cross-Blue Shield, 
Dental Insurer, etc.) which may or may not provide coverage.  The Pennington Biomedical 
Research Center is a research facility and provides medical treatment only as part of research 
protocols.  Should you require ongoing medical treatments, they must be provided by community 
physicians and hospitals. 
 
16- HIPAA 
Records that you give us permission to keep, and that identify you, will be kept confidential as 
required by law.  Federal Privacy Regulations provide safeguards for privacy, security, and 
authorized access.  Except when required by law, you will not be identified by name, social 
  144
security number, address, telephone number, or any other direct personal identifier in records 
disclosed outside of Pennington Biomedical Research Center (PBRC).  For records disclosed 
outside of PBRC, you will be assigned a unique code number. 
 
17- Signatures   
The study has been discussed with me and all my questions have been answered.  I understand 
that additional questions regarding the study should be directed to the study investigators. I agree 
with the terms above and acknowledge that I have been given a copy of the signed consent form. 
 
With my signature, I also acknowledge that I have been given either today or in the past a copy 
of the Notice of Privacy Practices for Protected Health Information. 
 
 
Printed Name of Volunteer 
 
    
Signature of Volunteer  Date  
 
  
Date of Birth of Volunteer  
 
    
Signature of Person Administering Informed Consent  Date  
 
Jeffrey N. Keller, Ph.D.,  Principal Investigator 
Frank Greenway, M.D.,  Medical Investigator 
 
I give my permission to the IDRP to contact me for future studies, for which I may be qualified 
to participate. 
 
______ Yes                 ______ No                      __________ Initials 
 
 
The study volunteer has indicated to me that the volunteer is unable to read.  I certify that I have 
read this consent form to the volunteer and explained that by completing the signature line above 
the volunteer has agreed to participate. 
 
 
    
Signature of Reader  Date  
18- Specimen Storage for Future Research  
 
Storage of Blood Sample for Future Research 
Biospecimens for future research:  
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You are being asked to allow some of your blood to be stored and used for research at a later 
time. These bodily materials are called biospecimens. The donation of biospecimens in this study 
is optional. No matter what you decide to do, it will not affect your study participation. You will 
still be allowed to take part in the study even if you don't want your specimens to be collected 
and used for future research. Some biospecimen samples will be stored and used for the study 
and other biospecimen samples will be stored for future studies.  The collection of samples may 
give scientists valuable research material that can help them to develop new diagnostic tests, new 
treatments, and new ways to prevent diseases. If you agree to have your samples stored, you can 
change your mind later. 
  
The samples will be stored indefinitely. If you agree to donate your samples, they may be given 
to other investigators for future research as well. The future research may take place at 
Pennington Biomedical and may involve Pennington Biomedical Researchers in this study. The 
future research may not take place at Pennington Biomedical Research Center and may not be 
reviewed by Pennington Biomedical Research Center’s Institutional Review Board. For privacy 
and confidentiality, your biospecimens will be labeled with a unique series of letters and 
numbers. Pennington Biomedical will store your biospecimens with this unique identifier and the 
minimum number of personal identifiers to meet laboratory standards. The research done with 
your specimens may help to develop new products in the future, or may be used to establish a 
cell line or test that could be patented or licensed. You will not receive any financial 
compensation for any patents, inventions or licenses developed from this research. 
 
Making your choice about future research: 
Please read about each biospecimen below.  It is your choice which samples will be collected, 
stored and used for future research for this study or future studies.  After reading about each 
below, sign next to “Yes” or “No” to show your choice about the collections for this research 
study and for future research studies.   
 
Blood 
If you give permission, approximately 3 teaspoons (1 tablespoon) of blood will be collected and 
stored by this study.  Your stored samples may be tested at Pennington Biomedical Research 
Center or other locations used in future research. Do you give permission for your blood to be 
collected and used in future research by this study? 
 
Yes, I give permission ______________________________    ______    
    Signature       Date 
    
No, I do not give permission _________________________    _______    
    Signature       Date 
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APPENDIX C 
MAXIMUM LIKELIHOOD ESTIMATION FOR MISSING VALUES  
 
Maximum Likelihood Estimates of Structural Model (N = 694) 
Computation of degrees of freedom (Default model) 
Number of distinct sample moments: 495 
Number of distinct parameters to be estimated: 116 
Degrees of freedom (495 - 116): 379 
Result (Default model) 
Minimum was achieved  
Chi-square = 718.163  
Degrees of freedom = 379  
Probability level = .000 
Fit Indices: 
CFI = .976 
RMSEA = .036; 90% CI: 032-.040 
Means for Neuropsychological Variables: (Group number 1 - Default model) 
   Estimate SE C.R. p =  
Memory Intercept   12.972 .127 101.824 < .001  
Memory Slope   .483 .062 7.780 < .001  
EA/PS Intercept   68.156 2.710 25.150 < .001  
EA/PS Slope   -12.703 .527 -24.107 < .001  
WM Intercept   9.037 .070 129.750 < .001  
WM Slope   -.026 .034 -.755 .450  
Language Intercept   27.398 .097 281.739 < .001  
Language Slope   .255 .036 7.155 < .001  
Covariances: 
   Estimate SE C.R. p = 
Memory Intercept <--> Memory Slope -.891 .162 -5.508 < .001 
Memory Intercept <--> Language Intercept 2.599 .263 9.901 < .001 
Memory Intercept <--> EA/PS Intercept 11.534 1.220 9.454 < .001 
EA/PS Intercept <--> Language Intercept 8.139 .806 10.092 < .001 
EA/PS Intercept <--> WM Intercept 5.105 .597 8.550 < .001 
WM Intercept <--> Language Intercept .913 .120 7.605 < .001 
Memory Intercept <--> Language Slope .149 .067 2.236 .025 
Memory Intercept <--> EA/PS Slope .353 .235 1.503 .133 
EA/PS Intercept <--> Language Slope .263 .180 1.467 .142 
Memory Slope <--> EA/PS Intercept 1.042 .406 2.566 .010 
Memory Slope <--> EA/PS Slope .273 .115 2.379 .017 
EA/PS Slope <--> Language Slope .135 .047 2.872 .004 
WM Slope <--> Language Slope .033 .013 2.525 .012 
Memory Slope <--> Language Slope .133 .031 4.331 < .001 
Memory Intercept <--> WM Intercept 1.217 .192 6.332 < .001 
Note(s): Values are based on raw untransformed data. Standard Error (SE); Critical Ratio (CR); 
Executive Attention/Processing Speed (EA/PS); Working Memory (WM).  
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APPENDIX D 
MAXIMUM LIKELIHOOD ESTIMATION FOR MISSING VALUES WITH PREDICTOR 
VARIABLES 
 
Maximum Likelihood Estimates of Predictor Model 
Computation of degrees of freedom (Default model) 
Number of distinct sample moments: 629 
Number of distinct parameters to be estimated: 151 
Degrees of freedom (629 - 151): 478 
Result (Default model) 
Minimum was achieved  
Chi-square = 1233.592  
Degrees of freedom = 478  
Probability level = .000 
Fit Indices: 
CFI = .949 
RMSEA = .048; 90% CI: 044-.051. 
 
Regression Weights Between the Neuropsychological Variables and Predictor Variables (N = 694) 
   Estimate Standard Error Critical Ratio p = 
Memory Intercept <--- Age -.148 .017 -8.814 < .001 
Memory Slope <--- Age -.025 .008 -3.016 .003 
EA/PS Intercept <--- Age -.666 .049 -13.695 < .001 
EA/PS Slope <--- Age -.029 .013 -2.243 .025 
Language Intercept <--- Age -.086 .010 -8.739 < .001 
Language Slope <--- Age -.013 .004 -3.341 < .001 
WM Intercept <--- Age -.041 .009 -4.566 < .001 
Language Intercept <--- Sex .440 .126 3.491 < .001 
Memory Intercept <--- Sex 1.636 .220 7.450 < .001 
EA/PS Intercept <--- Sex 1.972 .613 3.220 .001 
WM Intercept <--- Sex -.102 .127 -.800 .424 
Language Slope <--- Sex .129 .053 2.442 .015 
Language Intercept  <--- Race -.013 .009 -1.375 .169 
Memory Intercept <--- Race -.002 .018 -.089 .929 
Language Slope <--- Race -.003 .004 -.862 .389 
Memory Slope <--- Race -.004 .009 -.513 .608 
EA/PS Intercept <--- Race -.081 .047 -1.732 .083 
EA/PS Slope <--- Race .006 .014 .439 .661 
WM Intercept <--- Race -.017 .010 -1.710 .087 
WM Slope <--- Race -.002 .004 -.446 .656 
Language Intercept <--- Ed .191 .025 7.587 < .001 
Language Slope <--- Ed .008 .010 .778 .436 
Memory Slope <--- Ed -.027 .021 -1.277 .202 
Memory Intercept <--- Ed .327 .044 7.442 < .001 
EA/PS Intercept <--- Ed .693 .116 5.965 < .001 
WM Slope <--- Ed .168 .024 7.047 < .001 
Note(s): Values are based on raw data. Executive Attention/Processing Speed (EA/PS); Working Memory (WM); 
Education level (Ed); FS-IQ was excluded as MLE estimates resulted in a non-positive covariance matrix when 
estimated intelligence was entered into the model. 
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APPENDIX E 
VARIANCE ESTIMATES AND STANDARDIZED COEFFICIENTS FOR THE 
NEUROCOGNITIVE DOMAINS 
 
 
Variances: Estimate S.E. C.R. p ≤ 
Memory Intercept 79.737 5.68 14.039 0.001 
Memory Slope 13.039 1.055 12.359 0.001 
EA/PS Intercept 57.416 5.533 10.378 0.001 
EA/PS Slope 0.979 0.272 3.598 0.001 
WM Intercept 58.32 4.309 13.536 0.001 
WM Slope 1.545 0.747 2.068 0.039 
Language Slope 0.811 0.294 2.754 0.006 
Language Intercept 31.427 3.951 7.954 0.001 
Correlations between Neurocognitive Domains 
WM Slope <--> Language Slope 0.716
EA/PS Intercept <--> Language Intercept 0.660
Memory Intercept <--> Language Intercept 0.544
EA/PS Slope <--> Language Slope 0.507
Memory Slope <--> Language Slope 0.499
Memory <--> EA/PS Intercept 0.426
EA/PS Intercept <--> WM Intercept 0.414
WM Intercept <--> Language Intercept 0.337
Memory Intercept <--> Memory Slope -0.256
Memory Slope <--> EA/PS Slope 0.250
EA/PS Slope <--> WM Slope 0.241
Memory Intercept <--> WM Intercept 0.206
Memory Intercept <--> Language Slope 0.189
Memory Slope <--> WM Slope 0.146
Memory Slope <--> EA/PS Intercept 0.105
Memory Intercept <--> EA/PS Slope 0.095
EA/PS Intercept <--> Language Slope 0.076
Memory Intercept <--> WM Slope 0.034
EA/PS Intercept <--> WM Slope -0.028
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
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APPENDIX F 
STANDARDIZED ESTIMATES BETWEEN THE NEUROCOGNITIVE DOMAINS AND 
THE DEMOGRAPHIC PREDICTOR VARIABLES  
 
Variable (N = 553)  Predictor Estimate 
EA/PS Intercept <--- age -0.533 
Language Intercept <--- age -0.428 
Memory Intercept <--- age -0.319 
EA/PS Slope <--- age -0.234 
EA/PS Intercept <--- race -0.225 
Memory Intercept <--- sex 0.225 
WM Intercept <--- age -0.208 
Language Slope <--- age -0.187 
Language Slope <--- sex 0.177 
EA/PS Slope <--- sex -0.145 
Memory Intercept <--- race -0.141 
Memory Slope <--- age -0.135 
WM Intercept <--- race -0.129 
Language Intercept <--- race -0.111 
WM Intercept <--- sex -0.105 
Language Intercept <--- sex 0.079 
EA/PS Intercept <--- sex 0.072 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
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APPENDIX G 
RELEVANT PREDICTOR VARIABLES OF NEUROCOGNITIVE FUNCTIONING WITH 
APOE GENOTYPE 
 
Variables (N = 398)  Estimate S.E. C.R. p ≤ 
Memory Intercept <--- Age -0.441 0.066 -6.694 0.001 
Memory Slope <--- Age -0.044 0.031 -1.392 0.164 
EA/PS Intercept <--- Age -0.583 0.06 -9.737 0.001 
EA/PS Slope <--- Age -0.029 0.016 -1.839 0.066 
Language Intercept <--- Age -0.349 0.045 -7.805 0.001 
WM Intercept <--- Age -0.114 0.059 -1.921 0.055 
Memory Intercept <--- Sex 4.866 0.87 5.594 0.001 
EA/PS Intercept <--- Sex 1.309 0.736 1.778 0.075 
Language Intercept <--- Sex 1.429 0.629 2.272 0.023 
Language_Slope <--- Sex 0.269 0.231 1.163 0.245 
Memory Intercept <--- Education 0.135 0.166 0.812 0.417 
Language Intercept <--- Education 0.224 0.109 2.048 0.041 
Memory Intercept <--- FSIQ 0.323 0.054 5.975 0.001 
EA/PS Intercept <--- FSIQ 0.279 0.044 6.288 0.001 
Language Intercept <--- FSIQ 0.294 0.04 7.408 0.001 
WM Intercept <--- FSIQ 0.452 0.048 9.354 0.001 
EA/PS Intercept <--- Cardiovascular -1.052 0.337 -3.117 0.002 
EA/PS Intercept <--- Depression/Endocrine -0.939 0.564 -1.666 0.096 
Language Intercept <--- Depression/Endocrine -0.894 0.446 -2.005 0.045 
Memory Intercept <--- APOE-e4 -1.251 0.684 -1.831 0.067 
Notes: Executive Attention/Processing Speed (EA/PS); Working Memory (WM). 
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APPENDIX H 
AGE, SEX, RACE AS PREDICTORS OF HEALTH RISKS EFFECT ON 
NEUROCOGNITIVE FUNCTIONING 
 
Variables     Est. S.E. C.R. p ≤ 
Std 
Est. 
Neurocardiovascular <--- Age 0.03 0.01 5.83 .001 0.74 
EA/PS Intercept <--- Neurocardiovascular -17.14 3.11 -5.52 .001 -0.64 
Language Intercept <--- Neurocardiovascular -10.44 2.06 -5.07 .001 -0.50 
Memory Intercept <--- Neurocardiovascular -14.31 2.76 -5.19 .001 -0.45 
WM Intercept <--- FS-IQ 0.44 0.05 9.86 .001 0.45 
Language Intercept <--- FS-IQ 0.30 0.04 7.85 .001 0.40 
Neurocardiovascular <--- Sex -0.21 0.04 -4.87 .001 -0.36 
Language Slope <--- Neurocardiovascular -0.85 0.40 -2.10 .036 -0.29 
Depression/Endocrine <--- Sex 0.37 0.05 6.88 .001 0.28 
EA/PS Intercept <--- FS-IQ 0.27 0.04 6.88 .001 0.27 
Memory Intercept <--- FS-IQ 0.31 0.05 6.13 .001 0.27 
Neurocardiovascular <--- Race 0.32 0.08 3.87 .001 0.22 
EA/PS Slope <--- Neurocardiovascular -0.64 0.35 -1.83 .068 -0.19 
EA/PS Slope <--- FS-IQ 0.02 0.01 2.09 .037 0.19 
Memory Slope <--- Neurocardiovascular -2.02 0.76 -2.65 .008 -0.16 
Language Intercept <--- Depression/Endocrine -1.40 0.41 -3.41 .001 -0.15 
EA/PS Intercept <--- Depression/Endocrine -1.74 0.47 -3.68 .001 -0.14 
Language Intercept <--- Education 0.34 0.10 3.31 .001 0.14 
WM Intercept <--- Neurocardiovascular -3.69 1.51 -2.45 .014 -0.14 
EA/PS Slope <--- Depression/Endocrine -0.12 0.14 -0.85 .395 -0.08 
WM Intercept <--- Depression/Endocrine -0.78 0.56 -1.40 .162 -0.06 
Memory Intercept <--- Education 0.20 0.15 1.35 .179 0.05 
Language Slope <--- Depression/Endocrine 0.07 0.15 0.46 .646 0.05 
Language Slope <--- FS-IQ -0.01 0.01 -0.46 .644 -0.05 
WM Slope <--- Neurocardiovascular 0.20 0.57 0.35 .724 0.05 
WM Slope <--- Depression/Endocrine -0.09 0.24 -0.38 .706 -0.05 
Memory Slope <--- FS-IQ 0.02 0.02 0.73 .464 0.03 
WM Slope <--- FS-IQ 0.00 0.02 0.13 .901 0.02 
Memory Intercept <--- Depression/Endocrine -0.13 0.56 -0.23 .821 -0.01 
Memory Slope <--- Depression/Endocrine 0.00 0.28 0.01 .991 0.00 
Notes: Values are sorted by Standardized Regression Weights. 
Estimate (Est.); Standardized (Std Est.); Executive Attention/Processing Speed (EA/PS); Working 
Memory (WM). 
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APPENDIX I 
AGE, SEX, AND GENOTYPE AS PREDICTORS OF HEALTH RISKS EFFECT ON 
NEUROCOGNITIVE FUNCTIONING 
 
Variables     Est. S.E. C.R. p ≤ 
Std 
Est. 
EA/PS Intercept <--- Neurocardiovascular -25.42 7.89 -3.22 .001 -0.75
Language Intercept <--- Neurocardiovascular -15.45 4.95 -3.12 .002 -0.64
Neurocardiovascular <--- Age 0.02 0.01 3.28 .001 0.64
Memory Intercept <--- Neurocardiovascular -22.21 7.09 -3.14 .002 -0.56
WM Intercept <--- FS-IQ 0.47 0.05 8.83 .001 0.47
Language Intercept <--- FS-IQ 0.31 0.04 7.21 .001 0.45
WM Slope <--- Neurocardiovascular 2.28 1.09 2.09 .037 0.37
Depression/Endocrine <--- Sex 0.43 0.06 6.91 .001 0.33
EA/PS Intercept <--- FS-IQ 0.27 0.05 5.82 .001 0.28
Neurocardiovascular <--- Sex -0.13 0.04 -2.88 .004 -0.28
Memory Intercept <--- FS-IQ 0.31 0.06 5.26 .001 0.27
EA/PS Slope <--- FS-IQ 0.02 0.01 1.50 .134 0.17
WM Intercept <--- Neurocardiovascular -5.21 2.86 -1.82 .069 -0.15
Language Intercept <--- Depression/Endocrine -1.01 0.44 -2.30 .022 -0.12
Language Slope <--- Depression/Endocrine 0.16 0.17 0.96 .336 0.12
EA/PS Intercept <--- Depression/Endocrine -1.37 0.57 -2.41 .016 -0.12
EA/PS Slope <--- Neurocardiovascular -0.44 0.55 -0.81 .420 -0.11
Language Intercept <--- Education 0.22 0.11 2.01 .045 0.10
Depression/Endocrine <--- APOE-e4 0.14 0.07 1.99 .047 0.09
Memory Slope <--- Neurocardiovascular -1.50 1.22 -1.24 .217 -0.09
EA/PS Slope <--- Depression/Endocrine -0.12 0.16 -0.77 .440 -0.09
Memory Slope <--- FS-IQ 0.04 0.03 1.36 .175 0.08
WM Slope <--- FS-IQ -0.01 0.02 -0.56 .574 -0.07
Language Slope <--- FS-IQ -0.01 0.01 -0.49 .624 -0.06
Memory Slope <--- Depression/Endocrine 0.28 0.31 0.89 .373 0.05
WM Intercept <--- Depression/Endocrine -0.60 0.65 -0.93 .353 -0.05
WM Slope <--- Depression/Endocrine 0.08 0.28 0.28 .780 0.037
Language Slope <--- Neurocardiovascular -0.10 0.58 -0.17 .863 -0.03
Memory Intercept <--- Depression/Endocrine 0.23 0.66 0.36 .721 0.02
Memory Intercept <--- Education -0.01 0.17 -0.08 .938 0.00
Notes: Values are sorted by Standardized Regression Weights. 
Estimate (Est.); Standardized (Std Est.); Executive Attention/Processing Speed (EA/PS); Working 
Memory (WM). 
 
  
  153
VITA 
 
 
 Rebecca Kathryn MacAulay was born and raised in Los Angles, CA. She received her 
Bachelors of Arts in Psychology from the University of California at Los Angeles (UCLA), 
graduating magna cum laude with College Honors distinction. At UCLA, she completed her 
senior thesis on psychosocial moderators of the stress response in schizophrenia under the 
guidance of Dr. Cindy Yee-Bradbury, an expert in the area of neurocognitive and emotional 
functioning in schizophrenia.  As a Clinical Psychology graduate student at Louisiana State 
University (LSU), Rebecca has continued to foster her research interest in the complex interplay 
between neurocognitive functioning and psychosocial risk factors in severe mental illnesses and 
older adult populations under the guidance of Dr. Alex Cohen. She currently is completing her 
predoctoral internship in Clinical Neuropsychology at the Charleston Consortium (Medical 
University of South Carolina and Ralph H. Johnson VA Medical Center). Upon receiving her 
doctoral degree in Summer 2016, she will join the University of Maine faculty as an assistant 
professor who specializes in aging and cognition across the adult life span. 
  
